{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For AbbVie, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \n(Exact name of registrant as specified in its charter)\nDelaware |  | 32-0375147\n(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)  |  |  |  |  |  |  |  |  |  |  | \nLarge Accelerated Filer | \u2612 | Accelerated Filer | \u2610\nNon-Accelerated Filer | \u2610 | Smaller reporting company | \u2610\n |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, par value $0.01 per share |  | ABBV |  | New York Stock Exchange\n |  |  |  | Chicago Stock Exchange\n1.500% Senior Notes due 2023 |  | ABBV23B |  | New York Stock Exchange\n1.375% Senior Notes due 2024 |  | ABBV24 |  | New York Stock Exchange\n1.250% Senior Notes due 2024 |  | ABBV24B |  | New York Stock Exchange\n0.750% Senior Notes due 2027 |  | ABBV27 |  | New York Stock Exchange\n2.125% Senior Notes due 2028 |  | ABBV28 |  | New York Stock Exchange\n2.625% Senior Notes due 2028 |  | ABBV28B |  | New York Stock Exchange\n2.125% Senior Notes due 2029 |  | ABBV29 |  | New York Stock Exchange\n1.250% Senior Notes due 2031 |  | ABBV31 |  | New York Stock Exchange  |  | \n  |  |  |  |  |  |  |  | \nPART\u00a0I. | FINANCIAL INFORMATION\n |  | Page\n |  | \nItem 1. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 1\nItem 2. | MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 24\nItem 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 34\nItem 4. | CONTROLS AND PROCEDURES | 34\n |  | \nPART\u00a0II. | OTHER INFORMATION\n |  | \nItem 1. | LEGAL PROCEEDINGS | 35\n |  | \nItem 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 35\nItem 6. | EXHIBITS | 36  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data) |  |  |  |  |  | 2022 |  | 2021\nNet revenues |  |  |  |  |  | $ | 13,538 |  |  | $ | 13,010 | \n |  |  |  |  |  |  |  | \nCost of products sold |  |  |  |  |  | 4,052 |  |  | 4,213 | \nSelling, general and administrative |  |  |  |  |  | 3,127 |  |  | 2,842 | \nResearch and development |  |  |  |  |  | 1,497 |  |  | 1,667 | \nAcquired IPR&D and milestones |  |  |  |  |  | 145 |  |  | 185 | \n |  |  |  |  |  |  |  | \nTotal operating costs and expenses |  |  |  |  |  | 8,821 |  |  | 8,907 | \nOperating earnings |  |  |  |  |  | 4,717 |  |  | 4,103 | \n |  |  |  |  |  |  |  | \nInterest expense, net |  |  |  |  |  | 539 |  |  | 622 | \nNet foreign exchange loss |  |  |  |  |  | 25 |  |  | 9 | \nOther income, net |  |  |  |  |  | (776) |  |  | (395) | \nEarnings before income tax expense |  |  |  |  |  | 4,929 |  |  | 3,867 | \nIncome tax expense |  |  |  |  |  | 436 |  |  | 312 | \nNet earnings |  |  |  |  |  | 4,493 |  |  | 3,555 | \nNet earnings attributable to noncontrolling interest |  |  |  |  |  | 3 |  |  | 2 | \nNet earnings attributable to AbbVie Inc. |  |  |  |  |  | $ | 4,490 |  |  | $ | 3,553 | \n |  |  |  |  |  |  |  | \nPer share data |  |  |  |  |  |  |  | \nBasic earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 2.52 |  |  | $ | 2.00 | \nDiluted earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 2.51 |  |  | $ | 1.99 | \n |  |  |  |  |  |  |  | \nWeighted-average basic shares outstanding |  |  |  |  |  | 1,771 |  |  | 1,769 | \nWeighted-average diluted shares outstanding |  |  |  |  |  | 1,778 |  |  | 1,775 |   |  |  |  |  | \n2022 Form 10-Q| | 1  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  | 2022 |  | 2021\nNet earnings |  |  |  |  | $ | 4,493 |  |  | $ | 3,555 | \n |  |  |  |  |  |  | \nForeign currency translation adjustments, net of tax expense (benefit) of $(7) for the three months ended March 31, 2022 and $(25) for the three months ended March 31, 2021 |  |  |  |  | (231) |  |  | (677) | \nNet investment hedging activities, net of tax expense (benefit) of $37for the three months ended March 31, 2022 and $103for the three months ended March 31, 2021 |  |  |  |  | 130 |  |  | 374 | \nPension and post-employment benefits, net of tax expense (benefit) of $10for the three months ended March 31, 2022 and $19for the three months ended March 31, 2021 |  |  |  |  | 28 |  |  | 79 | \n |  |  |  |  |  |  | \nCash flow hedging activities, net of tax expense (benefit) of $(2) for the three months ended March 31, 2022 and $3for the three months ended March 31, 2021 |  |  |  |  | (12) |  |  | 46 | \nOther comprehensive loss |  |  |  |  | (85) |  |  | (178) | \nComprehensive income |  |  |  |  | 4,408 |  |  | 3,377 | \nComprehensive income attributable to noncontrolling interest |  |  |  |  | 3 |  |  | 2 | \nComprehensive income attributable to AbbVie Inc. |  |  |  |  | $ | 4,405 |  |  | $ | 3,375 |   |  |  |  |  | \n2022 Form 10-Q| | 2  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions,\u00a0except\u00a0share\u00a0data) | March 31,2022 |  | December 31,2021\n | (unaudited) |  | \nAssets |  |  | \nCurrent assets |  |  | \nCash and equivalents | $ | 6,098 |  |  | $ | 9,746 | \nShort-term investments | 1,474 |  |  | 84 | \nAccounts receivable, net | 10,733 |  |  | 9,977 | \nInventories | 3,483 |  |  | 3,128 | \nPrepaid expenses and other | 4,721 |  |  | 4,993 | \nTotal current assets | 26,509 |  |  | 27,928 | \n |  |  | \nInvestments | 260 |  |  | 277 | \nProperty and equipment, net | 5,075 |  |  | 5,110 | \nIntangible assets, net | 73,986 |  |  | 75,951 | \nGoodwill | 32,298 |  |  | 32,379 | \nOther assets | 5,083 |  |  | 4,884 | \nTotal assets | $ | 143,211 |  |  | $ | 146,529 | \n |  |  | \nLiabilities and Equity |  |  | \nCurrent liabilities |  |  | \nShort-term borrowings | $ | 12 |  |  | $ | 14 | \nCurrent portion of long-term debt and finance lease obligations | 9,940 |  |  | 12,481 | \nAccounts payable and accrued liabilities | 22,569 |  |  | 22,699 | \nTotal current liabilities | 32,521 |  |  | 35,194 | \n |  |  | \nLong-term debt and finance lease obligations | 63,522 |  |  | 64,189 | \nDeferred income taxes | 2,831 |  |  | 3,009 | \nOther long-term liabilities | 28,023 |  |  | 28,701 | \n |  |  | \nCommitments and contingencies |  |  | \n |  |  | \nStockholders' equity |  |  | \nCommon stock, $0.01par value,4,000,000,000shares authorized,1,811,430,573shares issued as of March 31, 2022 and1,803,195,293as of December 31, 2021 | 18 |  |  | 18 | \nCommon stock held in treasury, at cost,44,557,588shares as of March 31, 2022 and34,857,597as of December 31, 2021 | (4,585) |  |  | (3,143) | \nAdditional paid-in capital | 18,731 |  |  | 18,305 | \nRetained earnings | 5,103 |  |  | 3,127 | \nAccumulated other comprehensive loss | (2,984) |  |  | (2,899) | \nTotal stockholders' equity | 16,283 |  |  | 15,408 | \nNoncontrolling interest | 31 |  |  | 28 | \nTotal equity | 16,314 |  |  | 15,436 | \n |  |  | \nTotal liabilities and equity | $ | 143,211 |  |  | $ | 146,529 |   |  |  |  |  | \n2022 Form 10-Q| | 3  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Common shares outstanding |  | Common stock |  | Treasury stock |  | Additional paid-in capital |  | Retained earnings |  | Accumulated other comprehensive loss |  | Noncontrolling interest |  | Total\nBalance at December 31, 2020 | 1,765 |  |  | $ | 18 |  |  | $ | (2,264) |  |  | $ | 17,384 |  |  | $ | 1,055 |  |  | $ | (3,117) |  |  | $ | 21 |  |  | $ | 13,097 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,553 |  |  | \u2014 |  |  | \u2014 |  |  | 3,553 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (178) |  |  | \u2014 |  |  | (178) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,316) |  |  | \u2014 |  |  | \u2014 |  |  | (2,316) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchases of treasury stock | (7) |  |  | \u2014 |  |  | (787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (787) | \nStock-based compensation plans and other | 8 |  |  | \u2014 |  |  | 34 |  |  | 328 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 362 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 2 | \nBalance at March 31, 2021 | 1,766 |  |  | $ | 18 |  |  | $ | (3,017) |  |  | $ | 17,712 |  |  | $ | 2,292 |  |  | $ | (3,295) |  |  | $ | 23 |  |  | $ | 13,733 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,143) |  |  | $ | 18,305 |  |  | $ | 3,127 |  |  | $ | (2,899) |  |  | $ | 28 |  |  | $ | 15,436 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,490 |  |  | \u2014 |  |  | \u2014 |  |  | 4,490 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (85) |  |  | \u2014 |  |  | (85) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,514) |  |  | \u2014 |  |  | \u2014 |  |  | (2,514) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchases of treasury stock | (10) |  |  | \u2014 |  |  | (1,470) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,470) | \nStock-based compensation plans and other | 9 |  |  | \u2014 |  |  | 28 |  |  | 426 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 454 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 3 | \nBalance at March 31, 2022 | 1,767 |  |  | $ | 18 |  |  | $ | (4,585) |  |  | $ | 18,731 |  |  | $ | 5,103 |  |  | $ | (2,984) |  |  | $ | 31 |  |  | $ | 16,314 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  | \n2022 Form 10-Q| | 4  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedMarch 31,\n(in\u00a0millions)\u00a0(brackets\u00a0denote\u00a0cash\u00a0outflows) | 2022 |  | 2021\nCash flows from operating activities |  |  | \nNet earnings | $ | 4,493 |  |  | $ | 3,555 | \nAdjustments to reconcile net earnings to net cash from operating activities: |  |  | \nDepreciation | 198 |  |  | 206 | \nAmortization of intangible assets | 1,855 |  |  | 2,009 | \nDeferred income taxes | (194) |  |  | (28) | \nChange in fair value of contingent consideration liabilities | (748) |  |  | (343) | \nStock-based compensation | 306 |  |  | 269 | \nAcquired IPR&D and milestones | 145 |  |  | 185 | \n |  |  | \n |  |  | \n |  |  | \nOther, net | 128 |  |  | (20) | \nChanges in operating assets and liabilities, net of acquisitions: |  |  | \nAccounts receivable | (785) |  |  | (866) | \nInventories | (385) |  |  | (187) | \nPrepaid expenses and other assets | (285) |  |  | (330) | \nAccounts payable and other liabilities | (258) |  |  | 236 | \nIncome tax assets and liabilities, net | 438 |  |  | 191 | \nCash flows from operating activities | 4,908 |  |  | 4,877 | \n |  |  | \nCash flows from investing activities |  |  | \n |  |  | \nAcquisitions and investments | (185) |  |  | (198) | \nAcquisitions of property and equipment | (162) |  |  | (188) | \nPurchases of investment securities | (1,406) |  |  | (16) | \nSales and maturities of investment securities | 8 |  |  | 11 | \n |  |  | \nOther, net | 154 |  |  | 49 | \nCash flows from investing activities | (1,591) |  |  | (342) | \n |  |  | \nCash flows from financing activities |  |  | \n |  |  | \n |  |  | \n |  |  | \nProceeds from issuance of long-term debt | 2,000 |  |  | \u2014 | \nRepayments of long-term debt and finance lease obligations | (4,879) |  |  | \u2014 | \n |  |  | \nDividends paid | (2,526) |  |  | (2,322) | \nPurchases of treasury stock | (1,470) |  |  | (787) | \nProceeds from the exercise of stock options | 128 |  |  | 71 | \nPayments of contingent consideration liabilities | (246) |  |  | (132) | \nOther, net | 21 |  |  | (4) | \nCash flows from financing activities | (6,972) |  |  | (3,174) | \nEffect of exchange rate changes on cash and equivalents | 7 |  |  | (55) | \nNet change in cash and equivalents | (3,648) |  |  | 1,306 | \nCash and equivalents, beginning of period | 9,746 |  |  | 8,449 | \n |  |  | \nCash and equivalents, end of period | $ | 6,098 |  |  | $ | 9,755 | \n |  |  | \n |  |  | \n |  |  |   |  |  |  |  | \n2022 Form 10-Q| | 5  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  | 2022 |  | 2021\nInterest expense |  |  |  |  |  | $ | 548 |  |  | $ | 632 | \nInterest income |  |  |  |  |  | (9) |  |  | (10) | \nInterest expense, net |  |  |  |  |  | $ | 539 |  |  | $ | 622 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | March 31,2022 |  | December 31,2021\nFinished goods | $ | 1,220 |  |  | $ | 932 | \nWork-in-process | 1,235 |  |  | 1,193 | \nRaw materials | 1,028 |  |  | 1,003 | \nInventories | $ | 3,483 |  |  | $ | 3,128 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | March 31,2022 |  | December 31,2021\nProperty and equipment, gross | $ | 10,879 |  |  | $ | 10,727 | \nAccumulated depreciation | (5,804) |  |  | (5,617) | \nProperty and equipment, net | $ | 5,075 |  |  | $ | 5,110 |   |  |  |  |  | \n2022 Form 10-Q| | 6  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions, except per share data) |  |  |  |  |  | 2022 |  | 2021\nBasic EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  |  |  |  |  | $ | 4,490 |  |  | $ | 3,553 | \nEarnings allocated to participating securities |  |  |  |  |  | 22 |  |  | 24 | \nEarnings available to common shareholders |  |  |  |  |  | $ | 4,468 |  |  | $ | 3,529 | \nWeighted-average basic shares outstanding |  |  |  |  |  | 1,771 |  |  | 1,769 | \nBasic earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 2.52 |  |  | $ | 2.00 | \n |  |  |  |  |  |  |  | \nDiluted EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  |  |  |  |  | $ | 4,490 |  |  | $ | 3,553 | \nEarnings allocated to participating securities |  |  |  |  |  | 22 |  |  | 24 | \nEarnings available to common shareholders |  |  |  |  |  | $ | 4,468 |  |  | $ | 3,529 | \nWeighted-average shares of common stock outstanding |  |  |  |  |  | 1,771 |  |  | 1,769 | \nEffect of dilutive securities |  |  |  |  |  | 7 |  |  | 6 | \nWeighted-average diluted shares outstanding |  |  |  |  |  | 1,778 |  |  | 1,775 | \nDiluted earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 2.51 |  |  | $ | 1.99 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 7  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in millions) |  |  |  |  |  | 2022 |  | 2021\nUnited States - Janssen's share of profits (included in cost of products sold) |  |  |  |  |  | $ | 408 |  |  | $ | 465 | \nInternational - AbbVie's share of profits (included in net revenues) |  |  |  |  |  | 299 |  |  | 269 | \nGlobal - AbbVie's share of other costs (included in respective line items) |  |  |  |  |  | 64 |  |  | 70 |   |  |  |  |  | \n2022 Form 10-Q| | 8  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in millions) |  |  |  |  |  | 2022 |  | 2021\nGenentech's share of profits, including royalties (included in cost of products sold) |  |  |  |  |  | $ | 178 |  |  | $ | 159 | \nAbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  |  |  |  |  | 12 |  |  | 11 | \nAbbVie's share of development costs (included in R&D) |  |  |  |  |  | 27 |  |  | 42 |   |  | \n  |  |  |  |  | \n(in\u00a0millions) | \nBalance as of December 31, 2021 | $ | 32,379 | \nForeign currency translation adjustments | (81) | \nBalance as of March 31, 2022 | $ | 32,298 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n(in\u00a0millions) | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount |  | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount\nDefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  | \nDeveloped product rights | $ | 88,811 |  |  | $ | (20,095) |  |  | $ | 68,716 |  |  | $ | 88,945 |  |  | $ | (18,463) |  |  | $ | 70,482 | \nLicense agreements | 8,493 |  |  | (3,893) |  |  | 4,600 |  |  | 8,487 |  |  | (3,688) |  |  | 4,799 | \nTotal definite-lived intangible assets | 97,304 |  |  | (23,988) |  |  | 73,316 |  |  | 97,432 |  |  | (22,151) |  |  | 75,281 | \nIndefinite-lived intangible assets | 670 |  |  | \u2014 |  |  | 670 |  |  | 670 |  |  | \u2014 |  |  | 670 | \nTotal intangible assets, net | $ | 97,974 |  |  | $ | (23,988) |  |  | $ | 73,986 |  |  | $ | 98,102 |  |  | $ | (22,151) |  |  | $ | 75,951 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 9  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | Severance and employee benefits |  |  |  |  |  |  |  |  | Other integration\n |  |  |  |  | Three months endedMarch 31, |  |  |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  |  |  |  | 2022 |  | 2021 |  |  |  |  |  |  |  |  | 2022 |  | 2021\nCost of products sold |  |  |  |  |  |  |  |  | $ | 1 |  |  | $ | 6 |  |  |  |  |  |  |  |  |  | $ | 30 |  |  | $ | 15 | \nResearch and development |  |  |  |  |  |  |  |  | 3 |  |  | \u2014 |  |  |  |  |  |  |  |  |  | 6 |  |  | 51 | \nSelling, general and administrative |  |  |  |  |  |  |  |  | 4 |  |  | 17 |  |  |  |  |  |  |  |  |  | 66 |  |  | 50 | \nTotal charges |  |  |  |  |  |  |  |  | $ | 8 |  |  | $ | 23 |  |  |  |  |  |  |  |  |  | $ | 102 |  |  | $ | 116 |   |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Severance and employee benefits |  | Other integration\nAccrued balance as of December 31, 2021 | $ | 222 |  |  | $ | 33 | \nCharges | 8 |  |  | 98 | \n |  |  | \n |  |  | \nPayments and other adjustments | (22) |  |  | (98) | \nAccrued balance as of March 31, 2022 | $ | 208 |  |  | $ | 33 |   |  |  |  |  | \n(in\u00a0millions) | \nAccrued balance as of December 31, 2021 | $ | 33 | \nRestructuring charges | 48 | \nPayments and other adjustments | (9) | \nAccrued balance as of March 31, 2022 | $ | 72 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 10  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair value \u2013Derivatives in asset position |  | Fair value \u2013Derivatives\u00a0in\u00a0liability\u00a0position\n(in\u00a0millions) | Balance\u00a0sheet\u00a0caption | March 31, 2022 | December 31, 2021 |  | Balance\u00a0sheet\u00a0caption | March 31, 2022 | December 31, 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | $ | 28 |  | $ | 51 |  |  | Accounts payable and accrued liabilities | $ | 6 |  | $ | 2 | \n |  |  |  |  |  |  | \nDesignated as net investment hedges | Prepaid expenses and other | 48 |  | 149 |  |  | Accounts payable and accrued liabilities | \u2014 |  | \u2014 | \nDesignated as net investment hedges | Other assets | 47 |  | 15 |  |  | Other long-term liabilities | 4 |  | \u2014 | \nNot designated as hedges | Prepaid expenses and other | 63 |  | 26 |  |  | Accounts payable and accrued liabilities | 29 |  | 13 | \nInterest rate swap contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 1 |  | 7 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nDesignated as fair value hedges | Other assets | \u2014 |  | 26 |  |  | Other long-term liabilities | 173 |  | 15 | \nTotal derivatives |  | $ | 186 |  | $ | 267 |  |  |  | $ | 213 |  | $ | 37 |   |  |  |  |  | \n2022 Form 10-Q| | 11  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in millions) |  |  |  |  |  | 2022 |  | 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  |  | \nDesignated as cash flow hedges |  |  |  |  |  | $ | (6) |  |  | $ | 35 | \nDesignated as net investment hedges |  |  |  |  |  | 82 |  |  | 99 | \nInterest rate swap contracts designated as cash flow hedges |  |  |  |  |  | 4 |  |  | 1 | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) | Statement\u00a0of earnings caption |  |  |  |  |  | 2022 |  | 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Cost of products sold |  |  |  |  |  | $ | 8 |  |  | $ | (12) | \nDesignated as net investment hedges | Interest expense, net |  |  |  |  |  | 14 |  |  | 4 | \nNot designated as hedges | Net foreign exchange loss |  |  |  |  |  | (41) |  |  | (25) | \nTreasury rate lock agreements designated as cash flow hedges | Interest expense, net |  |  |  |  |  | 6 |  |  | 6 | \nInterest rate swap contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Interest expense, net |  |  |  |  |  | (2) |  |  | (7) | \nDesignated as fair value hedges | Interest expense, net |  |  |  |  |  | (184) |  |  | (57) | \nDebt designated as hedged item in fair value hedges | Interest expense, net |  |  |  |  |  | 184 |  |  | 57 |   |  |  |  |  | \n2022 Form 10-Q| | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 6,098 |  |  | $ | 3,417 |  |  | $ | 2,681 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 1,445 |  |  | \u2014 |  |  | 1,445 |  |  | \u2014 | \nDebt securities | 42 |  |  | \u2014 |  |  | 42 |  |  | \u2014 | \nEquity securities | 100 |  |  | 81 |  |  | 19 |  |  | \u2014 | \n |  |  |  |  |  |  | \nForeign currency contracts | 186 |  |  | \u2014 |  |  | 186 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 7,871 |  |  | $ | 3,498 |  |  | $ | 4,373 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 174 |  |  | $ | \u2014 |  |  | $ | 174 |  |  | $ | \u2014 | \nForeign currency contracts | 39 |  |  | \u2014 |  |  | 39 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 13,818 |  |  | \u2014 |  |  | \u2014 |  |  | 13,818 | \nTotal liabilities | $ | 14,031 |  |  | $ | \u2014 |  |  | $ | 213 |  |  | $ | 13,818 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 9,746 |  |  | $ | 4,451 |  |  | $ | 5,295 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 45 |  |  | \u2014 |  |  | 45 |  |  | \u2014 | \nDebt securities | 46 |  |  | \u2014 |  |  | 46 |  |  | \u2014 | \nEquity securities | 121 |  |  | 100 |  |  | 21 |  |  | \u2014 | \nInterest rate swap contracts | 26 |  |  | \u2014 |  |  | 26 |  |  | \u2014 | \nForeign currency contracts | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 10,225 |  |  | $ | 4,551 |  |  | $ | 5,674 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 22 |  |  | $ | \u2014 |  |  | $ | 22 |  |  | $ | \u2014 | \nForeign currency contracts | 15 |  |  | \u2014 |  |  | 15 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 14,887 |  |  | \u2014 |  |  | \u2014 |  |  | 14,887 | \nTotal liabilities | $ | 14,924 |  |  | $ | \u2014 |  |  | $ | 37 |  |  | $ | 14,887 |   |  |  |  |  | \n2022 Form 10-Q| | 13  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n(in\u00a0millions) | Range | Weighted average(a) |  | Range | Weighted average(a)\nDiscount rate | 0.9% -3.6% | 3.0% |  | 0.2%-2.6% | 1.7%\nProbability of payment for unachieved milestones | 89% -100% | 91% |  | 89% -100% | 90%\nProbability of payment for royalties by indication(b) | 56% -100% | 96% |  | 56% -100% | 96%\n |  |  |  |  | \nProjected year of payments | 2022-2034 | 2027 |  | 2022-2034 | 2027  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedMarch 31,\n(in\u00a0millions) |  | 2022 |  | 2021\nBeginning balance |  | $ | 14,887 |  |  | $ | 12,997 | \nChange in fair value recognized in net earnings |  | (748) |  |  | (343) | \nPayments |  | (321) |  |  | (132) | \nEnding balance |  | $ | 13,818 |  |  | $ | 12,522 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 12 |  | $ | 12 |  |  | $ | \u2014 |  |  | $ | 12 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 9,922 |  | 9,208 |  |  | 8,851 |  |  | 357 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 63,634 |  | 65,790 |  |  | 64,914 |  |  | 876 |  |  | \u2014 | \nTotal liabilities | $ | 73,568 |  | $ | 75,010 |  |  | $ | 73,765 |  |  | $ | 1,245 |  |  | $ | \u2014 |   |  |  |  |  | \n2022 Form 10-Q| | 14  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 14 |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 14 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 12,455 |  | 11,830 |  |  | 11,329 |  |  | 501 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 64,113 |  | 71,810 |  |  | 70,757 |  |  | 1,053 |  |  | \u2014 | \nTotal liabilities | $ | 76,582 |  | $ | 83,654 |  |  | $ | 82,086 |  |  | $ | 1,568 |  |  | $ | \u2014 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Definedbenefit\u00a0plans |  | Other\u00a0post-employment\u00a0plans\n |  |  | Three months endedMarch 31, |  | Three months endedMarch 31, |  | \n(in\u00a0millions) |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  | \nService cost |  |  |  |  | $ | 116 |  |  | $ | 112 |  |  | $ | 12 |  |  | $ | 12 |  |  |  |  | \nInterest cost |  |  |  |  | 74 |  |  | 58 |  |  | 6 |  |  | 5 |  |  |  |  | \nExpected return on plan assets |  |  |  |  | (180) |  |  | (166) |  |  | \u2014 |  |  | \u2014 |  |  |  |  | \nAmortization of prior service cost (credit) |  |  |  |  | 1 |  |  | 1 |  |  | (10) |  |  | (10) |  |  |  |  | \nAmortization of actuarial loss |  |  |  |  | 57 |  |  | 70 |  |  | 7 |  |  | 8 |  |  |  |  | \nNet periodic benefit cost |  |  |  |  | $ | 68 |  |  | $ | 75 |  |  | $ | 15 |  |  | $ | 15 |  |  |  |  |   |  |  |  |  | \n2022 Form 10-Q| | 15  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  | 2022 |  | 2021\nCost of products sold |  |  |  |  |  | $ | 19 |  |  | $ | 20 | \nResearch and development |  |  |  |  |  | 107 |  |  | 87 | \nSelling, general and administrative |  |  |  |  |  | 180 |  |  | 162 | \nPre-tax compensation expense |  |  |  |  |  | 306 |  |  | 269 | \nTax benefit |  |  |  |  |  | 56 |  |  | 48 | \nAfter-tax compensation expense |  |  |  |  |  | $ | 250 |  |  | $ | 221 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2022 |  | 2021\nDate Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share\n02/17/22 |  | 05/16/22 |  | $ | 1.41 |  |  | 10/29/21 |  | 02/15/22 |  | $ | 1.41 | \n |  |  |  |  |  | 09/10/21 |  | 11/15/21 |  | $ | 1.30 | \n |  |  |  |  |  | 06/17/21 |  | 08/16/21 |  | $ | 1.30 | \n |  |  |  |  |  | 02/18/21 |  | 05/14/21 |  | $ | 1.30 |   |  |  |  |  | \n2022 Form 10-Q| | 16  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2021 | $ | (570) |  |  | $ | (91) |  |  | $ | (2,546) |  |  |  |  | $ | 308 |  |  | $ | (2,899) | \nOther comprehensive income (loss) before reclassifications | (231) |  |  | 142 |  |  | (15) |  |  |  |  | (1) |  |  | (105) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (12) |  |  | 43 |  |  |  |  | (11) |  |  | 20 | \nNet current-period other comprehensive income (loss) | (231) |  |  | 130 |  |  | 28 |  |  |  |  | (12) |  |  | (85) | \nBalance as of March 31, 2022 | $ | (801) |  |  | $ | 39 |  |  | $ | (2,518) |  |  |  |  | $ | 296 |  |  | $ | (2,984) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2020 | $ | 583 |  |  | $ | (790) |  |  | $ | (3,067) |  |  |  |  | $ | 157 |  |  | $ | (3,117) | \nOther comprehensive income (loss) before reclassifications | (677) |  |  | 377 |  |  | 24 |  |  |  |  | 35 |  |  | (241) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (3) |  |  | 55 |  |  |  |  | 11 |  |  | 63 | \nNet current-period other comprehensive income (loss) | (677) |  |  | 374 |  |  | 79 |  |  |  |  | 46 |  |  | (178) | \nBalance as of March 31, 2021 | $ | (94) |  |  | $ | (416) |  |  | $ | (2,988) |  |  |  |  | $ | 203 |  |  | $ | (3,295) |   |  |  |  |  | \n2022 Form 10-Q| | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedMarch 31,\n(in millions) (brackets\u00a0denote\u00a0gains) |  |  |  |  | 2022 |  | 2021\nNet investment hedging activities |  |  |  |  |  |  | \nGains on derivative amount excluded from effectiveness testing(a) |  |  |  |  | $ | (14) |  |  | $ | (4) | \nTax expense |  |  |  |  | 2 |  |  | 1 | \nTotal reclassifications, net of tax |  |  |  |  | $ | (12) |  |  | $ | (3) | \nPension and post-employment benefits |  |  |  |  |  |  | \nAmortization of actuarial losses and other(b) |  |  |  |  | $ | 55 |  |  | $ | 69 | \nTax benefit |  |  |  |  | (12) |  |  | (14) | \nTotal reclassifications, net of tax |  |  |  |  | $ | 43 |  |  | $ | 55 | \nCash flow hedging activities |  |  |  |  |  |  | \nLosses (gains) on foreign currency forward exchange contracts(c) |  |  |  |  | $ | (8) |  |  | $ | 12 | \nGains on treasury rate lock agreements(a) |  |  |  |  | (6) |  |  | (6) | \nLosses on interest rate swap contracts(a) |  |  |  |  | 2 |  |  | 7 | \nTax expense (benefit) |  |  |  |  | 1 |  |  | (2) | \nTotal reclassifications, net of tax |  |  |  |  | $ | (11) |  |  | $ | 11 |   |  | \n  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 18  |  |  |  |  | \n2022 Form 10-Q| | 19  |  |  |  |  | \n2022 Form 10-Q| | 20  |  |  |  |  | \n2022 Form 10-Q| | 21  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n |  | \n(in\u00a0millions) |  |  |  |  |  | 2022 |  | 2021\nImmunology |  |  |  |  |  |  | \nHumira | United States |  |  |  |  | $ | 3,993 |  |  | $ | 3,907 | \n | International |  |  |  |  | 743 |  |  | 960 | \n | Total |  |  |  |  | $ | 4,736 |  |  | $ | 4,867 | \nSkyrizi | United States |  |  |  |  | $ | 781 |  |  | $ | 481 | \n | International |  |  |  |  | 159 |  |  | 93 | \n | Total |  |  |  |  | $ | 940 |  |  | $ | 574 | \nRinvoq | United States |  |  |  |  | $ | 311 |  |  | $ | 245 | \n | International |  |  |  |  | 154 |  |  | 58 | \n | Total |  |  |  |  | $ | 465 |  |  | $ | 303 | \nHematologic Oncology |  |  |  |  |  |  | \nImbruvica | United States |  |  |  |  | $ | 874 |  |  | $ | 999 | \n | Collaboration revenues |  |  |  |  | 299 |  |  | 269 | \n | Total |  |  |  |  | $ | 1,173 |  |  | $ | 1,268 | \nVenclexta | United States |  |  |  |  | $ | 228 |  |  | $ | 225 | \n | International |  |  |  |  | 245 |  |  | 180 | \n | Total |  |  |  |  | $ | 473 |  |  | $ | 405 | \nAesthetics |  |  |  |  |  |  | \nBotox Cosmetic | United States |  |  |  |  | $ | 413 |  |  | $ | 305 | \n | International |  |  |  |  | 228 |  |  | 172 | \n | Total |  |  |  |  | $ | 641 |  |  | $ | 477 | \nJuvederm Collection | United States |  |  |  |  | $ | 148 |  |  | $ | 123 | \n | International |  |  |  |  | 262 |  |  | 198 | \n | Total |  |  |  |  | $ | 410 |  |  | $ | 321 | \nOther Aesthetics | United States |  |  |  |  | $ | 285 |  |  | $ | 300 | \n | International |  |  |  |  | 38 |  |  | 43 | \n | Total |  |  |  |  | $ | 323 |  |  | $ | 343 | \nNeuroscience |  |  |  |  |  |  | \nBotox Therapeutic | United States |  |  |  |  | $ | 500 |  |  | $ | 429 | \n | International |  |  |  |  | 114 |  |  | 103 | \n | Total |  |  |  |  | $ | 614 |  |  | $ | 532 | \nVraylar | United States |  |  |  |  | $ | 427 |  |  | $ | 346 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nDuodopa | United States |  |  |  |  | $ | 24 |  |  | $ | 25 | \n | International |  |  |  |  | 97 |  |  | 104 | \n | Total |  |  |  |  | $ | 121 |  |  | $ | 129 | \nUbrelvy | United States |  |  |  |  | $ | 138 |  |  | $ | 81 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nQulipta | United States |  |  |  |  | $ | 11 |  |  | $ | \u2014 | \nOther Neuroscience | United States |  |  |  |  | $ | 173 |  |  | $ | 156 | \n | International |  |  |  |  | 4 |  |  | 4 | \n | Total |  |  |  |  | $ | 177 |  |  | $ | 160 |   |  |  |  |  | \n2022 Form 10-Q| | 22  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n |  | \n(in\u00a0millions) |  |  |  |  |  | 2022 |  | 2021\nEye Care |  |  |  |  |  |  | \nLumigan/Ganfort | United States |  |  |  |  | $ | 67 |  |  | $ | 66 | \n | International |  |  |  |  | 73 |  |  | 77 | \n | Total |  |  |  |  | $ | 140 |  |  | $ | 143 | \nAlphagan/Combigan | United States |  |  |  |  | $ | 70 |  |  | $ | 80 | \n | International |  |  |  |  | 37 |  |  | 38 | \n | Total |  |  |  |  | $ | 107 |  |  | $ | 118 | \nRestasis | United States |  |  |  |  | $ | 235 |  |  | $ | 267 | \n | International |  |  |  |  | 11 |  |  | 13 | \n | Total |  |  |  |  | $ | 246 |  |  | $ | 280 | \nOther Eye Care | United States |  |  |  |  | $ | 124 |  |  | $ | 117 | \n | International |  |  |  |  | 154 |  |  | 159 | \n | Total |  |  |  |  | $ | 278 |  |  | $ | 276 | \nOther Key Products |  |  |  |  |  |  | \nMavyret | United States |  |  |  |  | $ | 169 |  |  | $ | 170 | \n | International |  |  |  |  | 211 |  |  | 245 | \n | Total |  |  |  |  | $ | 380 |  |  | $ | 415 | \nCreon | United States |  |  |  |  | $ | 287 |  |  | $ | 274 | \nLinzess/Constella | United States |  |  |  |  | $ | 233 |  |  | $ | 215 | \n | International |  |  |  |  | 7 |  |  | 7 | \n | Total |  |  |  |  | $ | 240 |  |  | $ | 222 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nAll other |  |  |  |  |  | $ | 1,211 |  |  | $ | 1,476 | \nTotal net revenues |  |  |  |  | $ | 13,538 |  |  | $ | 13,010 |   |  |  |  |  | \n2022 Form 10-Q| | 23  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 24  |  |  |  |  | \n2022 Form 10-Q| | 25  |  |  |  |  | \n2022 Form 10-Q| | 26  |  |  |  |  | \n2022 Form 10-Q| | 27  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | Three months endedMarch 31, |  | Percent\u00a0change\n |  |  |  |  |  |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  |  |  |  |  |  | 2022 |  | 2021 | \nUnited States |  |  |  |  |  |  |  |  |  | $ | 10,348 |  |  | $ | 9,750 |  |  | 6.1 | % |  | 6.1 | %\nInternational |  |  |  |  |  |  |  |  |  | 3,190 |  |  | 3,260 |  |  | (2.1) | % |  | 3.2 | %\nNet revenues |  |  |  |  |  |  |  |  |  | $ | 13,538 |  |  | $ | 13,010 |  |  | 4.1 | % |  | 5.4 | %  |  |  |  |  | \n2022 Form 10-Q| | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | Three months endedMarch 31, |  | Percent\u00a0change\n |  |  |  |  |  |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  |  |  |  |  |  | 2022 |  | 2021 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHumira | United States |  |  |  |  |  |  |  |  |  | $ | 3,993 |  |  | $ | 3,907 |  |  | 2.2 | % |  | 2.2 | %\n | International |  |  |  |  |  |  |  |  |  | 743 |  |  | 960 |  |  | (22.6) | % |  | (17.9) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 4,736 |  |  | $ | 4,867 |  |  | (2.7) | % |  | (1.8) | %\nSkyrizi | United States |  |  |  |  |  |  |  |  |  | $ | 781 |  |  | $ | 481 |  |  | 62.3 | % |  | 62.3 | %\n | International |  |  |  |  |  |  |  |  |  | 159 |  |  | 93 |  |  | 71.2 | % |  | 82.9 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 940 |  |  | $ | 574 |  |  | 63.7 | % |  | 65.6 | %\nRinvoq | United States |  |  |  |  |  |  |  |  |  | $ | 311 |  |  | $ | 245 |  |  | 26.8 | % |  | 26.8 | %\n | International |  |  |  |  |  |  |  |  |  | 154 |  |  | 58 |  |  | >100.0 % |  | >100.0 %\n | Total |  |  |  |  |  |  |  |  |  | $ | 465 |  |  | $ | 303 |  |  | 53.6 | % |  | 57.3 | %\nHematologic Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nImbruvica | United States |  |  |  |  |  |  |  |  |  | $ | 874 |  |  | $ | 999 |  |  | (12.4) | % |  | (12.4) | %\n | Collaboration revenues |  |  |  |  |  |  |  |  |  | 299 |  |  | 269 |  |  | 11.0 | % |  | 11.0 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 1,173 |  |  | $ | 1,268 |  |  | (7.4) | % |  | (7.4) | %\nVenclexta | United States |  |  |  |  |  |  |  |  |  | $ | 228 |  |  | $ | 225 |  |  | 1.7 | % |  | 1.7 | %\n | International |  |  |  |  |  |  |  |  |  | 245 |  |  | 180 |  |  | 35.8 | % |  | 45.2 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 473 |  |  | $ | 405 |  |  | 16.9 | % |  | 21.1 | %\nAesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Cosmetic | United States |  |  |  |  |  |  |  |  |  | $ | 413 |  |  | $ | 305 |  |  | 35.5 | % |  | 35.5 | %\n | International |  |  |  |  |  |  |  |  |  | 228 |  |  | 172 |  |  | 32.5 | % |  | 38.6 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 641 |  |  | $ | 477 |  |  | 34.4 | % |  | 36.6 | %\nJuvederm Collection | United States |  |  |  |  |  |  |  |  |  | $ | 148 |  |  | $ | 123 |  |  | 20.1 | % |  | 20.1 | %\n | International |  |  |  |  |  |  |  |  |  | 262 |  |  | 198 |  |  | 32.2 | % |  | 37.7 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 410 |  |  | $ | 321 |  |  | 27.5 | % |  | 30.9 | %\nOther Aesthetics | United States |  |  |  |  |  |  |  |  |  | $ | 285 |  |  | $ | 300 |  |  | (4.9) | % |  | (4.9) | %\n | International |  |  |  |  |  |  |  |  |  | 38 |  |  | 43 |  |  | (9.9) | % |  | (6.2) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 323 |  |  | $ | 343 |  |  | (5.5) | % |  | (5.0) | %\nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Therapeutic | United States |  |  |  |  |  |  |  |  |  | $ | 500 |  |  | $ | 429 |  |  | 16.5 | % |  | 16.5 | %\n | International |  |  |  |  |  |  |  |  |  | 114 |  |  | 103 |  |  | 10.7 | % |  | 17.1 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 614 |  |  | $ | 532 |  |  | 15.4 | % |  | 16.6 | %\nVraylar | United States |  |  |  |  |  |  |  |  |  | $ | 427 |  |  | $ | 346 |  |  | 23.4 | % |  | 23.4 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDuodopa | United States |  |  |  |  |  |  |  |  |  | $ | 24 |  |  | $ | 25 |  |  | (5.6) | % |  | (5.6) | %\n | International |  |  |  |  |  |  |  |  |  | 97 |  |  | 104 |  |  | (6.9) | % |  | 0.5 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 121 |  |  | $ | 129 |  |  | (6.7) | % |  | (0.8) | %\nUbrelvy | United States |  |  |  |  |  |  |  |  |  | $ | 138 |  |  | $ | 81 |  |  | 70.0 | % |  | 70.0 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nQulipta | United States |  |  |  |  |  |  |  |  |  | $ | 11 |  |  | $ | \u2014 |  |  | n/m |  | n/m\nOther Neuroscience | United States |  |  |  |  |  |  |  |  |  | $ | 173 |  |  | $ | 156 |  |  | 11.0 | % |  | 11.0 | %\n | International |  |  |  |  |  |  |  |  |  | 4 |  |  | 4 |  |  | 11.4 | % |  | 12.2 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 177 |  |  | $ | 160 |  |  | 11.0 | % |  | 11.0 | %  |  |  |  |  | \n2022 Form 10-Q| | 29  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | Three months endedMarch 31, |  | Percent\u00a0change\n |  |  |  |  |  |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  |  |  |  |  |  | 2022 |  | 2021 | \nEye Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLumigan/Ganfort | United States |  |  |  |  |  |  |  |  |  | $ | 67 |  |  | $ | 66 |  |  | 1.5 | % |  | 1.5 | %\n | International |  |  |  |  |  |  |  |  |  | 73 |  |  | 77 |  |  | (5.7) | % |  | 0.7 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 140 |  |  | $ | 143 |  |  | (2.4) | % |  | 1.0 | %\nAlphagan/Combigan | United States |  |  |  |  |  |  |  |  |  | $ | 70 |  |  | $ | 80 |  |  | (11.5) | % |  | (11.5) | %\n | International |  |  |  |  |  |  |  |  |  | 37 |  |  | 38 |  |  | (3.9) | % |  | 5.5 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 107 |  |  | $ | 118 |  |  | (9.0) | % |  | (6.0) | %\nRestasis | United States |  |  |  |  |  |  |  |  |  | $ | 235 |  |  | $ | 267 |  |  | (11.9) | % |  | (11.9) | %\n | International |  |  |  |  |  |  |  |  |  | 11 |  |  | 13 |  |  | (18.1) | % |  | 1.9 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 246 |  |  | $ | 280 |  |  | (12.2) | % |  | (11.3) | %\nOther Eye Care | United States |  |  |  |  |  |  |  |  |  | $ | 124 |  |  | $ | 117 |  |  | 5.5 | % |  | 5.5 | %\n | International |  |  |  |  |  |  |  |  |  | 154 |  |  | 159 |  |  | (2.4) | % |  | 4.8 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 278 |  |  | $ | 276 |  |  | 0.9 | % |  | 5.1 | %\nOther Key Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMavyret | United States |  |  |  |  |  |  |  |  |  | $ | 169 |  |  | $ | 170 |  |  | (1.0) | % |  | (1.0) | %\n | International |  |  |  |  |  |  |  |  |  | 211 |  |  | 245 |  |  | (13.9) | % |  | (7.2) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 380 |  |  | $ | 415 |  |  | (8.6) | % |  | (4.6) | %\nCreon | United States |  |  |  |  |  |  |  |  |  | $ | 287 |  |  | $ | 274 |  |  | 4.7 | % |  | 4.7 | %\nLinzess/Constella | United States |  |  |  |  |  |  |  |  |  | $ | 233 |  |  | $ | 215 |  |  | 7.9 | % |  | 7.9 | %\n | International |  |  |  |  |  |  |  |  |  | 7 |  |  | 7 |  |  | 6.0 | % |  | 10.2 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 240 |  |  | $ | 222 |  |  | 7.8 | % |  | 7.9 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAll other |  |  |  |  |  |  |  |  |  |  | $ | 1,211 |  |  | $ | 1,476 |  |  | (18.0) | % |  | (17.1) | %\nTotal net revenues |  |  |  |  |  |  |  |  |  | $ | 13,538 |  |  | $ | 13,010 |  |  | 4.1 | % |  | 5.4 | %  |  |  |  |  | \n2022 Form 10-Q| | 30  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(dollars in\u00a0millions) |  |  |  |  |  |  |  | 2022 |  | 2021 |  | % change\nGross margin |  |  |  |  |  |  |  | $ | 9,486 |  | $ | 8,797 |  | 8 | %\nas a % of net revenues |  |  |  |  |  |  |  | 70 | % |  | 68 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(dollars in\u00a0millions) |  |  |  |  |  |  |  | 2022 |  | 2021 |  | % change\nSelling, general and administrative |  |  |  |  |  |  |  | $ | 3,127 |  | $ | 2,842 |  | 10 | %\nas a % of net revenues |  |  |  |  |  |  |  | 23 | % |  | 22 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(dollars in\u00a0millions) |  |  |  |  |  |  |  | 2022 |  | 2021 |  | % change\nResearch and development |  |  |  |  |  |  |  | $ | 1,497 |  | $ | 1,667 |  | (10) | %\nas a % of net revenues |  |  |  |  |  |  |  | 11 | % |  | 13 | % |  | \nAcquired IPR&D and milestones |  |  |  |  |  |  |  | $ | 145 |  | $ | 185 |  | (22) | %  |  |  |  |  | \n2022 Form 10-Q| | 31  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  | 2022 |  | 2021\nInterest expense |  |  |  |  |  | $ | 548 |  |  | $ | 632 | \nInterest income |  |  |  |  |  | (9) |  |  | (10) | \nInterest expense, net |  |  |  |  |  | $ | 539 |  |  | $ | 622 | \n |  |  |  |  |  |  |  | \nNet foreign exchange loss |  |  |  |  |  | $ | 25 |  |  | $ | 9 | \nOther income, net |  |  |  |  |  | (776) |  |  | (395) |   |  |  |  |  |  |  |  |  |  |  | \n | Three months endedMarch 31,\n(in\u00a0millions) | 2022 |  | 2021\nCash flows provided by (used in): |  |  | \nOperating activities | $ | 4,908 |  |  | $ | 4,877 | \nInvesting activities | (1,591) |  |  | (342) | \nFinancing activities | (6,972) |  |  | (3,174) |   |  |  |  |  | \n2022 Form 10-Q| | 32  |  |  |  |  | \n2022 Form 10-Q| | 33  |  | \n  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 34  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | (a)\u00a0TotalNumber\u00a0ofShares(or Units)Purchased |  | (b)\u00a0AveragePrice\u00a0Paidper\u00a0Share(or\u00a0Unit) |  | (c)\u00a0Total\u00a0Numberof\u00a0Shares\u00a0(orUnits)\u00a0Purchasedas\u00a0Part\u00a0of\u00a0PubliclyAnnounced\u00a0Plansor\u00a0Programs |  | (d)\u00a0MaximumNumber\u00a0(orApproximateDollar\u00a0Value)\u00a0ofShares\u00a0(or\u00a0Units)that\u00a0May\u00a0Yet\u00a0BePurchased\u00a0Underthe\u00a0Plans\u00a0orPrograms | \nJanuary 1, 2022 - January 31, 2022 | 715 |  | (1) | $135.74 | (1) | \u2014 |  |  | $2,523,316,993 | \nFebruary 1, 2022 - February 28, 2022 | 6,653,483 |  | (1) | $146.18 | (1) | 6,652,791 |  |  | $1,550,785,350 | \nMarch 1, 2022 - March 31, 2022 | 1,048,640 |  | (1) | $149.88 | (1) | 1,048,000 |  |  | $1,393,714,917 | \nTotal | 7,702,838 |  | (1) | $146.69 | (1) | 7,700,791 |  |  | $1,393,714,917 |   |  |  |  |  | \n2022 Form 10-Q| | 35  |  | \n  |  |  |  |  |  |  |  | \nExhibit\u00a0No. |  | Exhibit\u00a0Description\n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n10.1 |  | Form of AbbVie Inc. Performance-Vested Restricted Stock Unit Agreement*\n |  | \n10.2 |  | Form of AbbVie Inc. Performance Share Award Agreement*\n |  | \n10.3 |  | Form of AbbVie Inc. Non-Employee Director RSU Agreement (US)*\n |  | \n10.4 |  | Form of AbbVie Inc. Non-Qualified Stock Option Agreement*\n |  | \n10.5 |  | Form of AbbVie Inc. Retention RSU Agreement \u2013 Ratable Vesting*\n |  | \n10.6 |  | Form of AbbVie Inc. Retention RSU Agreement \u2013 Cliff Vesting with Dividend Equivalent Accrual*\n |  | \n31.1 |  | Certification of Chief Executive Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)).\n |  | \n31.2 |  | Certification of Chief Financial Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)).\n |  | \n32.1 |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002.\n |  | \n32.2 |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002.\n |  | \n101 |  | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form\u00a010-Q for the quarter ended March 31, 2022, filed on May\u00a06, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)\u00a0Condensed Consolidated Statements of Earnings; (ii)\u00a0Condensed Consolidated Statements of Comprehensive Income; (iii)\u00a0Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)\u00a0Condensed Consolidated Statements of Cash Flows; and (vi)\u00a0the Notes to Condensed Consolidated Financial Statements.\n |  | \n104 |  | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  | \n2022 Form 10-Q| | 36  |  |  |  |  |  |  |  | \n |  | ABBVIE INC.\n |  | \n |  | \n | By: | /s/ Robert A. Michael\n |  | Robert A. Michael\n |  | Vice Chairman, Finance and Commercial Operations and\n |  | Chief Financial Officer (Principal Financial Officer)  |  |  |  |  | \n2022 Form 10-Q| | 37"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For AbbVie, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \n(Exact name of registrant as specified in its charter)\nDelaware |  | 32-0375147\n(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)  |  |  |  |  |  |  |  |  |  |  | \nLarge Accelerated Filer | \u2612 | Accelerated Filer | \u2610\nNon-Accelerated Filer | \u2610 | Smaller reporting company | \u2610\n |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, par value $0.01 per share |  | ABBV |  | New York Stock Exchange\n |  |  |  | Chicago Stock Exchange\n1.500% Senior Notes due 2023 |  | ABBV23B |  | New York Stock Exchange\n1.375% Senior Notes due 2024 |  | ABBV24 |  | New York Stock Exchange\n1.250% Senior Notes due 2024 |  | ABBV24B |  | New York Stock Exchange\n0.750% Senior Notes due 2027 |  | ABBV27 |  | New York Stock Exchange\n2.125% Senior Notes due 2028 |  | ABBV28 |  | New York Stock Exchange\n2.625% Senior Notes due 2028 |  | ABBV28B |  | New York Stock Exchange\n2.125% Senior Notes due 2029 |  | ABBV29 |  | New York Stock Exchange\n1.250% Senior Notes due 2031 |  | ABBV31 |  | New York Stock Exchange  |  | \n  |  |  |  |  |  |  |  | \nPART\u00a0I. | FINANCIAL INFORMATION\n |  | Page\n |  | \nItem 1. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 1\nItem 2. | MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 25\nItem 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 35\nItem 4. | CONTROLS AND PROCEDURES | 35\n |  | \nPART\u00a0II. | OTHER INFORMATION\n |  | \nItem 1. | LEGAL PROCEEDINGS | 37\n |  | \nItem 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 37\nItem 6. | EXHIBITS | 38  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nNet revenues |  | $ | 14,583 |  |  | $ | 13,959 |  |  | $ | 28,121 |  |  | $ | 26,969 | \n |  |  |  |  |  |  |  | \nCost of products sold |  | 4,170 |  |  | 4,523 |  |  | 8,222 |  |  | 8,736 | \nSelling, general and administrative |  | 5,412 |  |  | 3,164 |  |  | 8,539 |  |  | 6,006 | \nResearch and development |  | 1,609 |  |  | 1,767 |  |  | 3,106 |  |  | 3,434 | \nAcquired IPR&D and milestones |  | 269 |  |  | 132 |  |  | 414 |  |  | 317 | \nOther operating income |  | (172) |  |  | (68) |  |  | (172) |  |  | (68) | \nTotal operating costs and expenses |  | 11,288 |  |  | 9,518 |  |  | 20,109 |  |  | 18,425 | \nOperating earnings |  | 3,295 |  |  | 4,441 |  |  | 8,012 |  |  | 8,544 | \n |  |  |  |  |  |  |  | \nInterest expense, net |  | 532 |  |  | 606 |  |  | 1,071 |  |  | 1,228 | \nNet foreign exchange loss |  | 47 |  |  | 14 |  |  | 72 |  |  | 23 | \nOther expense, net |  | 1,533 |  |  | 2,658 |  |  | 757 |  |  | 2,263 | \nEarnings before income tax expense |  | 1,183 |  |  | 1,163 |  |  | 6,112 |  |  | 5,030 | \nIncome tax expense |  | 255 |  |  | 394 |  |  | 691 |  |  | 706 | \nNet earnings |  | 928 |  |  | 769 |  |  | 5,421 |  |  | 4,324 | \nNet earnings attributable to noncontrolling interest |  | 4 |  |  | 3 |  |  | 7 |  |  | 5 | \nNet earnings attributable to AbbVie Inc. |  | $ | 924 |  |  | $ | 766 |  |  | $ | 5,414 |  |  | $ | 4,319 | \n |  |  |  |  |  |  |  | \nPer share data |  |  |  |  |  |  |  | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 0.52 |  |  | $ | 0.42 |  |  | $ | 3.04 |  |  | $ | 2.42 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 0.51 |  |  | $ | 0.42 |  |  | $ | 3.03 |  |  | $ | 2.41 | \n |  |  |  |  |  |  |  | \nWeighted-average basic shares outstanding |  | 1,770 |  |  | 1,769 |  |  | 1,770 |  |  | 1,769 | \nWeighted-average diluted shares outstanding |  | 1,776 |  |  | 1,776 |  |  | 1,777 |  |  | 1,776 |   |  |  |  |  | \n2022 Form 10-Q| | 1  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nNet earnings | $ | 928 |  |  | $ | 769 |  |  | $ | 5,421 |  |  | $ | 4,324 | \n |  |  |  |  |  |  | \nForeign currency translation adjustments, net of tax expense (benefit) of $(12) for the three months and $(19) for the six months ended June 30, 2022 and $1for the three months and $(24) for the six months ended June 30, 2021 | (823) |  |  | 244 |  |  | (1,054) |  |  | (433) | \nNet investment hedging activities, net of tax expense (benefit) of $146for the three months and $183for the six months ended June 30, 2022 and $(31) for the three months and $72for the six months ended June 30, 2021 | 536 |  |  | (114) |  |  | 666 |  |  | 260 | \nPension and post-employment benefits, net of tax expense (benefit) of $11for the three months and $21for the six months ended June 30, 2022 and $14for the three months and $33for the six months ended June 30, 2021 | 48 |  |  | 50 |  |  | 76 |  |  | 129 | \n |  |  |  |  |  |  | \nCash flow hedging activities, net of tax expense (benefit) of $5for the three months and $3for the six months ended June 30, 2022 and $\u2014for the three months and $3for the six months ended June 30, 2021 | 27 |  |  | 12 |  |  | 15 |  |  | 58 | \nOther comprehensive income (loss) | (212) |  |  | 192 |  |  | (297) |  |  | 14 | \nComprehensive income | 716 |  |  | 961 |  |  | 5,124 |  |  | 4,338 | \nComprehensive income attributable to noncontrolling interest | 4 |  |  | 3 |  |  | 7 |  |  | 5 | \nComprehensive income attributable to AbbVie Inc. | $ | 712 |  |  | $ | 958 |  |  | $ | 5,117 |  |  | $ | 4,333 |   |  |  |  |  | \n2022 Form 10-Q| | 2  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions,\u00a0except\u00a0share\u00a0data) | June 30,2022 |  | December 31,2021\n | (unaudited) |  | \nAssets |  |  | \nCurrent assets |  |  | \nCash and equivalents | $ | 8,521 |  |  | $ | 9,746 | \nShort-term investments | 1,440 |  |  | 84 | \nAccounts receivable, net | 11,237 |  |  | 9,977 | \nInventories | 3,396 |  |  | 3,128 | \nPrepaid expenses and other | 4,506 |  |  | 4,993 | \nTotal current assets | 29,100 |  |  | 27,928 | \n |  |  | \nInvestments | 244 |  |  | 277 | \nProperty and equipment, net | 4,958 |  |  | 5,110 | \nIntangible assets, net | 71,823 |  |  | 75,951 | \nGoodwill | 32,028 |  |  | 32,379 | \nOther assets | 5,033 |  |  | 4,884 | \nTotal assets | $ | 143,186 |  |  | $ | 146,529 | \n |  |  | \nLiabilities and Equity |  |  | \nCurrent liabilities |  |  | \nShort-term borrowings | $ | 17 |  |  | $ | 14 | \nCurrent portion of long-term debt and finance lease obligations | 11,913 |  |  | 12,481 | \nAccounts payable and accrued liabilities | 22,543 |  |  | 22,699 | \nTotal current liabilities | 34,473 |  |  | 35,194 | \n |  |  | \nLong-term debt and finance lease obligations | 61,002 |  |  | 64,189 | \nDeferred income taxes | 2,255 |  |  | 3,009 | \nOther long-term liabilities | 30,768 |  |  | 28,701 | \n |  |  | \nCommitments and contingencies |  |  | \n |  |  | \nStockholders' equity |  |  | \nCommon stock, $0.01par value,4,000,000,000shares authorized,1,812,622,099shares issued as of June 30, 2022 and1,803,195,293as of December 31, 2021 | 18 |  |  | 18 | \nCommon stock held in treasury, at cost,44,595,448shares as of June 30, 2022 and34,857,597as of December 31, 2021 | (4,591) |  |  | (3,143) | \nAdditional paid-in capital | 18,906 |  |  | 18,305 | \nRetained earnings | 3,516 |  |  | 3,127 | \nAccumulated other comprehensive loss | (3,196) |  |  | (2,899) | \nTotal stockholders' equity | 14,653 |  |  | 15,408 | \nNoncontrolling interest | 35 |  |  | 28 | \nTotal equity | 14,688 |  |  | 15,436 | \n |  |  | \nTotal liabilities and equity | $ | 143,186 |  |  | $ | 146,529 |   |  |  |  |  | \n2022 Form 10-Q| | 3  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Common shares outstanding |  | Common stock |  | Treasury stock |  | Additional paid-in capital |  | Retained earnings |  | Accumulated other comprehensive loss |  | Noncontrolling interest |  | Total\nBalance at March 31, 2021 | 1,766 |  |  | $ | 18 |  |  | $ | (3,017) |  |  | $ | 17,712 |  |  | $ | 2,292 |  |  | $ | (3,295) |  |  | $ | 23 |  |  | $ | 13,733 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 766 |  |  | \u2014 |  |  | \u2014 |  |  | 766 | \nOther comprehensive income, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 192 |  |  | \u2014 |  |  | 192 | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,318) |  |  | \u2014 |  |  | \u2014 |  |  | (2,318) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (10) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (10) | \nStock-based compensation plans and other | 1 |  |  | \u2014 |  |  | 5 |  |  | 224 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 229 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 2 | \nBalance at June 30, 2021 | 1,767 |  |  | $ | 18 |  |  | $ | (3,022) |  |  | $ | 17,936 |  |  | $ | 740 |  |  | $ | (3,103) |  |  | $ | 25 |  |  | $ | 12,594 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2022 | 1,767 |  |  | $ | 18 |  |  | $ | (4,585) |  |  | $ | 18,731 |  |  | $ | 5,103 |  |  | $ | (2,984) |  |  | $ | 31 |  |  | $ | 16,314 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 924 |  |  | \u2014 |  |  | \u2014 |  |  | 924 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (212) |  |  | \u2014 |  |  | (212) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,511) |  |  | \u2014 |  |  | \u2014 |  |  | (2,511) | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (9) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9) | \nStock-based compensation plans and other | 1 |  |  | \u2014 |  |  | 3 |  |  | 175 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 178 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 | \nBalance at June 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,591) |  |  | $ | 18,906 |  |  | $ | 3,516 |  |  | $ | (3,196) |  |  | $ | 35 |  |  | $ | 14,688 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2020 | 1,765 |  |  | $ | 18 |  |  | $ | (2,264) |  |  | $ | 17,384 |  |  | $ | 1,055 |  |  | $ | (3,117) |  |  | $ | 21 |  |  | $ | 13,097 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,319 |  |  | \u2014 |  |  | \u2014 |  |  | 4,319 | \nOther comprehensive income, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,634) |  |  | \u2014 |  |  | \u2014 |  |  | (4,634) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchases of treasury stock | (7) |  |  | \u2014 |  |  | (797) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (797) | \nStock-based compensation plans and other | 9 |  |  | \u2014 |  |  | 39 |  |  | 552 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 591 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 | \nBalance at June 30, 2021 | 1,767 |  |  | $ | 18 |  |  | $ | (3,022) |  |  | $ | 17,936 |  |  | $ | 740 |  |  | $ | (3,103) |  |  | $ | 25 |  |  | $ | 12,594 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,143) |  |  | $ | 18,305 |  |  | $ | 3,127 |  |  | $ | (2,899) |  |  | $ | 28 |  |  | $ | 15,436 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 5,414 |  |  | \u2014 |  |  | \u2014 |  |  | 5,414 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (297) |  |  | \u2014 |  |  | (297) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5,025) |  |  | \u2014 |  |  | \u2014 |  |  | (5,025) | \nPurchases of treasury stock | (10) |  |  | \u2014 |  |  | (1,479) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,479) | \nStock-based compensation plans and other | 10 |  |  |  |  | 31 |  |  | 601 |  |  |  |  | \u2014 |  |  | \u2014 |  |  | 632 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7 |  |  | 7 | \nBalance at June 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,591) |  |  | $ | 18,906 |  |  | $ | 3,516 |  |  | $ | (3,196) |  |  | $ | 35 |  |  | $ | 14,688 |   |  |  |  |  | \n2022 Form 10-Q| | 4  |  |  |  |  |  |  |  |  |  |  | \n | Six months endedJune 30,\n(in\u00a0millions)\u00a0(brackets\u00a0denote\u00a0cash\u00a0outflows) | 2022 |  | 2021\nCash flows from operating activities |  |  | \nNet earnings | $ | 5,421 |  |  | $ | 4,324 | \nAdjustments to reconcile net earnings to net cash from operating activities: |  |  | \nDepreciation | 401 |  |  | 407 | \nAmortization of intangible assets | 3,704 |  |  | 4,008 | \nDeferred income taxes | (794) |  |  | (119) | \nChange in fair value of contingent consideration liabilities | 861 |  |  | 2,349 | \nStock-based compensation | 413 |  |  | 428 | \nAcquired IPR&D and milestones | 414 |  |  | 317 | \nGain on divestitures | (172) |  |  | (68) | \nNon-cash litigation reserve adjustments, net of cash payments | 2,190 |  |  | 97 | \nOther, net | (86) |  |  | (30) | \nChanges in operating assets and liabilities, net of acquisitions: |  |  | \nAccounts receivable | (1,396) |  |  | (1,162) | \nInventories | (499) |  |  | (249) | \nPrepaid expenses and other assets | 14 |  |  | (281) | \nAccounts payable and other liabilities | (448) |  |  | 308 | \nIncome tax assets and liabilities, net | (110) |  |  | (562) | \nCash flows from operating activities | 9,913 |  |  | 9,767 | \n |  |  | \nCash flows from investing activities |  |  | \n |  |  | \nAcquisitions and investments | (394) |  |  | (345) | \nAcquisitions of property and equipment | (305) |  |  | (383) | \nPurchases of investment securities | (1,411) |  |  | (56) | \nSales and maturities of investment securities | 50 |  |  | 65 | \n |  |  | \nOther, net | 599 |  |  | 135 | \nCash flows from investing activities | (1,461) |  |  | (584) | \n |  |  | \nCash flows from financing activities |  |  | \n |  |  | \n |  |  | \n |  |  | \nProceeds from issuance of long-term debt | 2,000 |  |  | \u2014 | \nRepayments of long-term debt and finance lease obligations | (4,881) |  |  | (3,461) | \n |  |  | \nDividends paid | (5,033) |  |  | (4,632) | \nPurchases of treasury stock | (1,479) |  |  | (797) | \nProceeds from the exercise of stock options | 198 |  |  | 144 | \nPayments of contingent consideration liabilities | (482) |  |  | (313) | \nOther, net | 26 |  |  | 1 | \nCash flows from financing activities | (9,651) |  |  | (9,058) | \nEffect of exchange rate changes on cash and equivalents | (26) |  |  | (28) | \nNet change in cash and equivalents | (1,225) |  |  | 97 | \nCash and equivalents, beginning of period | 9,746 |  |  | 8,449 | \n |  |  | \nCash and equivalents, end of period | $ | 8,521 |  |  | $ | 8,546 | \n |  |  | \n |  |  | \n |  |  |   |  |  |  |  | \n2022 Form 10-Q| | 5  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest expense |  | $ | 556 |  |  | $ | 615 |  |  | $ | 1,104 |  |  | $ | 1,247 | \nInterest income |  | (24) |  |  | (9) |  |  | (33) |  |  | (19) | \nInterest expense, net |  | $ | 532 |  |  | $ | 606 |  |  | $ | 1,071 |  |  | $ | 1,228 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | June 30,2022 |  | December 31,2021\nFinished goods | $ | 1,158 |  |  | $ | 932 | \nWork-in-process | 1,250 |  |  | 1,193 | \nRaw materials | 988 |  |  | 1,003 | \nInventories | $ | 3,396 |  |  | $ | 3,128 |   |  |  |  |  | \n2022 Form 10-Q| | 6  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | June 30,2022 |  | December 31,2021\nProperty and equipment, gross | $ | 10,827 |  |  | $ | 10,727 | \nAccumulated depreciation | (5,869) |  |  | (5,617) | \nProperty and equipment, net | $ | 4,958 |  |  | $ | 5,110 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions, except per share data) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nBasic EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 924 |  |  | $ | 766 |  |  | $ | 5,414 |  |  | $ | 4,319 | \nEarnings allocated to participating securities |  | 11 |  |  | 17 |  |  | 26 |  |  | 34 | \nEarnings available to common shareholders |  | $ | 913 |  |  | $ | 749 |  |  | $ | 5,388 |  |  | $ | 4,285 | \nWeighted-average basic shares outstanding |  | 1,770 |  |  | 1,769 |  |  | 1,770 |  |  | 1,769 | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 0.52 |  |  | $ | 0.42 |  |  | $ | 3.04 |  |  | $ | 2.42 | \n |  |  |  |  |  |  |  | \nDiluted EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 924 |  |  | $ | 766 |  |  | $ | 5,414 |  |  | $ | 4,319 | \nEarnings allocated to participating securities |  | 11 |  |  | 17 |  |  | 26 |  |  | 34 | \nEarnings available to common shareholders |  | $ | 913 |  |  | $ | 749 |  |  | $ | 5,388 |  |  | $ | 4,285 | \nWeighted-average shares of common stock outstanding |  | 1,770 |  |  | 1,769 |  |  | 1,770 |  |  | 1,769 | \nEffect of dilutive securities |  | 6 |  |  | 7 |  |  | 7 |  |  | 7 | \nWeighted-average diluted shares outstanding |  | 1,776 |  |  | 1,776 |  |  | 1,777 |  |  | 1,776 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 0.51 |  |  | $ | 0.42 |  |  | $ | 3.03 |  |  | $ | 2.41 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 7  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nUnited States - Janssen's share of profits (included in cost of products sold) |  | $ | 404 |  |  | $ | 514 |  |  | $ | 812 |  |  | $ | 979 | \nInternational - AbbVie's share of profits (included in net revenues) |  | 283 |  |  | 282 |  |  | 582 |  |  | 551 | \nGlobal - AbbVie's share of other costs (included in respective line items) |  | 69 |  |  | 74 |  |  | 133 |  |  | 144 |   |  |  |  |  | \n2022 Form 10-Q| | 8  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nGenentech's share of profits, including royalties (included in cost of products sold) |  | $ | 196 |  |  | $ | 168 |  |  | $ | 374 |  |  | $ | 327 | \nAbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  | 5 |  |  | 8 |  |  | 17 |  |  | 19 | \nAbbVie's share of development costs (included in R&D) |  | 31 |  |  | 34 |  |  | 58 |  |  | 76 |   |  | \n  |  |  |  |  | \n(in\u00a0millions) | \nBalance as of December 31, 2021 | $ | 32,379 | \nForeign currency translation adjustments | (351) | \nBalance as of June 30, 2022 | $ | 32,028 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\n(in\u00a0millions) | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount |  | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount\nDefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  | \nDeveloped product rights | $ | 88,443 |  |  | $ | (21,679) |  |  | $ | 66,764 |  |  | $ | 88,945 |  |  | $ | (18,463) |  |  | $ | 70,482 | \nLicense agreements | 8,487 |  |  | (4,098) |  |  | 4,389 |  |  | 8,487 |  |  | (3,688) |  |  | 4,799 | \nTotal definite-lived intangible assets | 96,930 |  |  | (25,777) |  |  | 71,153 |  |  | 97,432 |  |  | (22,151) |  |  | 75,281 | \nIndefinite-lived intangible assets | 670 |  |  | \u2014 |  |  | 670 |  |  | 670 |  |  | \u2014 |  |  | 670 | \nTotal intangible assets, net | $ | 97,600 |  |  | $ | (25,777) |  |  | $ | 71,823 |  |  | $ | 98,102 |  |  | $ | (22,151) |  |  | $ | 75,951 |   |  |  |  |  | \n2022 Form 10-Q| | 9  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Severance and employee benefits |  |  |  |  | Other integration\n |  |  | Three months endedJune 30, |  | Six months endedJune 30, |  |  |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |  | 2022 | 2021 |  | 2022 |  | 2021\nCost of products sold |  |  |  |  | $ | (5) |  |  | $ | \u2014 |  |  | $ | (4) |  |  | $ | 6 |  |  |  |  |  |  | $ | 31 |  | $ | 25 |  |  | $ | 61 |  |  | $ | 40 | \nResearch and development |  |  |  |  | (2) |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  | 3 |  | 18 |  |  | 9 |  |  | 69 | \nSelling, general and administrative |  |  |  |  | (4) |  |  | 12 |  |  | \u2014 |  |  | 29 |  |  |  |  |  |  | 80 |  | 75 |  |  | 146 |  |  | 125 | \nTotal charges (benefits) |  |  |  |  | $ | (11) |  |  | $ | 12 |  |  | $ | (3) |  |  | $ | 35 |  |  |  |  |  |  | $ | 114 |  | $ | 118 |  |  | $ | 216 |  |  | $ | 234 |   |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Severance and employee benefits |  | Other integration\nAccrued balance as of December 31, 2021 | $ | 222 |  |  | $ | 33 | \nCharges (benefits) | (3) |  |  | 199 | \n |  |  | \n |  |  | \nPayments and other adjustments | (90) |  |  | (220) | \nAccrued balance as of June 30, 2022 | $ | 129 |  |  | $ | 12 |   |  |  |  |  | \n(in\u00a0millions) | \nAccrued balance as of December 31, 2021 | $ | 33 | \nRestructuring charges | 72 | \nPayments and other adjustments | (13) | \nAccrued balance as of June 30, 2022 | $ | 92 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 10  |  |  |  |  | \n2022 Form 10-Q| | 11  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair value \u2013Derivatives in asset position |  | Fair value \u2013Derivatives\u00a0in\u00a0liability\u00a0position\n(in\u00a0millions) | Balance\u00a0sheet\u00a0caption | June 30, 2022 | December 31, 2021 |  | Balance\u00a0sheet\u00a0caption | June 30, 2022 | December 31, 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | $ | 47 |  | $ | 51 |  |  | Accounts payable and accrued liabilities | $ | 5 |  | $ | 2 | \nDesignated as cash flow hedges | Other assets | 4 |  | \u2014 |  |  | Other long-term liabilities | \u2014 |  | \u2014 | \nDesignated as net investment hedges | Prepaid expenses and other | 32 |  | 149 |  |  | Accounts payable and accrued liabilities | \u2014 |  | \u2014 | \nDesignated as net investment hedges | Other assets | 129 |  | 15 |  |  | Other long-term liabilities | \u2014 |  | \u2014 | \nNot designated as hedges | Prepaid expenses and other | 22 |  | 26 |  |  | Accounts payable and accrued liabilities | 41 |  | 13 | \nInterest rate swap contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | 2 |  | \u2014 |  |  | Accounts payable and accrued liabilities | \u2014 |  | 7 | \n |  |  |  |  |  |  | \nDesignated as fair value hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 16 |  | \u2014 | \nDesignated as fair value hedges | Other assets | \u2014 |  | 26 |  |  | Other long-term liabilities | 256 |  | 15 | \nTotal derivatives |  | $ | 236 |  | $ | 267 |  |  |  | $ | 318 |  | $ | 37 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  |  | \nDesignated as cash flow hedges |  | $ | 53 |  |  | $ | (11) |  |  | $ | 47 |  |  | $ | 24 | \nDesignated as net investment hedges |  | 304 |  |  | (14) |  |  | 386 |  |  | 85 | \nInterest rate swap contracts designated as cash flow hedges |  | 2 |  |  | \u2014 |  |  | 6 |  |  | 1 | \n |  |  |  |  |  |  |  |   |  |  |  |  | \n2022 Form 10-Q| | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) | Statement\u00a0of earnings caption |  | 2022 |  | 2021 |  | 2022 |  | 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Cost of products sold |  | $ | 18 |  |  | $ | (22) |  |  | $ | 26 |  |  | $ | (34) | \nDesignated as net investment hedges | Interest expense, net |  | 24 |  |  | 5 |  |  | 38 |  |  | 9 | \nNot designated as hedges | Net foreign exchange loss |  | (123) |  |  | (3) |  |  | (164) |  |  | (28) | \nTreasury rate lock agreements designated as cash flow hedges | Interest expense, net |  | 6 |  |  | 6 |  |  | 12 |  |  | 12 | \nInterest rate swap contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Interest expense, net |  | (1) |  |  | (7) |  |  | (3) |  |  | (14) | \nDesignated as fair value hedges | Interest expense, net |  | (99) |  |  | (11) |  |  | (283) |  |  | (68) | \nDebt designated as hedged item in fair value hedges | Interest expense, net |  | 99 |  |  | 11 |  |  | 283 |  |  | 68 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 8,521 |  |  | $ | 4,212 |  |  | $ | 4,309 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 1,425 |  |  | \u2014 |  |  | 1,425 |  |  | \u2014 | \nDebt securities | 37 |  |  | \u2014 |  |  | 37 |  |  | \u2014 | \nEquity securities | 74 |  |  | 54 |  |  | 20 |  |  | \u2014 | \nInterest rate swap contracts | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 | \nForeign currency contracts | 234 |  |  | \u2014 |  |  | 234 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 10,293 |  |  | $ | 4,266 |  |  | $ | 6,027 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 272 |  |  | $ | \u2014 |  |  | $ | 272 |  |  | $ | \u2014 | \nForeign currency contracts | 46 |  |  | \u2014 |  |  | 46 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 15,178 |  |  | \u2014 |  |  | \u2014 |  |  | 15,178 | \nTotal liabilities | $ | 15,496 |  |  | $ | \u2014 |  |  | $ | 318 |  |  | $ | 15,178 |   |  |  |  |  | \n2022 Form 10-Q| | 13  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 9,746 |  |  | $ | 4,451 |  |  | $ | 5,295 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 45 |  |  | \u2014 |  |  | 45 |  |  | \u2014 | \nDebt securities | 46 |  |  | \u2014 |  |  | 46 |  |  | \u2014 | \nEquity securities | 121 |  |  | 100 |  |  | 21 |  |  | \u2014 | \nInterest rate swap contracts | 26 |  |  | \u2014 |  |  | 26 |  |  | \u2014 | \nForeign currency contracts | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 10,225 |  |  | $ | 4,551 |  |  | $ | 5,674 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 22 |  |  | $ | \u2014 |  |  | $ | 22 |  |  | $ | \u2014 | \nForeign currency contracts | 15 |  |  | \u2014 |  |  | 15 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 14,887 |  |  | \u2014 |  |  | \u2014 |  |  | 14,887 | \nTotal liabilities | $ | 14,924 |  |  | $ | \u2014 |  |  | $ | 37 |  |  | $ | 14,887 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\n(in\u00a0millions) | Range | Weighted average(a) |  | Range | Weighted average(a)\nDiscount rate | 2.4% -4.8% | 4.1% |  | 0.2%-2.6% | 1.7%\nProbability of payment for unachieved milestones | 89% -100% | 95% |  | 89% -100% | 90%\nProbability of payment for royalties by indication(b) | 56% -100% | 99% |  | 56% -100% | 96%\n |  |  |  |  | \nProjected year of payments | 2022-2034 | 2027 |  | 2022-2034 | 2027  |  |  |  |  | \n2022 Form 10-Q| | 14  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2022 |  | 2021\nBeginning balance |  | $ | 14,887 |  |  | $ | 12,997 | \nChange in fair value recognized in net earnings |  | 861 |  |  | 2,349 | \nPayments |  | (570) |  |  | (357) | \nEnding balance |  | $ | 15,178 |  |  | $ | 14,989 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 17 |  | $ | 17 |  |  | $ | \u2014 |  |  | $ | 17 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 11,918 |  | 11,906 |  |  | 11,549 |  |  | 357 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 61,202 |  | 57,471 |  |  | 56,674 |  |  | 797 |  |  | \u2014 | \nTotal liabilities | $ | 73,137 |  | $ | 69,394 |  |  | $ | 68,223 |  |  | $ | 1,171 |  |  | $ | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 14 |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 14 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 12,455 |  | 11,830 |  |  | 11,329 |  |  | 501 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 64,113 |  | 71,810 |  |  | 70,757 |  |  | 1,053 |  |  | \u2014 | \nTotal liabilities | $ | 76,582 |  | $ | 83,654 |  |  | $ | 82,086 |  |  | $ | 1,568 |  |  | $ | \u2014 |   |  |  |  |  | \n2022 Form 10-Q| | 15  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Definedbenefit\u00a0plans |  | Other\u00a0post-employment\u00a0plans\n | Three months endedJune 30, |  | Six months endedJune 30, |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021\nService cost | $ | 113 |  |  | $ | 109 |  |  | $ | 229 |  |  | $ | 221 |  |  | $ | 13 |  |  | $ | 12 |  |  | $ | 25 |  |  | $ | 24 | \nInterest cost | 75 |  |  | 60 |  |  | 149 |  |  | 118 |  |  | 6 |  |  | 4 |  |  | 12 |  |  | 9 | \nExpected return on plan assets | (179) |  |  | (166) |  |  | (359) |  |  | (332) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nAmortization of prior service cost (credit) | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | (9) |  |  | (9) |  |  | (19) |  |  | (19) | \nAmortization of actuarial loss | 59 |  |  | 75 |  |  | 116 |  |  | 145 |  |  | 6 |  |  | 8 |  |  | 13 |  |  | 16 | \nNet periodic benefit cost | $ | 68 |  |  | $ | 78 |  |  | $ | 136 |  |  | $ | 153 |  |  | $ | 16 |  |  | $ | 15 |  |  | $ | 31 |  |  | $ | 30 |   |  |  |  |  | \n2022 Form 10-Q| | 16  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nCost of products sold |  | $ | 6 |  |  | $ | 10 |  |  | $ | 25 |  |  | $ | 30 | \nResearch and development |  | 40 |  |  | 47 |  |  | 147 |  |  | 134 | \nSelling, general and administrative |  | 61 |  |  | 102 |  |  | 241 |  |  | 264 | \nPre-tax compensation expense |  | 107 |  |  | 159 |  |  | 413 |  |  | 428 | \nTax benefit |  | 21 |  |  | 26 |  |  | 77 |  |  | 74 | \nAfter-tax compensation expense |  | $ | 86 |  |  | $ | 133 |  |  | $ | 336 |  |  | $ | 354 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2022 |  | 2021\nDate Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share\n06/23/22 |  | 08/15/22 |  | $ | 1.41 |  |  | 10/29/21 |  | 02/15/22 |  | $ | 1.41 | \n02/17/22 |  | 05/16/22 |  | $ | 1.41 |  |  | 09/10/21 |  | 11/15/21 |  | $ | 1.30 | \n |  |  |  |  |  | 06/17/21 |  | 08/16/21 |  | $ | 1.30 | \n |  |  |  |  |  | 02/18/21 |  | 05/14/21 |  | $ | 1.30 |   |  |  |  |  | \n2022 Form 10-Q| | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2021 | $ | (570) |  |  | $ | (91) |  |  | $ | (2,546) |  |  |  |  | $ | 308 |  |  | $ | (2,899) | \nOther comprehensive income (loss) before reclassifications | (1,054) |  |  | 696 |  |  | (11) |  |  |  |  | 45 |  |  | (324) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (30) |  |  | 87 |  |  |  |  | (30) |  |  | 27 | \nNet current-period other comprehensive income (loss) | (1,054) |  |  | 666 |  |  | 76 |  |  |  |  | 15 |  |  | (297) | \nBalance as of June 30, 2022 | $ | (1,624) |  |  | $ | 575 |  |  | $ | (2,470) |  |  |  |  | $ | 323 |  |  | $ | (3,196) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2020 | $ | 583 |  |  | $ | (790) |  |  | $ | (3,067) |  |  |  |  | $ | 157 |  |  | $ | (3,117) | \nOther comprehensive income (loss) before reclassifications | (433) |  |  | 267 |  |  | 16 |  |  |  |  | 27 |  |  | (123) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (7) |  |  | 113 |  |  |  |  | 31 |  |  | 137 | \nNet current-period other comprehensive income (loss) | (433) |  |  | 260 |  |  | 129 |  |  |  |  | 58 |  |  | 14 | \nBalance as of June 30, 2021 | $ | 150 |  |  | $ | (530) |  |  | $ | (2,938) |  |  |  |  | $ | 215 |  |  | $ | (3,103) |   |  |  |  |  | \n2022 Form 10-Q| | 18  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) (brackets\u00a0denote\u00a0gains) | 2022 |  | 2021 |  | 2022 |  | 2021\nNet investment hedging activities |  |  |  |  |  |  | \nGains on derivative amount excluded from effectiveness testing(a) | $ | (24) |  |  | $ | (5) |  |  | $ | (38) |  |  | $ | (9) | \nTax expense | 6 |  |  | 1 |  |  | 8 |  |  | 2 | \nTotal reclassifications, net of tax | $ | (18) |  |  | $ | (4) |  |  | $ | (30) |  |  | $ | (7) | \nPension and post-employment benefits |  |  |  |  |  |  | \nAmortization of actuarial losses and other(b) | $ | 56 |  |  | $ | 74 |  |  | $ | 111 |  |  | $ | 143 | \nTax benefit | (12) |  |  | (16) |  |  | (24) |  |  | (30) | \nTotal reclassifications, net of tax | $ | 44 |  |  | $ | 58 |  |  | $ | 87 |  |  | $ | 113 | \nCash flow hedging activities |  |  |  |  |  |  | \nLosses (gains) on foreign currency forward exchange contracts(c) | $ | (18) |  |  | $ | 22 |  |  | $ | (26) |  |  | $ | 34 | \nGains on treasury rate lock agreements(a) | (6) |  |  | (6) |  |  | (12) |  |  | (12) | \nLosses on interest rate swap contracts(a) | 1 |  |  | 7 |  |  | 3 |  |  | 14 | \nTax expense (benefit) | 4 |  |  | (3) |  |  | 5 |  |  | (5) | \nTotal reclassifications, net of tax | $ | (19) |  |  | $ | 20 |  |  | $ | (30) |  |  | $ | 31 |   |  | \n  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 19  |  |  |  |  | \n2022 Form 10-Q| | 20  |  |  |  |  | \n2022 Form 10-Q| | 21  |  |  |  |  | \n2022 Form 10-Q| | 22  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n |  | \n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nImmunology |  |  |  |  |  |  | \nHumira | United States | $ | 4,664 |  |  | $ | 4,257 |  |  | $ | 8,657 |  |  | $ | 8,164 | \n | International | 699 |  |  | 811 |  |  | 1,442 |  |  | 1,771 | \n | Total | $ | 5,363 |  |  | $ | 5,068 |  |  | $ | 10,099 |  |  | $ | 9,935 | \nSkyrizi | United States | $ | 1,079 |  |  | $ | 565 |  |  | $ | 1,860 |  |  | $ | 1,046 | \n | International | 173 |  |  | 109 |  |  | 332 |  |  | 202 | \n | Total | $ | 1,252 |  |  | $ | 674 |  |  | $ | 2,192 |  |  | $ | 1,248 | \nRinvoq | United States | $ | 412 |  |  | $ | 296 |  |  | $ | 723 |  |  | $ | 541 | \n | International | 180 |  |  | 82 |  |  | 334 |  |  | 140 | \n | Total | $ | 592 |  |  | $ | 378 |  |  | $ | 1,057 |  |  | $ | 681 | \nHematologic Oncology |  |  |  |  |  |  | \nImbruvica | United States | $ | 862 |  |  | $ | 1,099 |  |  | $ | 1,736 |  |  | $ | 2,098 | \n | Collaboration revenues | 283 |  |  | 282 |  |  | 582 |  |  | 551 | \n | Total | $ | 1,145 |  |  | $ | 1,381 |  |  | $ | 2,318 |  |  | $ | 2,649 | \nVenclexta | United States | $ | 253 |  |  | $ | 223 |  |  | $ | 481 |  |  | $ | 448 | \n | International | 252 |  |  | 212 |  |  | 497 |  |  | 392 | \n | Total | $ | 505 |  |  | $ | 435 |  |  | $ | 978 |  |  | $ | 840 | \nAesthetics |  |  |  |  |  |  | \nBotox Cosmetic | United States | $ | 449 |  |  | $ | 366 |  |  | $ | 862 |  |  | $ | 671 | \n | International | 246 |  |  | 218 |  |  | 474 |  |  | 390 | \n | Total | $ | 695 |  |  | $ | 584 |  |  | $ | 1,336 |  |  | $ | 1,061 | \nJuvederm Collection | United States | $ | 147 |  |  | $ | 196 |  |  | $ | 295 |  |  | $ | 319 | \n | International | 197 |  |  | 232 |  |  | 459 |  |  | 430 | \n | Total | $ | 344 |  |  | $ | 428 |  |  | $ | 754 |  |  | $ | 749 | \nOther Aesthetics | United States | $ | 287 |  |  | $ | 363 |  |  | $ | 572 |  |  | $ | 663 | \n | International | 45 |  |  | 59 |  |  | 83 |  |  | 102 | \n | Total | $ | 332 |  |  | $ | 422 |  |  | $ | 655 |  |  | $ | 765 | \nNeuroscience |  |  |  |  |  |  | \nBotox Therapeutic | United States | $ | 557 |  |  | $ | 488 |  |  | $ | 1,057 |  |  | $ | 917 | \n | International | 121 |  |  | 115 |  |  | 235 |  |  | 218 | \n | Total | $ | 678 |  |  | $ | 603 |  |  | $ | 1,292 |  |  | $ | 1,135 | \nVraylar | United States | $ | 492 |  |  | $ | 432 |  |  | $ | 919 |  |  | $ | 778 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nDuodopa | United States | $ | 26 |  |  | $ | 25 |  |  | $ | 50 |  |  | $ | 50 | \n | International | 94 |  |  | 102 |  |  | 191 |  |  | 206 | \n | Total | $ | 120 |  |  | $ | 127 |  |  | $ | 241 |  |  | $ | 256 | \nUbrelvy | United States | $ | 185 |  |  | $ | 126 |  |  | $ | 323 |  |  | $ | 207 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nQulipta | United States | $ | 33 |  |  | $ | \u2014 |  |  | $ | 44 |  |  | $ | \u2014 | \nOther Neuroscience | United States | $ | 145 |  |  | $ | 167 |  |  | $ | 318 |  |  | $ | 323 | \n | International | 5 |  |  | 4 |  |  | 9 |  |  | 8 | \n | Total | $ | 150 |  |  | $ | 171 |  |  | $ | 327 |  |  | $ | 331 |   |  |  |  |  | \n2022 Form 10-Q| | 23  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n |  | \n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nEye Care |  |  |  |  |  |  | \nLumigan/Ganfort | United States | $ | 60 |  |  | $ | 72 |  |  | $ | 127 |  |  | $ | 138 | \n | International | 70 |  |  | 77 |  |  | 143 |  |  | 154 | \n | Total | $ | 130 |  |  | $ | 149 |  |  | $ | 270 |  |  | $ | 292 | \nAlphagan/Combigan | United States | $ | 54 |  |  | $ | 102 |  |  | $ | 124 |  |  | $ | 182 | \n | International | 38 |  |  | 40 |  |  | 75 |  |  | 78 | \n | Total | $ | 92 |  |  | $ | 142 |  |  | $ | 199 |  |  | $ | 260 | \nRestasis | United States | $ | 151 |  |  | $ | 312 |  |  | $ | 386 |  |  | $ | 579 | \n | International | 17 |  |  | 15 |  |  | 28 |  |  | 28 | \n | Total | $ | 168 |  |  | $ | 327 |  |  | $ | 414 |  |  | $ | 607 | \nOther Eye Care | United States | $ | 142 |  |  | $ | 130 |  |  | $ | 266 |  |  | $ | 247 | \n | International | 185 |  |  | 171 |  |  | 339 |  |  | 330 | \n | Total | $ | 327 |  |  | $ | 301 |  |  | $ | 605 |  |  | $ | 577 | \nOther Key Products |  |  |  |  |  |  | \nMavyret | United States | $ | 203 |  |  | $ | 204 |  |  | $ | 372 |  |  | $ | 374 | \n | International | 195 |  |  | 238 |  |  | 406 |  |  | 483 | \n | Total | $ | 398 |  |  | $ | 442 |  |  | $ | 778 |  |  | $ | 857 | \nCreon | United States | $ | 318 |  |  | $ | 280 |  |  | $ | 605 |  |  | $ | 554 | \nLinzess/Constella | United States | $ | 247 |  |  | $ | 260 |  |  | $ | 480 |  |  | $ | 475 | \n | International | 8 |  |  | 8 |  |  | 15 |  |  | 15 | \n | Total | $ | 255 |  |  | $ | 268 |  |  | $ | 495 |  |  | $ | 490 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nAll other |  | $ | 1,009 |  |  | $ | 1,221 |  |  | $ | 2,220 |  |  | $ | 2,697 | \nTotal net revenues | $ | 14,583 |  |  | $ | 13,959 |  |  | $ | 28,121 |  |  | $ | 26,969 |   |  |  |  |  | \n2022 Form 10-Q| | 24  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 25  |  |  |  |  | \n2022 Form 10-Q| | 26  |  |  |  |  | \n2022 Form 10-Q| | 27  |  |  |  |  | \n2022 Form 10-Q| | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Percent\u00a0change |  | Six months endedJune 30, |  | Percent\u00a0change\n |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \nUnited States |  | $ | 11,410 |  |  | $ | 10,804 |  |  | 5.6 | % |  | 5.6 | % |  | $ | 21,758 |  |  | $ | 20,554 |  |  | 5.9 | % |  | 5.9 | %\nInternational |  | 3,173 |  |  | 3,155 |  |  | 0.6 | % |  | 7.6 | % |  | 6,363 |  |  | 6,415 |  |  | (0.8) | % |  | 5.3 | %\nNet revenues |  | $ | 14,583 |  |  | $ | 13,959 |  |  | 4.5 | % |  | 6.1 | % |  | $ | 28,121 |  |  | $ | 26,969 |  |  | 4.3 | % |  | 5.7 | %  |  |  |  |  | \n2022 Form 10-Q| | 29  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedJune 30, |  | Percent\u00a0change |  | Six months endedJune 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHumira | United States |  | $ | 4,664 |  |  | $ | 4,257 |  |  | 9.6 | % |  | 9.6 | % |  | $ | 8,657 |  |  | $ | 8,164 |  |  | 6.0 | % |  | 6.0 | %\n | International |  | 699 |  |  | 811 |  |  | (13.8) | % |  | (7.3) | % |  | 1,442 |  |  | 1,771 |  |  | (18.6) | % |  | (13.1) | %\n | Total |  | $ | 5,363 |  |  | $ | 5,068 |  |  | 5.8 | % |  | 6.8 | % |  | $ | 10,099 |  |  | $ | 9,935 |  |  | 1.7 | % |  | 2.7 | %\nSkyrizi | United States |  | $ | 1,079 |  |  | $ | 565 |  |  | 91.1 | % |  | 91.1 | % |  | $ | 1,860 |  |  | $ | 1,046 |  |  | 77.8 | % |  | 77.8 | %\n | International |  | 173 |  |  | 109 |  |  | 59.1 | % |  | 73.9 | % |  | 332 |  |  | 202 |  |  | 64.7 | % |  | 78.1 | %\n | Total |  | $ | 1,252 |  |  | $ | 674 |  |  | 85.9 | % |  | 88.3 | % |  | $ | 2,192 |  |  | $ | 1,248 |  |  | 75.7 | % |  | 77.9 | %\nRinvoq | United States |  | $ | 412 |  |  | $ | 296 |  |  | 39.4 | % |  | 39.4 | % |  | $ | 723 |  |  | $ | 541 |  |  | 33.7 | % |  | 33.7 | %\n | International |  | 180 |  |  | 82 |  |  | >100.0 % |  | >100.0 % |  | 334 |  |  | 140 |  |  | >100.0 % |  | >100.0 %\n | Total |  | $ | 592 |  |  | $ | 378 |  |  | 56.3 | % |  | 60.7 | % |  | $ | 1,057 |  |  | $ | 681 |  |  | 55.1 | % |  | 59.2 | %\nHematologic Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nImbruvica | United States |  | $ | 862 |  |  | $ | 1,099 |  |  | (21.6) | % |  | (21.6) | % |  | $ | 1,736 |  |  | $ | 2,098 |  |  | (17.2) | % |  | (17.2) | %\n | Collaboration revenues |  | 283 |  |  | 282 |  |  | 0.5 | % |  | 0.5 | % |  | 582 |  |  | 551 |  |  | 5.6 | % |  | 5.6 | %\n | Total |  | $ | 1,145 |  |  | $ | 1,381 |  |  | (17.1) | % |  | (17.1) | % |  | $ | 2,318 |  |  | $ | 2,649 |  |  | (12.5) | % |  | (12.5) | %\nVenclexta | United States |  | $ | 253 |  |  | $ | 223 |  |  | 13.4 | % |  | 13.4 | % |  | $ | 481 |  |  | $ | 448 |  |  | 7.5 | % |  | 7.5 | %\n | International |  | 252 |  |  | 212 |  |  | 19.1 | % |  | 29.3 | % |  | 497 |  |  | 392 |  |  | 26.8 | % |  | 36.7 | %\n | Total |  | $ | 505 |  |  | $ | 435 |  |  | 16.2 | % |  | 21.2 | % |  | $ | 978 |  |  | $ | 840 |  |  | 16.5 | % |  | 21.1 | %\nAesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Cosmetic | United States |  | $ | 449 |  |  | $ | 366 |  |  | 22.4 | % |  | 22.4 | % |  | $ | 862 |  |  | $ | 671 |  |  | 28.3 | % |  | 28.3 | %\n | International |  | 246 |  |  | 218 |  |  | 12.9 | % |  | 19.2 | % |  | 474 |  |  | 390 |  |  | 21.5 | % |  | 27.7 | %\n | Total |  | $ | 695 |  |  | $ | 584 |  |  | 18.9 | % |  | 21.2 | % |  | $ | 1,336 |  |  | $ | 1,061 |  |  | 25.8 | % |  | 28.1 | %\nJuvederm Collection | United States |  | $ | 147 |  |  | $ | 196 |  |  | (24.9) | % |  | (24.9) | % |  | $ | 295 |  |  | $ | 319 |  |  | (7.5) | % |  | (7.5) | %\n | International |  | 197 |  |  | 232 |  |  | (15.0) | % |  | (8.1) | % |  | 459 |  |  | 430 |  |  | 6.7 | % |  | 13.0 | %\n | Total |  | $ | 344 |  |  | $ | 428 |  |  | (19.5) | % |  | (15.7) | % |  | $ | 754 |  |  | $ | 749 |  |  | 0.7 | % |  | 4.3 | %\nOther Aesthetics | United States |  | $ | 287 |  |  | $ | 363 |  |  | (20.9) | % |  | (20.9) | % |  | $ | 572 |  |  | $ | 663 |  |  | (13.6) | % |  | (13.6) | %\n | International |  | 45 |  |  | 59 |  |  | (24.4) | % |  | (20.2) | % |  | 83 |  |  | 102 |  |  | (18.3) | % |  | (14.3) | %\n | Total |  | $ | 332 |  |  | $ | 422 |  |  | (21.4) | % |  | (20.8) | % |  | $ | 655 |  |  | $ | 765 |  |  | (14.2) | % |  | (13.7) | %\nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Therapeutic | United States |  | $ | 557 |  |  | $ | 488 |  |  | 14.2 | % |  | 14.2 | % |  | $ | 1,057 |  |  | $ | 917 |  |  | 15.3 | % |  | 15.3 | %\n | International |  | 121 |  |  | 115 |  |  | 5.6 | % |  | 15.6 | % |  | 235 |  |  | 218 |  |  | 8.0 | % |  | 16.3 | %\n | Total |  | $ | 678 |  |  | $ | 603 |  |  | 12.6 | % |  | 14.5 | % |  | $ | 1,292 |  |  | $ | 1,135 |  |  | 13.9 | % |  | 15.5 | %\nVraylar | United States |  | $ | 492 |  |  | $ | 432 |  |  | 13.9 | % |  | 13.9 | % |  | $ | 919 |  |  | $ | 778 |  |  | 18.1 | % |  | 18.1 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDuodopa | United States |  | $ | 26 |  |  | $ | 25 |  |  | 3.2 | % |  | 3.2 | % |  | $ | 50 |  |  | $ | 50 |  |  | (1.2) | % |  | (1.2) | %\n | International |  | 94 |  |  | 102 |  |  | (7.4) | % |  | 2.2 | % |  | 191 |  |  | 206 |  |  | (7.2) | % |  | 1.3 | %\n | Total |  | $ | 120 |  |  | $ | 127 |  |  | (5.4) | % |  | 2.3 | % |  | $ | 241 |  |  | $ | 256 |  |  | (6.0) | % |  | 0.8 | %\nUbrelvy | United States |  | $ | 185 |  |  | $ | 126 |  |  | 47.6 | % |  | 47.6 | % |  | $ | 323 |  |  | $ | 207 |  |  | 56.4 | % |  | 56.4 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nQulipta | United States |  | $ | 33 |  |  | $ | \u2014 |  |  | n/m |  | n/m |  | $ | 44 |  |  | $ | \u2014 |  |  | n/m |  | n/m\nOther Neuroscience | United States |  | $ | 145 |  |  | $ | 167 |  |  | (13.6) | % |  | (13.6) | % |  | $ | 318 |  |  | $ | 323 |  |  | (1.7) | % |  | (1.7) | %\n | International |  | 5 |  |  | 4 |  |  | 9.6 | % |  | 12.9 | % |  | 9 |  |  | 8 |  |  | 10.4 | % |  | 12.6 | %\n | Total |  | $ | 150 |  |  | $ | 171 |  |  | (12.9) | % |  | (12.8) | % |  | $ | 327 |  |  | $ | 331 |  |  | (1.4) | % |  | (1.3) | %  |  |  |  |  | \n2022 Form 10-Q| | 30  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedJune 30, |  | Percent\u00a0change |  | Six months endedJune 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \nEye Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLumigan/Ganfort | United States |  | $ | 60 |  |  | $ | 72 |  |  | (17.4) | % |  | (17.4) | % |  | $ | 127 |  |  | $ | 138 |  |  | (8.3) | % |  | (8.3) | %\n | International |  | 70 |  |  | 77 |  |  | (8.1) | % |  | (0.9) | % |  | 143 |  |  | 154 |  |  | (6.9) | % |  | (0.1) | %\n | Total |  | $ | 130 |  |  | $ | 149 |  |  | (12.5) | % |  | (8.7) | % |  | $ | 270 |  |  | $ | 292 |  |  | (7.5) | % |  | (3.9) | %\nAlphagan/Combigan | United States |  | $ | 54 |  |  | $ | 102 |  |  | (48.5) | % |  | (48.5) | % |  | $ | 124 |  |  | $ | 182 |  |  | (32.3) | % |  | (32.3) | %\n | International |  | 38 |  |  | 40 |  |  | (2.3) | % |  | 6.6 | % |  | 75 |  |  | 78 |  |  | (3.1) | % |  | 6.0 | %\n | Total |  | $ | 92 |  |  | $ | 142 |  |  | (35.6) | % |  | (33.1) | % |  | $ | 199 |  |  | $ | 260 |  |  | (23.6) | % |  | (20.9) | %\nRestasis | United States |  | $ | 151 |  |  | $ | 312 |  |  | (51.5) | % |  | (51.5) | % |  | $ | 386 |  |  | $ | 579 |  |  | (33.2) | % |  | (33.2) | %\n | International |  | 17 |  |  | 15 |  |  | 14.9 | % |  | 24.2 | % |  | 28 |  |  | 28 |  |  | (0.2) | % |  | 14.0 | %\n | Total |  | $ | 168 |  |  | $ | 327 |  |  | (48.4) | % |  | (48.0) | % |  | $ | 414 |  |  | $ | 607 |  |  | (31.7) | % |  | (31.0) | %\nOther Eye Care | United States |  | $ | 142 |  |  | $ | 130 |  |  | 9.7 | % |  | 9.7 | % |  | $ | 266 |  |  | $ | 247 |  |  | 7.7 | % |  | 7.7 | %\n | International |  | 185 |  |  | 171 |  |  | 7.4 | % |  | 16.0 | % |  | 339 |  |  | 330 |  |  | 2.6 | % |  | 10.5 | %\n | Total |  | $ | 327 |  |  | $ | 301 |  |  | 8.4 | % |  | 13.2 | % |  | $ | 605 |  |  | $ | 577 |  |  | 4.8 | % |  | 9.3 | %\nOther Key Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMavyret | United States |  | $ | 203 |  |  | $ | 204 |  |  | 0.2 | % |  | 0.2 | % |  | $ | 372 |  |  | $ | 374 |  |  | (0.4) | % |  | (0.4) | %\n | International |  | 195 |  |  | 238 |  |  | (18.0) | % |  | (9.8) | % |  | 406 |  |  | 483 |  |  | (15.9) | % |  | (8.4) | %\n | Total |  | $ | 398 |  |  | $ | 442 |  |  | (9.7) | % |  | (5.3) | % |  | $ | 778 |  |  | $ | 857 |  |  | (9.1) | % |  | (4.9) | %\nCreon | United States |  | $ | 318 |  |  | $ | 280 |  |  | 13.6 | % |  | 13.6 | % |  | $ | 605 |  |  | $ | 554 |  |  | 9.2 | % |  | 9.2 | %\nLinzess/Constella | United States |  | $ | 247 |  |  | $ | 260 |  |  | (4.2) | % |  | (4.2) | % |  | $ | 480 |  |  | $ | 475 |  |  | 1.3 | % |  | 1.3 | %\n | International |  | 8 |  |  | 8 |  |  | (12.5) | % |  | (7.8) | % |  | 15 |  |  | 15 |  |  | (3.8) | % |  | 0.7 | %\n | Total |  | $ | 255 |  |  | $ | 268 |  |  | (4.5) | % |  | (4.4) | % |  | $ | 495 |  |  | $ | 490 |  |  | 1.1 | % |  | 1.2 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAll other |  |  | $ | 1,009 |  |  | $ | 1,221 |  |  | (17.5) | % |  | (16.4) | % |  | $ | 2,220 |  |  | $ | 2,697 |  |  | (17.8) | % |  | (16.8) | %\nTotal net revenues |  | $ | 14,583 |  |  | $ | 13,959 |  |  | 4.5 | % |  | 6.1 | % |  | $ | 28,121 |  |  | $ | 26,969 |  |  | 4.3 | % |  | 5.7 | %  |  |  |  |  | \n2022 Form 10-Q| | 31  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\nGross margin |  | $ | 10,413 |  | $ | 9,436 |  | 10 | % |  | $ | 19,899 |  | $ | 18,233 |  | 9 | %\nas a % of net revenues |  | 71 | % |  | 68 | % |  |  |  | 71 | % |  | 68 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\nSelling, general and administrative |  | $ | 5,412 |  | $ | 3,164 |  | 71 | % |  | $ | 8,539 |  | $ | 6,006 |  | 42 | %\nas a % of net revenues |  | 37 | % |  | 23 | % |  |  |  | 30 | % |  | 22 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\nResearch and development |  | $ | 1,609 |  |  | $ | 1,767 |  |  | (9) | % |  | $ | 3,106 |  | $ | 3,434 |  | (10) | %\nas a % of net revenues |  | 11 | % |  | 13 | % |  |  |  | 11 | % |  | 13 | % |  | \nAcquired IPR&D and milestones |  | $ | 269 |  |  | $ | 132 |  |  | >100% |  | $ | 414 |  | $ | 317 |  | 31 | %  |  |  |  |  | \n2022 Form 10-Q| | 32  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest expense |  | $ | 556 |  |  | $ | 615 |  |  | $ | 1,104 |  |  | $ | 1,247 | \nInterest income |  | (24) |  |  | (9) |  |  | (33) |  |  | (19) | \nInterest expense, net |  | $ | 532 |  |  | $ | 606 |  |  | $ | 1,071 |  |  | $ | 1,228 | \n |  |  |  |  |  |  |  | \nNet foreign exchange loss |  | $ | 47 |  |  | $ | 14 |  |  | $ | 72 |  |  | $ | 23 | \nOther expense, net |  | 1,533 |  |  | 2,658 |  |  | 757 |  |  | 2,263 |   |  |  |  |  | \n2022 Form 10-Q| | 33  |  |  |  |  |  |  |  |  |  |  | \n | Six months endedJune 30,\n(in\u00a0millions) | 2022 |  | 2021\nCash flows provided by (used in): |  |  | \nOperating activities | $ | 9,913 |  |  | $ | 9,767 | \nInvesting activities | (1,461) |  |  | (584) | \nFinancing activities | (9,651) |  |  | (9,058) |   |  |  |  |  | \n2022 Form 10-Q| | 34  |  | \n  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 35  |  |  |  |  | \n2022 Form 10-Q| | 36  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | (a)\u00a0TotalNumber\u00a0ofShares(or Units)Purchased |  | (b)\u00a0AveragePrice\u00a0Paidper\u00a0Share(or\u00a0Unit) |  | (c)\u00a0Total\u00a0Numberof\u00a0Shares\u00a0(orUnits)\u00a0Purchasedas\u00a0Part\u00a0of\u00a0PubliclyAnnounced\u00a0Plansor\u00a0Programs |  | (d)\u00a0MaximumNumber\u00a0(orApproximateDollar\u00a0Value)\u00a0ofShares\u00a0(or\u00a0Units)that\u00a0May\u00a0Yet\u00a0BePurchased\u00a0Underthe\u00a0Plans\u00a0orPrograms | \nApril 1, 2022 - April 30, 2022 | 28,809 |  | (1) | $162.39 | (1) | \u2014 |  |  | $1,393,714,917 | \nMay 1, 2022 - May 31, 2022 | 839 |  | (1) | $151.92 | (1) | \u2014 |  |  | $1,393,714,917 | \nJune 1, 2022 - June 30, 2022 | 989 |  | (1) | $146.78 | (1) | \u2014 |  |  | $1,393,714,917 | \nTotal | 30,637 |  | (1) | $161.60 | (1) | \u2014 |  |  | $1,393,714,917 |   |  |  |  |  | \n2022 Form 10-Q| | 37  |  | \n  |  |  |  |  |  |  |  | \nExhibit\u00a0No. |  | Exhibit\u00a0Description\n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n10.6 |  | AbbVie Non-Employee Directors\u2019 Fee Plan, as amended and restated*\n |  | \n31.1 |  | Certification of Chief Executive Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)).\n |  | \n31.2 |  | Certification of Chief Financial Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)).\n |  | \n32.1 |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002.\n |  | \n32.2 |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002.\n |  | \n101 |  | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form\u00a010-Q for the quarter ended June 30, 2022, filed on August\u00a04, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)\u00a0Condensed Consolidated Statements of Earnings; (ii)\u00a0Condensed Consolidated Statements of Comprehensive Income; (iii)\u00a0Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)\u00a0Condensed Consolidated Statements of Cash Flows; and (vi)\u00a0the Notes to Condensed Consolidated Financial Statements.\n |  | \n104 |  | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  | \n2022 Form 10-Q| | 38  |  |  |  |  |  |  |  | \n |  | ABBVIE INC.\n |  | \n |  | \n | By: | /s/ Scott T. Reents\n |  | Scott T. Reents\n |  | Senior Vice President,\n |  | Chief Financial Officer (Principal Financial Officer)  |  |  |  |  | \n2022 Form 10-Q| | 39"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For AbbVie, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \n(Exact name of registrant as specified in its charter)\nDelaware |  | 32-0375147\n(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)  |  |  |  |  |  |  |  |  |  |  | \nLarge Accelerated Filer | \u2612 | Accelerated Filer | \u2610\nNon-Accelerated Filer | \u2610 | Smaller reporting company | \u2610\n |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, par value $0.01 per share |  | ABBV |  | New York Stock Exchange\n |  |  |  | Chicago Stock Exchange\n1.500% Senior Notes due 2023 |  | ABBV23B |  | New York Stock Exchange\n1.375% Senior Notes due 2024 |  | ABBV24 |  | New York Stock Exchange\n1.250% Senior Notes due 2024 |  | ABBV24B |  | New York Stock Exchange\n0.750% Senior Notes due 2027 |  | ABBV27 |  | New York Stock Exchange\n2.125% Senior Notes due 2028 |  | ABBV28 |  | New York Stock Exchange\n2.625% Senior Notes due 2028 |  | ABBV28B |  | New York Stock Exchange\n2.125% Senior Notes due 2029 |  | ABBV29 |  | New York Stock Exchange\n1.250% Senior Notes due 2031 |  | ABBV31 |  | New York Stock Exchange  |  | \n  |  |  |  |  |  |  |  | \nPART\u00a0I. | FINANCIAL INFORMATION\n |  | Page\n |  | \nItem 1. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 1\nItem 2. | MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 25\nItem 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 36\nItem 4. | CONTROLS AND PROCEDURES | 36\n |  | \nPART\u00a0II. | OTHER INFORMATION\n |  | \nItem 1. | LEGAL PROCEEDINGS | 37\n |  | \nItem 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 37\nItem 6. | EXHIBITS | 38  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nNet revenues |  | $ | 14,812 |  |  | $ | 14,342 |  |  | $ | 42,933 |  |  | $ | 41,311 | \n |  |  |  |  |  |  |  | \nCost of products sold |  | 5,022 |  |  | 4,390 |  |  | 13,244 |  |  | 13,126 | \nSelling, general and administrative |  | 3,304 |  |  | 3,083 |  |  | 11,843 |  |  | 9,089 | \nResearch and development |  | 1,614 |  |  | 1,661 |  |  | 4,720 |  |  | 5,095 | \nAcquired IPR&D and milestones |  | 40 |  |  | 402 |  |  | 454 |  |  | 719 | \nOther operating expense, net |  | 229 |  |  | 500 |  |  | 57 |  |  | 432 | \nTotal operating costs and expenses |  | 10,209 |  |  | 10,036 |  |  | 30,318 |  |  | 28,461 | \nOperating earnings |  | 4,603 |  |  | 4,306 |  |  | 12,615 |  |  | 12,850 | \n |  |  |  |  |  |  |  | \nInterest expense, net |  | 497 |  |  | 585 |  |  | 1,568 |  |  | 1,813 | \nNet foreign exchange loss |  | 36 |  |  | 12 |  |  | 108 |  |  | 35 | \nOther expense (income), net |  | (330) |  |  | 21 |  |  | 427 |  |  | 2,284 | \nEarnings before income tax expense |  | 4,400 |  |  | 3,688 |  |  | 10,512 |  |  | 8,718 | \nIncome tax expense |  | 448 |  |  | 508 |  |  | 1,139 |  |  | 1,214 | \nNet earnings |  | 3,952 |  |  | 3,180 |  |  | 9,373 |  |  | 7,504 | \nNet earnings attributable to noncontrolling interest |  | 3 |  |  | 1 |  |  | 10 |  |  | 6 | \nNet earnings attributable to AbbVie Inc. |  | $ | 3,949 |  |  | $ | 3,179 |  |  | $ | 9,363 |  |  | $ | 7,498 | \n |  |  |  |  |  |  |  | \nPer share data |  |  |  |  |  |  |  | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 2.22 |  |  | $ | 1.78 |  |  | $ | 5.26 |  |  | $ | 4.21 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 2.21 |  |  | $ | 1.78 |  |  | $ | 5.24 |  |  | $ | 4.19 | \n |  |  |  |  |  |  |  | \nWeighted-average basic shares outstanding |  | 1,771 |  |  | 1,770 |  |  | 1,771 |  |  | 1,769 | \nWeighted-average diluted shares outstanding |  | 1,776 |  |  | 1,777 |  |  | 1,777 |  |  | 1,776 |   |  |  |  |  | \n2022 Form 10-Q| | 1  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nNet earnings | $ | 3,952 |  |  | $ | 3,180 |  |  | $ | 9,373 |  |  | $ | 7,504 | \n |  |  |  |  |  |  | \nForeign currency translation adjustments, net of tax expense (benefit) of $(11) for the three months and $(30) for the nine months ended September 30, 2022 and $(8) for the three months and $(32) for the nine months ended September 30, 2021 | (989) |  |  | (361) |  |  | (2,043) |  |  | (794) | \nNet investment hedging activities, net of tax expense (benefit) of $165for the three months and $348for the nine months ended September 30, 2022 and $51for the three months and $123for the nine months ended September 30, 2021 | 599 |  |  | 184 |  |  | 1,265 |  |  | 444 | \nPension and post-employment benefits, net of tax expense (benefit) of $14for the three months and $35for the nine months ended September 30, 2022 and $17for the three months and $50for the nine months ended September 30, 2021 | 60 |  |  | 67 |  |  | 136 |  |  | 196 | \n |  |  |  |  |  |  | \nCash flow hedging activities, net of tax expense (benefit) of $14for the three months and $17for the nine months ended September 30, 2022 and $13for the three months and $16for the nine months ended September 30, 2021 | 83 |  |  | 57 |  |  | 98 |  |  | 115 | \nOther comprehensive loss | (247) |  |  | (53) |  |  | (544) |  |  | (39) | \nComprehensive income | 3,705 |  |  | 3,127 |  |  | 8,829 |  |  | 7,465 | \nComprehensive income attributable to noncontrolling interest | 3 |  |  | 1 |  |  | 10 |  |  | 6 | \nComprehensive income attributable to AbbVie Inc. | $ | 3,702 |  |  | $ | 3,126 |  |  | $ | 8,819 |  |  | $ | 7,459 |   |  |  |  |  | \n2022 Form 10-Q| | 2  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions,\u00a0except\u00a0share\u00a0data) | September 30,2022 |  | December 31,2021\n | (unaudited) |  | \nAssets |  |  | \nCurrent assets |  |  | \nCash and equivalents | $ | 11,832 |  |  | $ | 9,746 | \nShort-term investments | 47 |  |  | 84 | \nAccounts receivable, net | 10,743 |  |  | 9,977 | \nInventories | 3,172 |  |  | 3,128 | \nPrepaid expenses and other | 4,570 |  |  | 4,993 | \nTotal current assets | 30,364 |  |  | 27,928 | \n |  |  | \nInvestments | 235 |  |  | 277 | \nProperty and equipment, net | 4,893 |  |  | 5,110 | \nIntangible assets, net | 68,725 |  |  | 75,951 | \nGoodwill | 31,726 |  |  | 32,379 | \nOther assets | 5,382 |  |  | 4,884 | \nTotal assets | $ | 141,325 |  |  | $ | 146,529 | \n |  |  | \nLiabilities and Equity |  |  | \nCurrent liabilities |  |  | \nShort-term borrowings | $ | 10 |  |  | $ | 14 | \nCurrent portion of long-term debt and finance lease obligations | 9,197 |  |  | 12,481 | \nAccounts payable and accrued liabilities | 23,505 |  |  | 22,699 | \nTotal current liabilities | 32,712 |  |  | 35,194 | \n |  |  | \nLong-term debt and finance lease obligations | 60,399 |  |  | 64,189 | \nDeferred income taxes | 1,972 |  |  | 3,009 | \nOther long-term liabilities | 30,215 |  |  | 28,701 | \n |  |  | \nCommitments and contingencies |  |  | \n |  |  | \nStockholders' equity |  |  | \nCommon stock, $0.01par value,4,000,000,000shares authorized,1,812,973,038shares issued as of September 30, 2022 and1,803,195,293as of December 31, 2021 | 18 |  |  | 18 | \nCommon stock held in treasury, at cost,44,572,117shares as of September 30, 2022 and34,857,597as of December 31, 2021 | (4,590) |  |  | (3,143) | \nAdditional paid-in capital | 19,056 |  |  | 18,305 | \nRetained earnings | 4,953 |  |  | 3,127 | \nAccumulated other comprehensive loss | (3,443) |  |  | (2,899) | \nTotal stockholders' equity | 15,994 |  |  | 15,408 | \nNoncontrolling interest | 33 |  |  | 28 | \nTotal equity | 16,027 |  |  | 15,436 | \n |  |  | \nTotal liabilities and equity | $ | 141,325 |  |  | $ | 146,529 |   |  |  |  |  | \n2022 Form 10-Q| | 3  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Common shares outstanding |  | Common stock |  | Treasury stock |  | Additional paid-in capital |  | Retained earnings |  | Accumulated other comprehensive loss |  | Noncontrolling interest |  | Total\nBalance at June 30, 2021 | 1,767 |  |  | $ | 18 |  |  | $ | (3,022) |  |  | $ | 17,936 |  |  | $ | 740 |  |  | $ | (3,103) |  |  | $ | 25 |  |  | $ | 12,594 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,179 |  |  | \u2014 |  |  | \u2014 |  |  | 3,179 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (53) |  |  | \u2014 |  |  | (53) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,319) |  |  | \u2014 |  |  | \u2014 |  |  | (2,319) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (6) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6) | \nStock-based compensation plans and other | 1 |  |  | \u2014 |  |  | 8 |  |  | 172 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 180 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 2 | \nBalance at September 30, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,020) |  |  | $ | 18,108 |  |  | $ | 1,600 |  |  | $ | (3,156) |  |  | $ | 27 |  |  | $ | 13,577 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,591) |  |  | $ | 18,906 |  |  | $ | 3,516 |  |  | $ | (3,196) |  |  | $ | 35 |  |  | $ | 14,688 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,949 |  |  | \u2014 |  |  | \u2014 |  |  | 3,949 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (247) |  |  | \u2014 |  |  | (247) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,512) |  |  | \u2014 |  |  | \u2014 |  |  | (2,512) | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) | \nStock-based compensation plans and other | \u2014 |  |  | \u2014 |  |  | 5 |  |  | 150 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 155 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | (2) | \nBalance at September 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,590) |  |  | $ | 19,056 |  |  | $ | 4,953 |  |  | $ | (3,443) |  |  | $ | 33 |  |  | $ | 16,027 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2020 | 1,765 |  |  | $ | 18 |  |  | $ | (2,264) |  |  | $ | 17,384 |  |  | $ | 1,055 |  |  | $ | (3,117) |  |  | $ | 21 |  |  | $ | 13,097 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7,498 |  |  | \u2014 |  |  | \u2014 |  |  | 7,498 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (39) |  |  | \u2014 |  |  | (39) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6,953) |  |  | \u2014 |  |  | \u2014 |  |  | (6,953) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchases of treasury stock | (7) |  |  | \u2014 |  |  | (803) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (803) | \nStock-based compensation plans and other | 10 |  |  | \u2014 |  |  | 47 |  |  | 724 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 771 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6 |  |  | 6 | \nBalance at September 30, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,020) |  |  | $ | 18,108 |  |  | $ | 1,600 |  |  | $ | (3,156) |  |  | $ | 27 |  |  | $ | 13,577 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,143) |  |  | $ | 18,305 |  |  | $ | 3,127 |  |  | $ | (2,899) |  |  | $ | 28 |  |  | $ | 15,436 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 9,363 |  |  | \u2014 |  |  | \u2014 |  |  | 9,363 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (544) |  |  | \u2014 |  |  | (544) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7,537) |  |  | \u2014 |  |  | \u2014 |  |  | (7,537) | \nPurchases of treasury stock | (10) |  |  | \u2014 |  |  | (1,483) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,483) | \nStock-based compensation plans and other | 10 |  |  | \u2014 |  |  | 36 |  |  | 751 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 787 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 5 |  |  | 5 | \nBalance at September 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,590) |  |  | $ | 19,056 |  |  | $ | 4,953 |  |  | $ | (3,443) |  |  | $ | 33 |  |  | $ | 16,027 |   |  |  |  |  | \n2022 Form 10-Q| | 4  |  |  |  |  |  |  |  |  |  |  | \n | Nine months endedSeptember 30,\n(in\u00a0millions)\u00a0(brackets\u00a0denote\u00a0cash\u00a0outflows) | 2022 |  | 2021\nCash flows from operating activities |  |  | \nNet earnings | $ | 9,373 |  |  | $ | 7,504 | \nAdjustments to reconcile net earnings to net cash from operating activities: |  |  | \nDepreciation | 582 |  |  | 630 | \nAmortization of intangible assets | 5,728 |  |  | 5,912 | \nDeferred income taxes | (1,415) |  |  | (153) | \nChange in fair value of contingent consideration liabilities | 647 |  |  | 2,447 | \nStock-based compensation | 539 |  |  | 563 | \nAcquired IPR&D and milestones | 454 |  |  | 719 | \nOther charges related to collaborations | \u2014 |  |  | 500 | \nGain on divestitures | (172) |  |  | (68) | \nNon-cash litigation reserve adjustments, net of cash payments | 2,261 |  |  | 21 | \nImpairment of intangible assets | 770 |  |  | 50 | \nOther, net | (151) |  |  | (185) | \nChanges in operating assets and liabilities, net of acquisitions: |  |  | \nAccounts receivable | (1,039) |  |  | (572) | \nInventories | (516) |  |  | (30) | \nPrepaid expenses and other assets | (60) |  |  | (462) | \nAccounts payable and other liabilities | 330 |  |  | 1,454 | \nIncome tax assets and liabilities, net | 184 |  |  | (628) | \nCash flows from operating activities | 17,515 |  |  | 17,702 | \n |  |  | \nCash flows from investing activities |  |  | \n |  |  | \nAcquisitions and investments | (494) |  |  | (837) | \nAcquisitions of property and equipment | (482) |  |  | (600) | \nPurchases of investment securities | (1,428) |  |  | (73) | \nSales and maturities of investment securities | 1,460 |  |  | 88 | \n |  |  | \nOther, net | 769 |  |  | 223 | \nCash flows from investing activities | (175) |  |  | (1,199) | \n |  |  | \nCash flows from financing activities |  |  | \n |  |  | \n |  |  | \n |  |  | \nProceeds from issuance of long-term debt | 2,000 |  |  | 1,000 | \nRepayments of long-term debt and finance lease obligations | (7,582) |  |  | (5,662) | \n |  |  | \nDividends paid | (7,537) |  |  | (6,947) | \nPurchases of treasury stock | (1,483) |  |  | (803) | \nProceeds from the exercise of stock options | 209 |  |  | 169 | \nPayments of contingent consideration liabilities | (817) |  |  | (480) | \nOther, net | 41 |  |  | 22 | \nCash flows from financing activities | (15,169) |  |  | (12,701) | \nEffect of exchange rate changes on cash and equivalents | (85) |  |  | (69) | \nNet change in cash and equivalents | 2,086 |  |  | 3,733 | \nCash and equivalents, beginning of period | 9,746 |  |  | 8,449 | \n |  |  | \nCash and equivalents, end of period | $ | 11,832 |  |  | $ | 12,182 | \n |  |  | \n |  |  | \n |  |  |   |  |  |  |  | \n2022 Form 10-Q| | 5  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest expense |  | $ | 560 |  |  | $ | 596 |  |  | $ | 1,664 |  |  | $ | 1,843 | \nInterest income |  | (63) |  |  | (11) |  |  | (96) |  |  | (30) | \nInterest expense, net |  | $ | 497 |  |  | $ | 585 |  |  | $ | 1,568 |  |  | $ | 1,813 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | September 30,2022 |  | December 31,2021\nFinished goods | $ | 903 |  |  | $ | 932 | \nWork-in-process | 1,309 |  |  | 1,193 | \nRaw materials | 960 |  |  | 1,003 | \nInventories | $ | 3,172 |  |  | $ | 3,128 |   |  |  |  |  | \n2022 Form 10-Q| | 6  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | September 30,2022 |  | December 31,2021\nProperty and equipment, gross | $ | 10,679 |  |  | $ | 10,727 | \nAccumulated depreciation | (5,786) |  |  | (5,617) | \nProperty and equipment, net | $ | 4,893 |  |  | $ | 5,110 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions, except per share data) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nBasic EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 3,949 |  |  | $ | 3,179 |  |  | $ | 9,363 |  |  | $ | 7,498 | \nEarnings allocated to participating securities |  | 18 |  |  | 21 |  |  | 43 |  |  | 53 | \nEarnings available to common shareholders |  | $ | 3,931 |  |  | $ | 3,158 |  |  | $ | 9,320 |  |  | $ | 7,445 | \nWeighted-average basic shares outstanding |  | 1,771 |  |  | 1,770 |  |  | 1,771 |  |  | 1,769 | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 2.22 |  |  | $ | 1.78 |  |  | $ | 5.26 |  |  | $ | 4.21 | \n |  |  |  |  |  |  |  | \nDiluted EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 3,949 |  |  | $ | 3,179 |  |  | $ | 9,363 |  |  | $ | 7,498 | \nEarnings allocated to participating securities |  | 18 |  |  | 21 |  |  | 43 |  |  | 53 | \nEarnings available to common shareholders |  | $ | 3,931 |  |  | $ | 3,158 |  |  | $ | 9,320 |  |  | $ | 7,445 | \nWeighted-average shares of common stock outstanding |  | 1,771 |  |  | 1,770 |  |  | 1,771 |  |  | 1,769 | \nEffect of dilutive securities |  | 5 |  |  | 7 |  |  | 6 |  |  | 7 | \nWeighted-average diluted shares outstanding |  | 1,776 |  |  | 1,777 |  |  | 1,777 |  |  | 1,776 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 2.21 |  |  | $ | 1.78 |  |  | $ | 5.24 |  |  | $ | 4.19 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 7  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 8  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nUnited States - Janssen's share of profits (included in cost of products sold) |  | $ | 398 |  |  | $ | 518 |  |  | $ | 1,210 |  |  | $ | 1,497 | \nInternational - AbbVie's share of profits (included in net revenues) |  | 286 |  |  | 265 |  |  | 868 |  |  | 816 | \nGlobal - AbbVie's share of other costs (included in respective line items) |  | 63 |  |  | 76 |  |  | 196 |  |  | 220 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nGenentech's share of profits, including royalties (included in cost of products sold) |  | $ | 204 |  |  | $ | 187 |  |  | $ | 578 |  |  | $ | 514 | \nAbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  | 10 |  |  | 10 |  |  | 27 |  |  | 29 | \nAbbVie's share of development costs (included in R&D) |  | 29 |  |  | 34 |  |  | 87 |  |  | 110 |   |  |  |  |  | \n2022 Form 10-Q| | 9  |  | \n  |  |  |  |  | \n(in\u00a0millions) | \nBalance as of December 31, 2021 | $ | 32,379 | \nForeign currency translation adjustments | (653) | \nBalance as of September 30, 2022 | $ | 31,726 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\n(in\u00a0millions) | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount |  | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount\nDefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  | \nDeveloped product rights | $ | 87,313 |  |  | $ | (23,368) |  |  | $ | 63,945 |  |  | $ | 88,945 |  |  | $ | (18,463) |  |  | $ | 70,482 | \nLicense agreements | 8,486 |  |  | (4,376) |  |  | 4,110 |  |  | 8,487 |  |  | (3,688) |  |  | 4,799 | \nTotal definite-lived intangible assets | 95,799 |  |  | (27,744) |  |  | 68,055 |  |  | 97,432 |  |  | (22,151) |  |  | 75,281 | \nIndefinite-lived intangible assets | 670 |  |  | \u2014 |  |  | 670 |  |  | 670 |  |  | \u2014 |  |  | 670 | \nTotal intangible assets, net | $ | 96,469 |  |  | $ | (27,744) |  |  | $ | 68,725 |  |  | $ | 98,102 |  |  | $ | (22,151) |  |  | $ | 75,951 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 10  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Severance and employee benefits |  |  |  |  | Other integration\n |  |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30, |  |  |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |  | 2022 | 2021 |  | 2022 |  | 2021\nCost of products sold |  |  |  |  | $ | \u2014 |  |  | $ | 2 |  |  | $ | (4) |  |  | $ | 8 |  |  |  |  |  |  | $ | 24 |  | $ | 44 |  |  | $ | 85 |  |  | $ | 84 | \nResearch and development |  |  |  |  | 1 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  |  |  |  |  | 3 |  | 18 |  |  | 12 |  |  | 87 | \nSelling, general and administrative |  |  |  |  | 4 |  |  | 18 |  |  | 4 |  |  | 47 |  |  |  |  |  |  | 84 |  | 88 |  |  | 230 |  |  | 213 | \nTotal charges |  |  |  |  | $ | 5 |  |  | $ | 20 |  |  | $ | 2 |  |  | $ | 55 |  |  |  |  |  |  | $ | 111 |  | $ | 150 |  |  | $ | 327 |  |  | $ | 384 |   |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Severance and employee benefits |  | Other integration\nAccrued balance as of December 31, 2021 | $ | 222 |  |  | $ | 33 | \nCharges | 2 |  |  | 316 | \n |  |  | \n |  |  | \nPayments and other adjustments | (107) |  |  | (343) | \nAccrued balance as of September 30, 2022 | $ | 117 |  |  | $ | 6 |   |  |  |  |  | \n(in\u00a0millions) | \nAccrued balance as of December 31, 2021 | $ | 33 | \nRestructuring charges | 112 | \nPayments and other adjustments | (25) | \nAccrued balance as of September 30, 2022 | $ | 120 |   |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 11  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair value \u2013Derivatives in asset position |  | Fair value \u2013Derivatives\u00a0in\u00a0liability\u00a0position\n(in\u00a0millions) | Balance\u00a0sheet\u00a0caption | September 30, 2022 | December 31, 2021 |  | Balance\u00a0sheet\u00a0caption | September 30, 2022 | December 31, 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | $ | 153 |  | $ | 51 |  |  | Accounts payable and accrued liabilities | $ | 9 |  | $ | 2 | \nDesignated as cash flow hedges | Other assets | 1 |  | \u2014 |  |  | Other long-term liabilities | \u2014 |  | \u2014 | \nDesignated as net investment hedges | Prepaid expenses and other | 70 |  | 149 |  |  | Accounts payable and accrued liabilities | \u2014 |  | \u2014 | \nDesignated as net investment hedges | Other assets | 283 |  | 15 |  |  | Other long-term liabilities | \u2014 |  | \u2014 | \nNot designated as hedges | Prepaid expenses and other | 60 |  | 26 |  |  | Accounts payable and accrued liabilities | 86 |  | 13 | \nInterest rate swap contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | 2 |  | \u2014 |  |  | Accounts payable and accrued liabilities | \u2014 |  | 7 | \nDesignated as fair value hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 21 |  | \u2014 | \nDesignated as fair value hedges | Other assets | \u2014 |  | 26 |  |  | Other long-term liabilities | 393 |  | 15 | \nTotal derivatives |  | $ | 569 |  | $ | 267 |  |  |  | $ | 509 |  | $ | 37 |   |  |  |  |  | \n2022 Form 10-Q| | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  |  | \nDesignated as cash flow hedges |  | $ | 124 |  |  | $ | 43 |  |  | $ | 171 |  |  | $ | 67 | \nDesignated as net investment hedges |  | 362 |  |  | 101 |  |  | 748 |  |  | 186 | \nInterest rate swap contracts designated as cash flow hedges |  | \u2014 |  |  | (1) |  |  | 6 |  |  | \u2014 | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) | Statement\u00a0of earnings caption |  | 2022 |  | 2021 |  | 2022 |  | 2021\nForeign currency forward exchange contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Cost of products sold |  | $ | 21 |  |  | $ | (28) |  |  | $ | 47 |  |  | $ | (62) | \nDesignated as net investment hedges | Interest expense, net |  | 29 |  |  | 7 |  |  | 67 |  |  | 16 | \nNot designated as hedges | Net foreign exchange loss |  | (121) |  |  | (25) |  |  | (285) |  |  | (53) | \nTreasury rate lock agreements designated as cash flow hedges | Interest expense, net |  | 6 |  |  | 6 |  |  | 18 |  |  | 18 | \nInterest rate swap contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Interest expense, net |  | \u2014 |  |  | (6) |  |  | (3) |  |  | (20) | \nDesignated as fair value hedges | Interest expense, net |  | (141) |  |  | (5) |  |  | (424) |  |  | (73) | \nDebt designated as hedged item in fair value hedges | Interest expense, net |  | 141 |  |  | 5 |  |  | 424 |  |  | 73 |   |  |  |  |  | \n2022 Form 10-Q| | 13  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 11,832 |  |  | $ | 4,303 |  |  | $ | 7,529 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 36 |  |  | \u2014 |  |  | 36 |  |  | \u2014 | \nDebt securities | 31 |  |  | \u2014 |  |  | 31 |  |  | \u2014 | \nEquity securities | 72 |  |  | 50 |  |  | 22 |  |  | \u2014 | \nInterest rate swap contracts | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 | \nForeign currency contracts | 567 |  |  | \u2014 |  |  | 567 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 12,540 |  |  | $ | 4,353 |  |  | $ | 8,187 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 414 |  |  | $ | \u2014 |  |  | $ | 414 |  |  | $ | \u2014 | \nForeign currency contracts | 95 |  |  | \u2014 |  |  | 95 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 14,556 |  |  | \u2014 |  |  | \u2014 |  |  | 14,556 | \nTotal liabilities | $ | 15,065 |  |  | $ | \u2014 |  |  | $ | 509 |  |  | $ | 14,556 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 9,746 |  |  | $ | 4,451 |  |  | $ | 5,295 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 45 |  |  | \u2014 |  |  | 45 |  |  | \u2014 | \nDebt securities | 46 |  |  | \u2014 |  |  | 46 |  |  | \u2014 | \nEquity securities | 121 |  |  | 100 |  |  | 21 |  |  | \u2014 | \nInterest rate swap contracts | 26 |  |  | \u2014 |  |  | 26 |  |  | \u2014 | \nForeign currency contracts | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 10,225 |  |  | $ | 4,551 |  |  | $ | 5,674 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 22 |  |  | $ | \u2014 |  |  | $ | 22 |  |  | $ | \u2014 | \nForeign currency contracts | 15 |  |  | \u2014 |  |  | 15 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 14,887 |  |  | \u2014 |  |  | \u2014 |  |  | 14,887 | \nTotal liabilities | $ | 14,924 |  |  | $ | \u2014 |  |  | $ | 37 |  |  | $ | 14,887 |   |  |  |  |  | \n2022 Form 10-Q| | 14  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\n(in\u00a0millions) | Range | Weighted average(a) |  | Range | Weighted average(a)\nDiscount rate | 4.1% -5.5% | 5.0% |  | 0.2%-2.6% | 1.7%\nProbability of payment for unachieved milestones | 89% -100% | 91% |  | 89% -100% | 90%\nProbability of payment for royalties by indication(b) | 56% -100% | 98% |  | 56% -100% | 96%\n |  |  |  |  | \nProjected year of payments | 2022-2034 | 2027 |  | 2022-2034 | 2027  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2022 |  | 2021\nBeginning balance |  | $ | 14,887 |  |  | $ | 12,997 | \nChange in fair value recognized in net earnings |  | 647 |  |  | 2,447 | \nPayments |  | (978) |  |  | (525) | \nEnding balance |  | $ | 14,556 |  |  | $ | 14,919 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 10 |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 10 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 9,215 |  | 9,191 |  |  | 9,071 |  |  | 120 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 60,740 |  | 53,834 |  |  | 53,093 |  |  | 741 |  |  | \u2014 | \nTotal liabilities | $ | 69,965 |  | $ | 63,035 |  |  | $ | 62,164 |  |  | $ | 871 |  |  | $ | \u2014 |   |  |  |  |  | \n2022 Form 10-Q| | 15  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 14 |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 14 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 12,455 |  | 11,830 |  |  | 11,329 |  |  | 501 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 64,113 |  | 71,810 |  |  | 70,757 |  |  | 1,053 |  |  | \u2014 | \nTotal liabilities | $ | 76,582 |  | $ | 83,654 |  |  | $ | 82,086 |  |  | $ | 1,568 |  |  | $ | \u2014 |   |  |  |  |  | \n2022 Form 10-Q| | 16  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Definedbenefit\u00a0plans |  | Other\u00a0post-employment\u00a0plans\n | Three months endedSeptember 30, |  | Nine months endedSeptember 30, |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021\nService cost | $ | 113 |  |  | $ | 110 |  |  | $ | 342 |  |  | $ | 331 |  |  | $ | 13 |  |  | $ | 12 |  |  | $ | 38 |  |  | $ | 36 | \nInterest cost | 74 |  |  | 59 |  |  | 223 |  |  | 177 |  |  | 6 |  |  | 5 |  |  | 18 |  |  | 14 | \nExpected return on plan assets | (177) |  |  | (166) |  |  | (536) |  |  | (498) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nAmortization of prior service cost (credit) | 1 |  |  | 1 |  |  | 2 |  |  | 2 |  |  | (10) |  |  | (10) |  |  | (29) |  |  | (29) | \nAmortization of actuarial loss | 57 |  |  | 72 |  |  | 173 |  |  | 217 |  |  | 7 |  |  | 8 |  |  | 20 |  |  | 24 | \nNet periodic benefit cost | $ | 68 |  |  | $ | 76 |  |  | $ | 204 |  |  | $ | 229 |  |  | $ | 16 |  |  | $ | 15 |  |  | $ | 47 |  |  | $ | 45 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nCost of products sold |  | $ | 8 |  |  | $ | 9 |  |  | $ | 33 |  |  | $ | 39 | \nResearch and development |  | 47 |  |  | 47 |  |  | 194 |  |  | 181 | \nSelling, general and administrative |  | 71 |  |  | 79 |  |  | 312 |  |  | 343 | \nPre-tax compensation expense |  | 126 |  |  | 135 |  |  | 539 |  |  | 563 | \nTax benefit |  | 25 |  |  | 27 |  |  | 102 |  |  | 101 | \nAfter-tax compensation expense |  | $ | 101 |  |  | $ | 108 |  |  | $ | 437 |  |  | $ | 462 |   |  |  |  |  | \n2022 Form 10-Q| | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2022 |  | 2021\nDate Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share\n10/28/22 |  | 02/15/23 |  | $ | 1.48 |  |  | 10/29/21 |  | 02/15/22 |  | $ | 1.41 | \n09/09/22 |  | 11/15/22 |  | $ | 1.41 |  |  | 09/10/21 |  | 11/15/21 |  | $ | 1.30 | \n06/23/22 |  | 08/15/22 |  | $ | 1.41 |  |  | 06/17/21 |  | 08/16/21 |  | $ | 1.30 | \n02/17/22 |  | 05/16/22 |  | $ | 1.41 |  |  | 02/18/21 |  | 05/14/21 |  | $ | 1.30 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2021 | $ | (570) |  |  | $ | (91) |  |  | $ | (2,546) |  |  |  |  | $ | 308 |  |  | $ | (2,899) | \nOther comprehensive income (loss) before reclassifications | (2,043) |  |  | 1,318 |  |  | 6 |  |  |  |  | 151 |  |  | (568) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (53) |  |  | 130 |  |  |  |  | (53) |  |  | 24 | \nNet current-period other comprehensive income (loss) | (2,043) |  |  | 1,265 |  |  | 136 |  |  |  |  | 98 |  |  | (544) | \nBalance as of September 30, 2022 | $ | (2,613) |  |  | $ | 1,174 |  |  | $ | (2,410) |  |  |  |  | $ | 406 |  |  | $ | (3,443) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2020 | $ | 583 |  |  | $ | (790) |  |  | $ | (3,067) |  |  |  |  | $ | 157 |  |  | $ | (3,117) | \nOther comprehensive income (loss) before reclassifications | (794) |  |  | 457 |  |  | 27 |  |  |  |  | 60 |  |  | (250) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (13) |  |  | 169 |  |  |  |  | 55 |  |  | 211 | \nNet current-period other comprehensive income (loss) | (794) |  |  | 444 |  |  | 196 |  |  |  |  | 115 |  |  | (39) | \nBalance as of September 30, 2021 | $ | (211) |  |  | $ | (346) |  |  | $ | (2,871) |  |  |  |  | $ | 272 |  |  | $ | (3,156) |   |  |  |  |  | \n2022 Form 10-Q| | 18  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) (brackets\u00a0denote\u00a0gains) | 2022 |  | 2021 |  | 2022 |  | 2021\nNet investment hedging activities |  |  |  |  |  |  | \nGains on derivative amount excluded from effectiveness testing(a) | $ | (29) |  |  | $ | (7) |  |  | $ | (67) |  |  | $ | (16) | \nTax expense | 6 |  |  | 1 |  |  | 14 |  |  | 3 | \nTotal reclassifications, net of tax | $ | (23) |  |  | $ | (6) |  |  | $ | (53) |  |  | $ | (13) | \nPension and post-employment benefits |  |  |  |  |  |  | \nAmortization of actuarial losses and other(b) | $ | 55 |  |  | $ | 71 |  |  | $ | 166 |  |  | $ | 214 | \nTax benefit | (12) |  |  | (15) |  |  | (36) |  |  | (45) | \nTotal reclassifications, net of tax | $ | 43 |  |  | $ | 56 |  |  | $ | 130 |  |  | $ | 169 | \nCash flow hedging activities |  |  |  |  |  |  | \nLosses (gains) on foreign currency forward exchange contracts(c) | $ | (21) |  |  | $ | 28 |  |  | $ | (47) |  |  | $ | 62 | \nGains on treasury rate lock agreements(a) | (6) |  |  | (6) |  |  | (18) |  |  | (18) | \nLosses on interest rate swap contracts(a) | \u2014 |  |  | 6 |  |  | 3 |  |  | 20 | \nTax expense (benefit) | 4 |  |  | (4) |  |  | 9 |  |  | (9) | \nTotal reclassifications, net of tax | $ | (23) |  |  | $ | 24 |  |  | $ | (53) |  |  | $ | 55 |   |  | \n  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 19  |  |  |  |  | \n2022 Form 10-Q| | 20  |  |  |  |  | \n2022 Form 10-Q| | 21  |  |  |  |  | \n2022 Form 10-Q| | 22  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n |  | \n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nImmunology |  |  |  |  |  |  | \nHumira | United States | $ | 4,956 |  |  | $ | 4,613 |  |  | $ | 13,613 |  |  | $ | 12,777 | \n | International | 603 |  |  | 812 |  |  | 2,045 |  |  | 2,583 | \n | Total | $ | 5,559 |  |  | $ | 5,425 |  |  | $ | 15,658 |  |  | $ | 15,360 | \nSkyrizi | United States | $ | 1,221 |  |  | $ | 679 |  |  | $ | 3,081 |  |  | $ | 1,725 | \n | International | 176 |  |  | 117 |  |  | 508 |  |  | 319 | \n | Total | $ | 1,397 |  |  | $ | 796 |  |  | $ | 3,589 |  |  | $ | 2,044 | \nRinvoq | United States | $ | 505 |  |  | $ | 348 |  |  | $ | 1,228 |  |  | $ | 889 | \n | International | 190 |  |  | 105 |  |  | 524 |  |  | 245 | \n | Total | $ | 695 |  |  | $ | 453 |  |  | $ | 1,752 |  |  | $ | 1,134 | \nHematologic Oncology |  |  |  |  |  |  | \nImbruvica | United States | $ | 849 |  |  | $ | 1,109 |  |  | $ | 2,585 |  |  | $ | 3,207 | \n | Collaboration revenues | 286 |  |  | 265 |  |  | 868 |  |  | 816 | \n | Total | $ | 1,135 |  |  | $ | 1,374 |  |  | $ | 3,453 |  |  | $ | 4,023 | \nVenclexta | United States | $ | 259 |  |  | $ | 237 |  |  | $ | 740 |  |  | $ | 685 | \n | International | 256 |  |  | 255 |  |  | 753 |  |  | 647 | \n | Total | $ | 515 |  |  | $ | 492 |  |  | $ | 1,493 |  |  | $ | 1,332 | \nAesthetics |  |  |  |  |  |  | \nBotox Cosmetic | United States | $ | 370 |  |  | $ | 356 |  |  | $ | 1,232 |  |  | $ | 1,027 | \n | International | 267 |  |  | 189 |  |  | 741 |  |  | 579 | \n | Total | $ | 637 |  |  | $ | 545 |  |  | $ | 1,973 |  |  | $ | 1,606 | \nJuvederm Collection | United States | $ | 125 |  |  | $ | 159 |  |  | $ | 420 |  |  | $ | 478 | \n | International | 227 |  |  | 195 |  |  | 686 |  |  | 625 | \n | Total | $ | 352 |  |  | $ | 354 |  |  | $ | 1,106 |  |  | $ | 1,103 | \nOther Aesthetics | United States | $ | 265 |  |  | $ | 305 |  |  | $ | 837 |  |  | $ | 968 | \n | International | 47 |  |  | 47 |  |  | 130 |  |  | 149 | \n | Total | $ | 312 |  |  | $ | 352 |  |  | $ | 967 |  |  | $ | 1,117 | \nNeuroscience |  |  |  |  |  |  | \nBotox Therapeutic | United States | $ | 584 |  |  | $ | 534 |  |  | $ | 1,641 |  |  | $ | 1,451 | \n | International | 115 |  |  | 111 |  |  | 350 |  |  | 329 | \n | Total | $ | 699 |  |  | $ | 645 |  |  | $ | 1,991 |  |  | $ | 1,780 | \nVraylar | United States | $ | 554 |  |  | $ | 461 |  |  | $ | 1,473 |  |  | $ | 1,239 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nDuodopa | United States | $ | 22 |  |  | $ | 23 |  |  | $ | 72 |  |  | $ | 73 | \n | International | 88 |  |  | 104 |  |  | 279 |  |  | 310 | \n | Total | $ | 110 |  |  | $ | 127 |  |  | $ | 351 |  |  | $ | 383 | \nUbrelvy | United States | $ | 160 |  |  | $ | 162 |  |  | $ | 483 |  |  | $ | 369 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nQulipta | United States | $ | 62 |  |  | $ | \u2014 |  |  | $ | 106 |  |  | $ | \u2014 | \nOther Neuroscience | United States | $ | 82 |  |  | $ | 166 |  |  | $ | 400 |  |  | $ | 489 | \n | International | 5 |  |  | 5 |  |  | 14 |  |  | 13 | \n | Total | $ | 87 |  |  | $ | 171 |  |  | $ | 414 |  |  | $ | 502 |   |  |  |  |  | \n2022 Form 10-Q| | 23  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n |  | \n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nEye Care |  |  |  |  |  |  | \nLumigan/Ganfort | United States | $ | 59 |  |  | $ | 63 |  |  | $ | 186 |  |  | $ | 201 | \n | International | 62 |  |  | 75 |  |  | 205 |  |  | 229 | \n | Total | $ | 121 |  |  | $ | 138 |  |  | $ | 391 |  |  | $ | 430 | \nAlphagan/Combigan | United States | $ | 37 |  |  | $ | 89 |  |  | $ | 161 |  |  | $ | 271 | \n | International | 36 |  |  | 39 |  |  | 111 |  |  | 117 | \n | Total | $ | 73 |  |  | $ | 128 |  |  | $ | 272 |  |  | $ | 388 | \nRestasis | United States | $ | 132 |  |  | $ | 305 |  |  | $ | 518 |  |  | $ | 884 | \n | International | 10 |  |  | 14 |  |  | 38 |  |  | 42 | \n | Total | $ | 142 |  |  | $ | 319 |  |  | $ | 556 |  |  | $ | 926 | \nOther Eye Care | United States | $ | 134 |  |  | $ | 128 |  |  | $ | 400 |  |  | $ | 375 | \n | International | 153 |  |  | 158 |  |  | 492 |  |  | 488 | \n | Total | $ | 287 |  |  | $ | 286 |  |  | $ | 892 |  |  | $ | 863 | \nOther Key Products |  |  |  |  |  |  | \nMavyret | United States | $ | 190 |  |  | $ | 183 |  |  | $ | 562 |  |  | $ | 557 | \n | International | 193 |  |  | 243 |  |  | 599 |  |  | 726 | \n | Total | $ | 383 |  |  | $ | 426 |  |  | $ | 1,161 |  |  | $ | 1,283 | \nCreon | United States | $ | 336 |  |  | $ | 310 |  |  | $ | 941 |  |  | $ | 864 | \nLinzess/Constella | United States | $ | 262 |  |  | $ | 253 |  |  | $ | 742 |  |  | $ | 728 | \n | International | 9 |  |  | 8 |  |  | 24 |  |  | 23 | \n | Total | $ | 271 |  |  | $ | 261 |  |  | $ | 766 |  |  | $ | 751 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nAll other |  | $ | 925 |  |  | $ | 1,117 |  |  | $ | 3,145 |  |  | $ | 3,814 | \nTotal net revenues | $ | 14,812 |  |  | $ | 14,342 |  |  | $ | 42,933 |  |  | $ | 41,311 |   |  |  |  |  | \n2022 Form 10-Q| | 24  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 25  |  |  |  |  | \n2022 Form 10-Q| | 26  |  |  |  |  | \n2022 Form 10-Q| | 27  |  |  |  |  | \n2022 Form 10-Q| | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Percent\u00a0change |  | Nine months endedSeptember 30, |  | Percent\u00a0change\n |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \nUnited States |  | $ | 11,763 |  |  | $ | 11,279 |  |  | 4.3 | % |  | 4.3 | % |  | $ | 33,521 |  |  | $ | 31,833 |  |  | 5.3 | % |  | 5.3 | %\nInternational |  | 3,049 |  |  | 3,063 |  |  | (0.4) | % |  | 9.6 | % |  | 9,412 |  |  | 9,478 |  |  | (0.7) | % |  | 6.7 | %\nNet revenues |  | $ | 14,812 |  |  | $ | 14,342 |  |  | 3.3 | % |  | 5.4 | % |  | $ | 42,933 |  |  | $ | 41,311 |  |  | 3.9 | % |  | 5.6 | %  |  |  |  |  | \n2022 Form 10-Q| | 29  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedSeptember 30, |  | Percent\u00a0change |  | Nine months endedSeptember 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHumira | United States |  | $ | 4,956 |  |  | $ | 4,613 |  |  | 7.4 | % |  | 7.4 | % |  | $ | 13,613 |  |  | $ | 12,777 |  |  | 6.5 | % |  | 6.5 | %\n | International |  | 603 |  |  | 812 |  |  | (25.9) | % |  | (16.8) | % |  | 2,045 |  |  | 2,583 |  |  | (20.9) | % |  | (14.3) | %\n | Total |  | $ | 5,559 |  |  | $ | 5,425 |  |  | 2.5 | % |  | 3.9 | % |  | $ | 15,658 |  |  | $ | 15,360 |  |  | 1.9 | % |  | 3.0 | %\nSkyrizi | United States |  | $ | 1,221 |  |  | $ | 679 |  |  | 79.8 | % |  | 79.8 | % |  | $ | 3,081 |  |  | $ | 1,725 |  |  | 78.6 | % |  | 78.6 | %\n | International |  | 176 |  |  | 117 |  |  | 50.1 | % |  | 70.0 | % |  | 508 |  |  | 319 |  |  | 59.3 | % |  | 75.1 | %\n | Total |  | $ | 1,397 |  |  | $ | 796 |  |  | 75.4 | % |  | 78.3 | % |  | $ | 3,589 |  |  | $ | 2,044 |  |  | 75.6 | % |  | 78.1 | %\nRinvoq | United States |  | $ | 505 |  |  | $ | 348 |  |  | 44.7 | % |  | 44.7 | % |  | $ | 1,228 |  |  | $ | 889 |  |  | 38.0 | % |  | 38.0 | %\n | International |  | 190 |  |  | 105 |  |  | 82.9 | % |  | >100.0 % |  | 524 |  |  | 245 |  |  | >100.0 % |  | >100.0 %\n | Total |  | $ | 695 |  |  | $ | 453 |  |  | 53.5 | % |  | 59.3 | % |  | $ | 1,752 |  |  | $ | 1,134 |  |  | 54.5 | % |  | 59.3 | %\nHematologic Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nImbruvica | United States |  | $ | 849 |  |  | $ | 1,109 |  |  | (23.5) | % |  | (23.5) | % |  | $ | 2,585 |  |  | $ | 3,207 |  |  | (19.4) | % |  | (19.4) | %\n | Collaboration revenues |  | 286 |  |  | 265 |  |  | 7.6 | % |  | 7.6 | % |  | 868 |  |  | 816 |  |  | 6.3 | % |  | 6.3 | %\n | Total |  | $ | 1,135 |  |  | $ | 1,374 |  |  | (17.4) | % |  | (17.4) | % |  | $ | 3,453 |  |  | $ | 4,023 |  |  | (14.2) | % |  | (14.2) | %\nVenclexta | United States |  | $ | 259 |  |  | $ | 237 |  |  | 9.2 | % |  | 9.2 | % |  | $ | 740 |  |  | $ | 685 |  |  | 8.1 | % |  | 8.1 | %\n | International |  | 256 |  |  | 255 |  |  | 0.1 | % |  | 13.2 | % |  | 753 |  |  | 647 |  |  | 16.2 | % |  | 27.3 | %\n | Total |  | $ | 515 |  |  | $ | 492 |  |  | 4.5 | % |  | 11.3 | % |  | $ | 1,493 |  |  | $ | 1,332 |  |  | 12.1 | % |  | 17.5 | %\nAesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Cosmetic | United States |  | $ | 370 |  |  | $ | 356 |  |  | 4.1 | % |  | 4.1 | % |  | $ | 1,232 |  |  | $ | 1,027 |  |  | 20.0 | % |  | 20.0 | %\n | International |  | 267 |  |  | 189 |  |  | 41.0 | % |  | 54.5 | % |  | 741 |  |  | 579 |  |  | 27.9 | % |  | 36.8 | %\n | Total |  | $ | 637 |  |  | $ | 545 |  |  | 16.9 | % |  | 21.6 | % |  | $ | 1,973 |  |  | $ | 1,606 |  |  | 22.8 | % |  | 26.0 | %\nJuvederm Collection | United States |  | $ | 125 |  |  | $ | 159 |  |  | (21.9) | % |  | (21.9) | % |  | $ | 420 |  |  | $ | 478 |  |  | (12.3) | % |  | (12.3) | %\n | International |  | 227 |  |  | 195 |  |  | 16.9 | % |  | 27.7 | % |  | 686 |  |  | 625 |  |  | 9.9 | % |  | 17.6 | %\n | Total |  | $ | 352 |  |  | $ | 354 |  |  | (0.6) | % |  | 5.3 | % |  | $ | 1,106 |  |  | $ | 1,103 |  |  | 0.3 | % |  | 4.6 | %\nOther Aesthetics | United States |  | $ | 265 |  |  | $ | 305 |  |  | (13.1) | % |  | (13.1) | % |  | $ | 837 |  |  | $ | 968 |  |  | (13.4) | % |  | (13.4) | %\n | International |  | 47 |  |  | 47 |  |  | (0.8) | % |  | 8.3 | % |  | 130 |  |  | 149 |  |  | (12.8) | % |  | (7.2) | %\n | Total |  | $ | 312 |  |  | $ | 352 |  |  | (11.4) | % |  | (10.2) | % |  | $ | 967 |  |  | $ | 1,117 |  |  | (13.4) | % |  | (12.7) | %\nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Therapeutic | United States |  | $ | 584 |  |  | $ | 534 |  |  | 9.2 | % |  | 9.2 | % |  | $ | 1,641 |  |  | $ | 1,451 |  |  | 13.1 | % |  | 13.1 | %\n | International |  | 115 |  |  | 111 |  |  | 3.6 | % |  | 14.2 | % |  | 350 |  |  | 329 |  |  | 6.5 | % |  | 15.0 | %\n | Total |  | $ | 699 |  |  | $ | 645 |  |  | 8.2 | % |  | 10.0 | % |  | $ | 1,991 |  |  | $ | 1,780 |  |  | 11.9 | % |  | 13.5 | %\nVraylar | United States |  | $ | 554 |  |  | $ | 461 |  |  | 20.1 | % |  | 20.1 | % |  | $ | 1,473 |  |  | $ | 1,239 |  |  | 18.9 | % |  | 18.9 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDuodopa | United States |  | $ | 22 |  |  | $ | 23 |  |  | (4.9) | % |  | (4.9) | % |  | $ | 72 |  |  | $ | 73 |  |  | (2.4) | % |  | (2.4) | %\n | International |  | 88 |  |  | 104 |  |  | (15.0) | % |  | (2.6) | % |  | 279 |  |  | 310 |  |  | (9.8) | % |  | \u2014 | %\n | Total |  | $ | 110 |  |  | $ | 127 |  |  | (13.1) | % |  | (3.0) | % |  | $ | 351 |  |  | $ | 383 |  |  | (8.4) | % |  | (0.5) | %\nUbrelvy | United States |  | $ | 160 |  |  | $ | 162 |  |  | (1.4) | % |  | (1.4) | % |  | $ | 483 |  |  | $ | 369 |  |  | 31.0 | % |  | 31.0 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nQulipta | United States |  | $ | 62 |  |  | $ | \u2014 |  |  | n/m |  | n/m |  | $ | 106 |  |  | $ | \u2014 |  |  | n/m |  | n/m\nOther Neuroscience | United States |  | $ | 82 |  |  | $ | 166 |  |  | (50.5) | % |  | (50.5) | % |  | $ | 400 |  |  | $ | 489 |  |  | (18.3) | % |  | (18.3) | %\n | International |  | 5 |  |  | 5 |  |  | 10.2 | % |  | 14.1 | % |  | 14 |  |  | 13 |  |  | 10.3 | % |  | 13.1 | %\n | Total |  | $ | 87 |  |  | $ | 171 |  |  | (49.0) | % |  | (48.9) | % |  | $ | 414 |  |  | $ | 502 |  |  | (17.6) | % |  | (17.5) | %  |  |  |  |  | \n2022 Form 10-Q| | 30  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedSeptember 30, |  | Percent\u00a0change |  | Nine months endedSeptember 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \nEye Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLumigan/Ganfort | United States |  | $ | 59 |  |  | $ | 63 |  |  | (4.4) | % |  | (4.4) | % |  | $ | 186 |  |  | $ | 201 |  |  | (7.1) | % |  | (7.1) | %\n | International |  | 62 |  |  | 75 |  |  | (18.7) | % |  | (8.7) | % |  | 205 |  |  | 229 |  |  | (10.8) | % |  | (2.9) | %\n | Total |  | $ | 121 |  |  | $ | 138 |  |  | (12.2) | % |  | (6.7) | % |  | $ | 391 |  |  | $ | 430 |  |  | (9.0) | % |  | (4.8) | %\nAlphagan/Combigan | United States |  | $ | 37 |  |  | $ | 89 |  |  | (58.2) | % |  | (58.2) | % |  | $ | 161 |  |  | $ | 271 |  |  | (40.8) | % |  | (40.8) | %\n | International |  | 36 |  |  | 39 |  |  | (8.9) | % |  | 2.9 | % |  | 111 |  |  | 117 |  |  | (5.1) | % |  | 4.9 | %\n | Total |  | $ | 73 |  |  | $ | 128 |  |  | (43.0) | % |  | (39.4) | % |  | $ | 272 |  |  | $ | 388 |  |  | (30.0) | % |  | (27.0) | %\nRestasis | United States |  | $ | 132 |  |  | $ | 305 |  |  | (56.7) | % |  | (56.7) | % |  | $ | 518 |  |  | $ | 884 |  |  | (41.3) | % |  | (41.3) | %\n | International |  | 10 |  |  | 14 |  |  | (30.7) | % |  | (37.7) | % |  | 38 |  |  | 42 |  |  | (10.1) | % |  | (2.8) | %\n | Total |  | $ | 142 |  |  | $ | 319 |  |  | (55.6) | % |  | (55.9) | % |  | $ | 556 |  |  | $ | 926 |  |  | (39.9) | % |  | (39.6) | %\nOther Eye Care | United States |  | $ | 134 |  |  | $ | 128 |  |  | 3.7 | % |  | 3.7 | % |  | $ | 400 |  |  | $ | 375 |  |  | 6.3 | % |  | 6.3 | %\n | International |  | 153 |  |  | 158 |  |  | (2.7) | % |  | 9.1 | % |  | 492 |  |  | 488 |  |  | 0.9 | % |  | 10.1 | %\n | Total |  | $ | 287 |  |  | $ | 286 |  |  | 0.1 | % |  | 6.6 | % |  | $ | 892 |  |  | $ | 863 |  |  | 3.3 | % |  | 8.5 | %\nOther Key Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMavyret | United States |  | $ | 190 |  |  | $ | 183 |  |  | 3.5 | % |  | 3.5 | % |  | $ | 562 |  |  | $ | 557 |  |  | 0.9 | % |  | 0.9 | %\n | International |  | 193 |  |  | 243 |  |  | (20.6) | % |  | (10.3) | % |  | 599 |  |  | 726 |  |  | (17.5) | % |  | (9.1) | %\n | Total |  | $ | 383 |  |  | $ | 426 |  |  | (10.2) | % |  | (4.4) | % |  | $ | 1,161 |  |  | $ | 1,283 |  |  | (9.5) | % |  | (4.7) | %\nCreon | United States |  | $ | 336 |  |  | $ | 310 |  |  | 8.5 | % |  | 8.5 | % |  | $ | 941 |  |  | $ | 864 |  |  | 9.0 | % |  | 9.0 | %\nLinzess/Constella | United States |  | $ | 262 |  |  | $ | 253 |  |  | 3.4 | % |  | 3.4 | % |  | $ | 742 |  |  | $ | 728 |  |  | 2.0 | % |  | 2.0 | %\n | International |  | 9 |  |  | 8 |  |  | 16.0 | % |  | 25.8 | % |  | 24 |  |  | 23 |  |  | 3.2 | % |  | 9.6 | %\n | Total |  | $ | 271 |  |  | $ | 261 |  |  | 3.8 | % |  | 4.1 | % |  | $ | 766 |  |  | $ | 751 |  |  | 2.0 | % |  | 2.2 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAll other |  |  | $ | 925 |  |  | $ | 1,117 |  |  | (16.8) | % |  | (15.3) | % |  | $ | 3,145 |  |  | $ | 3,814 |  |  | (17.5) | % |  | (16.3) | %\nTotal net revenues |  | $ | 14,812 |  |  | $ | 14,342 |  |  | 3.3 | % |  | 5.4 | % |  | $ | 42,933 |  |  | $ | 41,311 |  |  | 3.9 | % |  | 5.6 | %  |  |  |  |  | \n2022 Form 10-Q| | 31  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\nGross margin |  | $ | 9,790 |  | $ | 9,952 |  | (2) | % |  | $ | 29,689 |  | $ | 28,185 |  | 5 | %\nas a % of net revenues |  | 66 | % |  | 69 | % |  |  |  | 69 | % |  | 68 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\nSelling, general and administrative |  | $ | 3,304 |  | $ | 3,083 |  | 7 | % |  | $ | 11,843 |  | $ | 9,089 |  | 30 | %\nas a % of net revenues |  | 22 | % |  | 21 | % |  |  |  | 28 | % |  | 22 | % |  |   |  |  |  |  | \n2022 Form 10-Q| | 32  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\nResearch and development |  | $ | 1,614 |  |  | $ | 1,661 |  |  | (3) | % |  | $ | 4,720 |  | $ | 5,095 |  | (7) | %\nas a % of net revenues |  | 11 | % |  | 12 | % |  |  |  | 11 | % |  | 12 | % |  | \nAcquired IPR&D and milestones |  | $ | 40 |  |  | $ | 402 |  |  | (90) | % |  | $ | 454 |  | $ | 719 |  | (37) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest expense |  | $ | 560 |  |  | $ | 596 |  |  | $ | 1,664 |  |  | $ | 1,843 | \nInterest income |  | (63) |  |  | (11) |  |  | (96) |  |  | (30) | \nInterest expense, net |  | $ | 497 |  |  | $ | 585 |  |  | $ | 1,568 |  |  | $ | 1,813 | \n |  |  |  |  |  |  |  | \nNet foreign exchange loss |  | $ | 36 |  |  | $ | 12 |  |  | $ | 108 |  |  | $ | 35 | \nOther expense (income), net |  | (330) |  |  | 21 |  |  | 427 |  |  | 2,284 |   |  |  |  |  | \n2022 Form 10-Q| | 33  |  |  |  |  |  |  |  |  |  |  | \n | Nine months endedSeptember 30,\n(in\u00a0millions) | 2022 |  | 2021\nCash flows provided by (used in): |  |  | \nOperating activities | $ | 17,515 |  |  | $ | 17,702 | \nInvesting activities | (175) |  |  | (1,199) | \nFinancing activities | (15,169) |  |  | (12,701) |   |  |  |  |  | \n2022 Form 10-Q| | 34  |  |  |  |  | \n2022 Form 10-Q| | 35  |  | \n  |  | \n  |  |  |  |  | \n2022 Form 10-Q| | 36  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | (a)\u00a0TotalNumber\u00a0ofShares(or Units)Purchased |  | (b)\u00a0AveragePrice\u00a0Paidper\u00a0Share(or\u00a0Unit) |  | (c)\u00a0Total\u00a0Numberof\u00a0Shares\u00a0(orUnits)\u00a0Purchasedas\u00a0Part\u00a0of\u00a0PubliclyAnnounced\u00a0Plansor\u00a0Programs |  | (d)\u00a0MaximumNumber\u00a0(orApproximateDollar\u00a0Value)\u00a0ofShares\u00a0(or\u00a0Units)that\u00a0May\u00a0Yet\u00a0BePurchased\u00a0Underthe\u00a0Plans\u00a0orPrograms | \nJuly 1, 2022 - July 31, 2022 | 893 |  | (1) | $152.92 | (1) | \u2014 |  |  | $1,393,714,917 | \nAugust 1, 2022 - August 30, 2022 | 1,023 |  | (1) | $140.00 | (1) | \u2014 |  |  | $1,393,714,917 | \nSeptember 1, 2022 - September 30, 2022 | 1,052 |  | (1) | $137.87 | (1) | \u2014 |  |  | $1,393,714,917 | \nTotal | 2,968 |  | (1) | $143.13 | (1) | \u2014 |  |  | $1,393,714,917 |   |  |  |  |  | \n2022 Form 10-Q| | 37  |  | \n  |  |  |  |  |  |  |  |  |  |  | \nExhibit\u00a0No. |  | Exhibit\u00a0Description | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n |  |  | \n10.1 |  | *Form of Agreement Regarding Change in Control by and between AbbVie Inc. and its named executive officers (incorporated by reference to Exhibit 10.1 to the company's Current Report on Form 8-K filed on October 14, 2022).** | \n |  |  | \n10.2 |  | AbbVie Deferred Compensation PlanPlus.** | \n |  |  | \n31.1 |  | Certification of Chief Executive Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n31.2 |  | Certification of Chief Financial Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n32.1 |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n32.2 |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n101 |  | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form\u00a010-Q for the quarter ended September 30, 2022, filed on November\u00a04, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)\u00a0Condensed Consolidated Statements of Earnings; (ii)\u00a0Condensed Consolidated Statements of Comprehensive Income; (iii)\u00a0Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)\u00a0Condensed Consolidated Statements of Cash Flows; and (vi)\u00a0the Notes to Condensed Consolidated Financial Statements. | \n |  |  | \n104 |  | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). |   |  |  |  |  | \n2022 Form 10-Q| | 38  |  |  |  |  |  |  |  | \n |  | ABBVIE INC.\n |  | \n |  | \n | By: | /s/ Scott T. Reents\n |  | Scott T. Reents\n |  | Senior Vice President,\n |  | Chief Financial Officer (Principal Financial Officer)  |  |  |  |  | \n2022 Form 10-Q| | 39"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For AbbVie, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \n(Exact name of registrant as specified in its charter)\nDelaware |  | 32-0375147\n(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)  |  |  |  |  |  |  |  |  |  |  | \nLarge Accelerated Filer | \u2612 | Accelerated Filer | \u2610\nNon-Accelerated Filer | \u2610 | Smaller reporting company | \u2610\n |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, par value $0.01 per share |  | ABBV |  | New York Stock Exchange\n |  |  |  | Chicago Stock Exchange\n1.500% Senior Notes due 2023 |  | ABBV23B |  | New York Stock Exchange\n1.375% Senior Notes due 2024 |  | ABBV24 |  | New York Stock Exchange\n1.250% Senior Notes due 2024 |  | ABBV24B |  | New York Stock Exchange\n0.750% Senior Notes due 2027 |  | ABBV27 |  | New York Stock Exchange\n2.125% Senior Notes due 2028 |  | ABBV28 |  | New York Stock Exchange\n2.625% Senior Notes due 2028 |  | ABBV28B |  | New York Stock Exchange\n2.125% Senior Notes due 2029 |  | ABBV29 |  | New York Stock Exchange\n1.250% Senior Notes due 2031 |  | ABBV31 |  | New York Stock Exchange  |  | \n  |  |  |  |  |  |  |  | \nPART\u00a0I. | FINANCIAL INFORMATION\n |  | Page\n |  | \nItem 1. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 1\nItem 2. | MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 24\nItem 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 32\nItem 4. | CONTROLS AND PROCEDURES | 32\n |  | \nPART\u00a0II. | OTHER INFORMATION\n |  | \nItem 1. | LEGAL PROCEEDINGS | 33\n |  | \nItem 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 33\nItem 6. | EXHIBITS | 34  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data) |  |  |  |  |  | 2023 |  | 2022\nNet revenues |  |  |  |  |  | $ | 12,225 |  |  | $ | 13,538 | \n |  |  |  |  |  |  |  | \nCost of products sold |  |  |  |  |  | 3,986 |  |  | 4,052 | \nSelling, general and administrative |  |  |  |  |  | 3,039 |  |  | 3,127 | \nResearch and development |  |  |  |  |  | 2,292 |  |  | 1,497 | \nAcquired IPR&D and milestones |  |  |  |  |  | 150 |  |  | 145 | \nOther operating income |  |  |  |  |  | (10) |  |  | \u2014 | \nTotal operating costs and expenses |  |  |  |  |  | 9,457 |  |  | 8,821 | \nOperating earnings |  |  |  |  |  | 2,768 |  |  | 4,717 | \n |  |  |  |  |  |  |  | \nInterest expense, net |  |  |  |  |  | 454 |  |  | 539 | \nNet foreign exchange loss |  |  |  |  |  | 35 |  |  | 25 | \nOther expense (income), net |  |  |  |  |  | 1,804 |  |  | (776) | \nEarnings before income tax expense |  |  |  |  |  | 475 |  |  | 4,929 | \nIncome tax expense |  |  |  |  |  | 234 |  |  | 436 | \nNet earnings |  |  |  |  |  | 241 |  |  | 4,493 | \nNet earnings attributable to noncontrolling interest |  |  |  |  |  | 2 |  |  | 3 | \nNet earnings attributable to AbbVie Inc. |  |  |  |  |  | $ | 239 |  |  | $ | 4,490 | \n |  |  |  |  |  |  |  | \nPer share data |  |  |  |  |  |  |  | \nBasic earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 0.13 |  |  | $ | 2.52 | \nDiluted earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 0.13 |  |  | $ | 2.51 | \n |  |  |  |  |  |  |  | \nWeighted-average basic shares outstanding |  |  |  |  |  | 1,770 |  |  | 1,771 | \nWeighted-average diluted shares outstanding |  |  |  |  |  | 1,776 |  |  | 1,778 |   |  |  |  |  | \n2023 Form 10-Q| | 1  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  | 2023 |  | 2022\nNet earnings |  |  |  |  | $ | 241 |  |  | $ | 4,493 | \n |  |  |  |  |  |  | \nForeign currency translation adjustments, net of tax expense (benefit) of $12for the three months ended March 31, 2023 and $(7) for the three months ended March 31, 2022 |  |  |  |  | 194 |  |  | (231) | \nNet investment hedging activities, net of tax expense (benefit) of $(60) for the three months ended March 31, 2023 and $37for the three months ended March 31, 2022 |  |  |  |  | (224) |  |  | 130 | \nPension and post-employment benefits, net of tax expense (benefit) of $14for the three months ended March 31, 2023 and $10for the three months ended March 31, 2022 |  |  |  |  | 38 |  |  | 28 | \nCash flow hedging activities, net of tax expense (benefit) of $(4) for the three months ended March 31, 2023 and $(2) for the three months ended March 31, 2022 |  |  |  |  | (41) |  |  | (12) | \nOther comprehensive loss |  |  |  |  | (33) |  |  | (85) | \nComprehensive income |  |  |  |  | 208 |  |  | 4,408 | \nComprehensive income attributable to noncontrolling interest |  |  |  |  | 2 |  |  | 3 | \nComprehensive income attributable to AbbVie Inc. |  |  |  |  | $ | 206 |  |  | $ | 4,405 |   |  |  |  |  | \n2023 Form 10-Q| | 2  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions,\u00a0except\u00a0share\u00a0data) | March 31,2023 |  | December 31,2022\n | (unaudited) |  | \nAssets |  |  | \nCurrent assets |  |  | \nCash and equivalents | $ | 6,711 |  |  | $ | 9,201 | \nShort-term investments | 11 |  |  | 28 | \nAccounts receivable, net | 11,473 |  |  | 11,254 | \nInventories | 3,833 |  |  | 3,579 | \nPrepaid expenses and other | 4,460 |  |  | 4,401 | \nTotal current assets | 26,488 |  |  | 28,463 | \n |  |  | \nInvestments | 257 |  |  | 241 | \nProperty and equipment, net | 4,931 |  |  | 4,935 | \nIntangible assets, net | 64,848 |  |  | 67,439 | \nGoodwill | 32,220 |  |  | 32,156 | \nOther assets | 5,800 |  |  | 5,571 | \nTotal assets | $ | 134,544 |  |  | $ | 138,805 | \n |  |  | \nLiabilities and Equity |  |  | \nCurrent liabilities |  |  | \nShort-term borrowings | $ | 1 |  |  | $ | 1 | \nCurrent portion of long-term debt and finance lease obligations | 2,800 |  |  | 4,135 | \nAccounts payable and accrued liabilities | 24,789 |  |  | 25,402 | \nTotal current liabilities | 27,590 |  |  | 29,538 | \n |  |  | \nLong-term debt and finance lease obligations | 59,292 |  |  | 59,135 | \nDeferred income taxes | 2,110 |  |  | 2,190 | \nOther long-term liabilities | 32,249 |  |  | 30,655 | \n |  |  | \nCommitments and contingencies |  |  | \n |  |  | \nStockholders' equity |  |  | \nCommon stock, $0.01par value,4,000,000,000shares authorized,1,821,082,016shares issued as of March 31, 2023 and1,813,770,294as of December 31, 2022 | 18 |  |  | 18 | \nCommon stock held in treasury, at cost,57,113,024shares as of March 31, 2023 and44,589,000as of December 31, 2022 | (6,524) |  |  | (4,594) | \nAdditional paid-in capital | 19,619 |  |  | 19,245 | \nRetained earnings | 2,393 |  |  | 4,784 | \nAccumulated other comprehensive loss | (2,232) |  |  | (2,199) | \nTotal stockholders' equity | 13,274 |  |  | 17,254 | \nNoncontrolling interest | 29 |  |  | 33 | \nTotal equity | 13,303 |  |  | 17,287 | \n |  |  | \nTotal liabilities and equity | $ | 134,544 |  |  | $ | 138,805 |   |  |  |  |  | \n2023 Form 10-Q| | 3  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Common shares outstanding |  | Common stock |  | Treasury stock |  | Additional paid-in capital |  | Retained earnings |  | Accumulated other comprehensive loss |  | Noncontrolling interest |  | Total\nBalance at December 31, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,143) |  |  | $ | 18,305 |  |  | $ | 3,127 |  |  | $ | (2,899) |  |  | $ | 28 |  |  | $ | 15,436 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,490 |  |  | \u2014 |  |  | \u2014 |  |  | 4,490 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (85) |  |  | \u2014 |  |  | (85) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,514) |  |  | \u2014 |  |  | \u2014 |  |  | (2,514) | \nPurchases of treasury stock | (10) |  |  | \u2014 |  |  | (1,470) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,470) | \nStock-based compensation plans and other | 9 |  |  | \u2014 |  |  | 28 |  |  | 426 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 454 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 3 | \nBalance at March 31, 2022 | 1,767 |  |  | $ | 18 |  |  | $ | (4,585) |  |  | $ | 18,731 |  |  | $ | 5,103 |  |  | $ | (2,984) |  |  | $ | 31 |  |  | $ | 16,314 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2022 | 1,769 |  |  | $ | 18 |  |  | $ | (4,594) |  |  | $ | 19,245 |  |  | $ | 4,784 |  |  | $ | (2,199) |  |  | $ | 33 |  |  | $ | 17,287 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 239 |  |  | \u2014 |  |  | \u2014 |  |  | 239 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (33) |  |  | \u2014 |  |  | (33) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,630) |  |  | \u2014 |  |  | \u2014 |  |  | (2,630) | \nPurchases of treasury stock | (12) |  |  | \u2014 |  |  | (1,955) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,955) | \nStock-based compensation plans and other | 7 |  |  | \u2014 |  |  | 25 |  |  | 374 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 399 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | (4) | \nBalance at March 31, 2023 | 1,764 |  |  | $ | 18 |  |  | $ | (6,524) |  |  | $ | 19,619 |  |  | $ | 2,393 |  |  | $ | (2,232) |  |  | $ | 29 |  |  | $ | 13,303 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  | \n2023 Form 10-Q| | 4  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedMarch 31,\n(in\u00a0millions)\u00a0(brackets\u00a0denote\u00a0cash\u00a0outflows) | 2023 |  | 2022\nCash flows from operating activities |  |  | \nNet earnings | $ | 241 |  |  | $ | 4,493 | \nAdjustments to reconcile net earnings to net cash from operating activities: |  |  | \nDepreciation | 179 |  |  | 198 | \nAmortization of intangible assets | 1,948 |  |  | 1,855 | \nDeferred income taxes | (267) |  |  | (194) | \nChange in fair value of contingent consideration liabilities | 1,872 |  |  | (748) | \nStock-based compensation | 313 |  |  | 306 | \nAcquired IPR&D and milestones | 150 |  |  | 145 | \nImpairment of intangible assets | 710 |  |  | \u2014 | \nOther, net | (128) |  |  | 128 | \nChanges in operating assets and liabilities, net of acquisitions: |  |  | \nAccounts receivable | (195) |  |  | (785) | \nInventories | (185) |  |  | (385) | \nPrepaid expenses and other assets | (167) |  |  | (285) | \nAccounts payable and other liabilities | (465) |  |  | (258) | \nIncome tax assets and liabilities, net | 187 |  |  | 438 | \nCash flows from operating activities | 4,193 |  |  | 4,908 | \n |  |  | \nCash flows from investing activities |  |  | \nAcquisitions and investments | (353) |  |  | (185) | \nAcquisitions of property and equipment | (175) |  |  | (162) | \nPurchases of investment securities | (19) |  |  | (1,406) | \nSales and maturities of investment securities | 22 |  |  | 8 | \nOther, net | 26 |  |  | 154 | \nCash flows from investing activities | (499) |  |  | (1,591) | \n |  |  | \nCash flows from financing activities |  |  | \nProceeds from issuance of long-term debt | \u2014 |  |  | 2,000 | \nRepayments of long-term debt and finance lease obligations | (1,351) |  |  | (4,879) | \nDividends paid | (2,661) |  |  | (2,526) | \nPurchases of treasury stock | (1,955) |  |  | (1,470) | \nProceeds from the exercise of stock options | 65 |  |  | 128 | \nPayments of contingent consideration liabilities | (311) |  |  | (246) | \nOther, net | 21 |  |  | 21 | \nCash flows from financing activities | (6,192) |  |  | (6,972) | \nEffect of exchange rate changes on cash and equivalents | 8 |  |  | 7 | \nNet change in cash and equivalents | (2,490) |  |  | (3,648) | \nCash and equivalents, beginning of period | 9,201 |  |  | 9,746 | \n |  |  | \nCash and equivalents, end of period | $ | 6,711 |  |  | $ | 6,098 | \n |  |  | \n |  |  | \n |  |  |   |  |  |  |  | \n2023 Form 10-Q| | 5  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  | 2023 |  | 2022\nInterest expense |  |  |  |  |  | $ | 553 |  |  | $ | 548 | \nInterest income |  |  |  |  |  | (99) |  |  | (9) | \nInterest expense, net |  |  |  |  |  | $ | 454 |  |  | $ | 539 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | March 31,2023 |  | December 31,2022\nFinished goods | $ | 1,319 |  |  | $ | 1,162 | \nWork-in-process | 1,312 |  |  | 1,417 | \nRaw materials | 1,202 |  |  | 1,000 | \nInventories | $ | 3,833 |  |  | $ | 3,579 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | March 31,2023 |  | December 31,2022\nProperty and equipment, gross | $ | 11,142 |  |  | $ | 10,986 | \nAccumulated depreciation | (6,211) |  |  | (6,051) | \nProperty and equipment, net | $ | 4,931 |  |  | $ | 4,935 |   |  |  |  |  | \n2023 Form 10-Q| | 6  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions, except per share data) |  |  |  |  |  | 2023 |  | 2022\nBasic EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  |  |  |  |  | $ | 239 |  |  | $ | 4,490 | \nEarnings allocated to participating securities |  |  |  |  |  | 11 |  |  | 22 | \nEarnings available to common shareholders |  |  |  |  |  | $ | 228 |  |  | $ | 4,468 | \nWeighted-average basic shares outstanding |  |  |  |  |  | 1,770 |  |  | 1,771 | \nBasic earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 0.13 |  |  | $ | 2.52 | \n |  |  |  |  |  |  |  | \nDiluted EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  |  |  |  |  | $ | 239 |  |  | $ | 4,490 | \nEarnings allocated to participating securities |  |  |  |  |  | 11 |  |  | 22 | \nEarnings available to common shareholders |  |  |  |  |  | $ | 228 |  |  | $ | 4,468 | \nWeighted-average shares of common stock outstanding |  |  |  |  |  | 1,770 |  |  | 1,771 | \nEffect of dilutive securities |  |  |  |  |  | 6 |  |  | 7 | \nWeighted-average diluted shares outstanding |  |  |  |  |  | 1,776 |  |  | 1,778 | \nDiluted earnings per share attributable to AbbVie Inc. |  |  |  |  |  | $ | 0.13 |  |  | $ | 2.51 |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 7  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in millions) |  |  |  |  |  | 2023 |  | 2022\nUnited States - Janssen's share of profits (included in cost of products sold) |  |  |  |  |  | $ | 297 |  |  | $ | 408 | \nInternational - AbbVie's share of profits (included in net revenues) |  |  |  |  |  | 240 |  |  | 299 | \nGlobal - AbbVie's share of other costs (included in respective line items) |  |  |  |  |  | 55 |  |  | 64 |   |  |  |  |  | \n2023 Form 10-Q| | 8  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in millions) |  |  |  |  |  | 2023 |  | 2022\nGenentech's share of profits, including royalties (included in cost of products sold) |  |  |  |  |  | $ | 202 |  |  | $ | 178 | \nAbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  |  |  |  |  | 11 |  |  | 12 | \nAbbVie's share of development costs (included in R&D) |  |  |  |  |  | 28 |  |  | 27 |   |  | \n  |  |  |  |  | \n(in\u00a0millions) | \nBalance as of December 31, 2022 | $ | 32,156 | \nForeign currency translation adjustments | 64 | \nBalance as of March 31, 2023 | $ | 32,220 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\n(in\u00a0millions) | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount |  | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount\nDefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  | \nDeveloped product rights | $ | 87,622 |  |  | $ | (26,635) |  |  | $ | 60,987 |  |  | $ | 87,698 |  |  | $ | (25,003) |  |  | $ | 62,695 | \nLicense agreements | 8,474 |  |  | (4,902) |  |  | 3,572 |  |  | 8,474 |  |  | (4,642) |  |  | 3,832 | \nTotal definite-lived intangible assets | 96,096 |  |  | (31,537) |  |  | 64,559 |  |  | 96,172 |  |  | (29,645) |  |  | 66,527 | \nIndefinite-lived intangible assets | 289 |  |  | \u2014 |  |  | 289 |  |  | 912 |  |  | \u2014 |  |  | 912 | \nTotal intangible assets, net | $ | 96,385 |  |  | $ | (31,537) |  |  | $ | 64,848 |  |  | $ | 97,084 |  |  | $ | (29,645) |  |  | $ | 67,439 |   |  |  |  |  | \n2023 Form 10-Q| | 9  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2023 |  | 2022\nCost of products sold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 14 |  |  | $ | 31 | \nResearch and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \u2014 |  |  | 9 | \nSelling, general and administrative |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 44 |  |  | 70 | \nTotal charges |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 58 |  |  | $ | 110 |   |  |  |  |  | \n(in millions) | \nAccrued balance as of December 31, 2022 | $ | 107 | \nCharges | 58 | \nPayments and other adjustments | (69) | \nAccrued balance as of March 31, 2023 | $ | 96 |   |  |  |  |  | \n(in\u00a0millions) | \nAccrued balance as of December 31, 2022 | $ | 176 | \nRestructuring charges | 17 | \nPayments and other adjustments | (24) | \nAccrued balance as of March 31, 2023 | $ | 169 |   |  |  |  |  | \n2023 Form 10-Q| | 10  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 11  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair value \u2013Derivatives in asset position |  | Fair value \u2013Derivatives\u00a0in\u00a0liability\u00a0position\n(in\u00a0millions) | Balance\u00a0sheet\u00a0caption | March 31, 2023 | December 31, 2022 |  | Balance\u00a0sheet\u00a0caption | March 31, 2023 | December 31, 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | $ | 32 |  | $ | 49 |  |  | Accounts payable and accrued liabilities | $ | 12 |  | $ | 8 | \nDesignated as cash flow hedges | Other assets | 1 |  | 1 |  |  | Other long-term liabilities | 1 |  | \u2014 | \nDesignated as net investment hedges | Prepaid expenses and other | 3 |  | 6 |  |  | Accounts payable and accrued liabilities | 78 |  | 36 | \nDesignated as net investment hedges | Other assets | 37 |  | 74 |  |  | Other long-term liabilities | 57 |  | 47 | \nNot designated as hedges | Prepaid expenses and other | 77 |  | 33 |  |  | Accounts payable and accrued liabilities | 28 |  | 41 | \nInterest rate swap contracts |  |  |  |  |  |  | \nDesignated as fair value hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 17 |  | 17 | \nDesignated as fair value hedges | Other assets | 11 |  | \u2014 |  |  | Other long-term liabilities | 351 |  | 375 | \nTotal derivatives |  | $ | 161 |  | $ | 163 |  |  |  | $ | 544 |  | $ | 524 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in millions) |  |  |  |  |  | 2023 |  | 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  |  | \nDesignated as cash flow hedges |  |  |  |  |  | $ | (9) |  |  | $ | (6) | \nDesignated as net investment hedges |  |  |  |  |  | (94) |  |  | 82 | \nInterest rate swap contracts designated as cash flow hedges |  |  |  |  |  | \u2014 |  |  | 4 | \n |  |  |  |  |  |  |  |   |  |  |  |  | \n2023 Form 10-Q| | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) | Statement\u00a0of earnings caption |  |  |  |  |  | 2023 |  | 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Cost of products sold |  |  |  |  |  | $ | 30 |  |  | $ | 8 | \nDesignated as net investment hedges | Interest expense, net |  |  |  |  |  | 28 |  |  | 14 | \nNot designated as hedges | Net foreign exchange loss |  |  |  |  |  | 30 |  |  | (41) | \nTreasury rate lock agreements designated as cash flow hedges | Interest expense, net |  |  |  |  |  | 6 |  |  | 6 | \nInterest rate swap contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Interest expense, net |  |  |  |  |  | \u2014 |  |  | (2) | \nDesignated as fair value hedges | Interest expense, net |  |  |  |  |  | 35 |  |  | (184) | \nDebt designated as hedged item in fair value hedges | Interest expense, net |  |  |  |  |  | (35) |  |  | 184 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 6,711 |  |  | $ | 3,297 |  |  | $ | 3,414 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 10 |  |  | \u2014 |  |  | 10 |  |  | \u2014 | \nDebt securities | 33 |  |  | \u2014 |  |  | 33 |  |  | \u2014 | \nEquity securities | 110 |  |  | 80 |  |  | 30 |  |  | \u2014 | \nInterest rate swap contracts | 11 |  |  | \u2014 |  |  | 11 |  |  | \u2014 | \nForeign currency contracts | 150 |  |  | \u2014 |  |  | 150 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 7,025 |  |  | $ | 3,377 |  |  | $ | 3,648 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 368 |  |  | $ | \u2014 |  |  | $ | 368 |  |  | $ | \u2014 | \nForeign currency contracts | 176 |  |  | \u2014 |  |  | 176 |  |  | \u2014 | \n |  |  |  |  |  |  | \nContingent consideration | 17,931 |  |  | \u2014 |  |  | \u2014 |  |  | 17,931 | \nTotal liabilities | $ | 18,475 |  |  | $ | \u2014 |  |  | $ | 544 |  |  | $ | 17,931 |   |  |  |  |  | \n2023 Form 10-Q| | 13  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 9,201 |  |  | $ | 4,201 |  |  | $ | 5,000 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 21 |  |  | \u2014 |  |  | 21 |  |  | \u2014 | \nDebt securities | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nEquity securities | 91 |  |  | 59 |  |  | 32 |  |  | \u2014 | \nForeign currency contracts | 163 |  |  | \u2014 |  |  | 163 |  |  | \u2014 | \nTotal assets | $ | 9,504 |  |  | $ | 4,260 |  |  | $ | 5,244 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 392 |  |  | $ | \u2014 |  |  | $ | 392 |  |  | $ | \u2014 | \nForeign currency contracts | 132 |  |  | \u2014 |  |  | 132 |  |  | \u2014 | \nContingent consideration | 16,384 |  |  | \u2014 |  |  | \u2014 |  |  | 16,384 | \nTotal liabilities | $ | 16,908 |  |  | $ | \u2014 |  |  | $ | 524 |  |  | $ | 16,384 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\n(in\u00a0millions) | Range | Weighted average(a) |  | Range | Weighted average(a)\nDiscount rate | 4.2% -5.4% | 4.5% |  | 4.7%-5.1% | 4.8%\nProbability of payment for unachieved milestones | 100% -100% | 100% |  | 100% -100% | 100%\nProbability of payment for royalties by indication(b) | 89% -100% | 100% |  | 56% -100% | 99%\n |  |  |  |  | \nProjected year of payments | 2023-2034 | 2028 |  | 2023-2034 | 2028  |  |  |  |  | \n2023 Form 10-Q| | 14  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedMarch 31,\n(in\u00a0millions) |  | 2023 |  | 2022\nBeginning balance |  | $ | 16,384 |  |  | $ | 14,887 | \nChange in fair value recognized in net earnings |  | 1,872 |  |  | (748) | \nPayments |  | (325) |  |  | (321) | \nEnding balance |  | $ | 17,931 |  |  | $ | 13,818 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 1 |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 2,816 |  | 2,793 |  |  | 2,703 |  |  | 90 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 59,590 |  | 55,784 |  |  | 55,058 |  |  | 726 |  |  | \u2014 | \nTotal liabilities | $ | 62,407 |  | $ | 58,578 |  |  | $ | 57,761 |  |  | $ | 817 |  |  | $ | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 1 |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 4,152 |  | 4,121 |  |  | 3,930 |  |  | 191 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 59,463 |  | 54,073 |  |  | 53,365 |  |  | 708 |  |  | \u2014 | \nTotal liabilities | $ | 63,616 |  | $ | 58,195 |  |  | $ | 57,295 |  |  | $ | 900 |  |  | $ | \u2014 |   |  |  |  |  | \n2023 Form 10-Q| | 15  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Definedbenefit\u00a0plans |  |  |  |  |  | Other\u00a0post-employment\u00a0plans\n |  |  | Three months endedMarch 31, |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022\nService cost |  |  |  |  | $ | 68 |  |  | $ | 116 |  |  |  |  |  |  | $ | 8 |  |  | $ | 12 | \nInterest cost |  |  |  |  | 107 |  |  | 74 |  |  |  |  |  |  | 9 |  |  | 6 | \nExpected return on plan assets |  |  |  |  | (180) |  |  | (180) |  |  |  |  |  |  | \u2014 |  |  | \u2014 | \nAmortization of prior service cost (credit) |  |  |  |  | \u2014 |  |  | 1 |  |  |  |  |  |  | (9) |  |  | (10) | \nAmortization of actuarial loss |  |  |  |  | 4 |  |  | 57 |  |  |  |  |  |  | 3 |  |  | 7 | \nNet periodic benefit cost |  |  |  |  | $ | (1) |  |  | $ | 68 |  |  |  |  |  |  | $ | 11 |  |  | $ | 15 |   |  |  |  |  | \n2023 Form 10-Q| | 16  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  | 2023 |  | 2022\nCost of products sold |  |  |  |  |  | $ | 20 |  |  | $ | 19 | \nResearch and development |  |  |  |  |  | 117 |  |  | 107 | \nSelling, general and administrative |  |  |  |  |  | 176 |  |  | 180 | \nPre-tax compensation expense |  |  |  |  |  | 313 |  |  | 306 | \nTax benefit |  |  |  |  |  | 55 |  |  | 56 | \nAfter-tax compensation expense |  |  |  |  |  | $ | 258 |  |  | $ | 250 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2023 |  | 2022\nDate Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share\n02/16/23 |  | 05/15/23 |  | $ | 1.48 |  |  | 10/28/22 |  | 02/15/23 |  | $ | 1.48 | \n |  |  |  |  |  | 09/09/22 |  | 11/15/22 |  | $ | 1.41 | \n |  |  |  |  |  | 06/23/22 |  | 08/15/22 |  | $ | 1.41 | \n |  |  |  |  |  | 02/17/22 |  | 05/16/22 |  | $ | 1.41 |   |  |  |  |  | \n2023 Form 10-Q| | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2022 | $ | (1,513) |  |  | $ | 464 |  |  | $ | (1,458) |  |  |  |  | $ | 308 |  |  | $ | (2,199) | \nOther comprehensive income (loss) before reclassifications | 194 |  |  | (202) |  |  | 40 |  |  |  |  | (10) |  |  | 22 | \nNet gains reclassified from accumulated other comprehensive loss | \u2014 |  |  | (22) |  |  | (2) |  |  |  |  | (31) |  |  | (55) | \nNet current-period other comprehensive income (loss) | 194 |  |  | (224) |  |  | 38 |  |  |  |  | (41) |  |  | (33) | \nBalance as of March 31, 2023 | $ | (1,319) |  |  | $ | 240 |  |  | $ | (1,420) |  |  |  |  | $ | 267 |  |  | $ | (2,232) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2021 | $ | (570) |  |  | $ | (91) |  |  | $ | (2,546) |  |  |  |  | $ | 308 |  |  | $ | (2,899) | \nOther comprehensive income (loss) before reclassifications | (231) |  |  | 142 |  |  | (15) |  |  |  |  | (1) |  |  | (105) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (12) |  |  | 43 |  |  |  |  | (11) |  |  | 20 | \nNet current-period other comprehensive income (loss) | (231) |  |  | 130 |  |  | 28 |  |  |  |  | (12) |  |  | (85) | \nBalance as of March 31, 2022 | $ | (801) |  |  | $ | 39 |  |  | $ | (2,518) |  |  |  |  | $ | 296 |  |  | $ | (2,984) |   |  |  |  |  | \n2023 Form 10-Q| | 18  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedMarch 31,\n(in millions) (brackets\u00a0denote\u00a0gains) |  |  |  |  | 2023 |  | 2022\nNet investment hedging activities |  |  |  |  |  |  | \nGains on derivative amount excluded from effectiveness testing(a) |  |  |  |  | $ | (28) |  |  | $ | (14) | \nTax expense |  |  |  |  | 6 |  |  | 2 | \nTotal reclassifications, net of tax |  |  |  |  | $ | (22) |  |  | $ | (12) | \nPension and post-employment benefits |  |  |  |  |  |  | \nAmortization of actuarial losses and other(b) |  |  |  |  | $ | (2) |  |  | $ | 55 | \nTax benefit |  |  |  |  | \u2014 |  |  | (12) | \nTotal reclassifications, net of tax |  |  |  |  | $ | (2) |  |  | $ | 43 | \nCash flow hedging activities |  |  |  |  |  |  | \nLosses (gains) on foreign currency forward exchange contracts(c) |  |  |  |  | $ | (30) |  |  | $ | (8) | \nGains on treasury rate lock agreements(a) |  |  |  |  | (6) |  |  | (6) | \nLosses on interest rate swap contracts(a) |  |  |  |  | \u2014 |  |  | 2 | \nTax expense (benefit) |  |  |  |  | 5 |  |  | 1 | \nTotal reclassifications, net of tax |  |  |  |  | $ | (31) |  |  | $ | (11) |   |  | \n  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 19  |  |  |  |  | \n2023 Form 10-Q| | 20  |  |  |  |  | \n2023 Form 10-Q| | 21  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n |  | \n(in\u00a0millions) |  |  |  |  |  | 2023 |  | 2022\nImmunology |  |  |  |  |  |  | \nHumira | United States |  |  |  |  | $ | 2,948 |  |  | $ | 3,993 | \n | International |  |  |  |  | 593 |  |  | 743 | \n | Total |  |  |  |  | $ | 3,541 |  |  | $ | 4,736 | \nSkyrizi | United States |  |  |  |  | $ | 1,139 |  |  | $ | 781 | \n | International |  |  |  |  | 221 |  |  | 159 | \n | Total |  |  |  |  | $ | 1,360 |  |  | $ | 940 | \nRinvoq | United States |  |  |  |  | $ | 449 |  |  | $ | 311 | \n | International |  |  |  |  | 237 |  |  | 154 | \n | Total |  |  |  |  | $ | 686 |  |  | $ | 465 | \nHematologic Oncology |  |  |  |  |  |  | \nImbruvica | United States |  |  |  |  | $ | 638 |  |  | $ | 874 | \n | Collaboration revenues |  |  |  |  | 240 |  |  | 299 | \n | Total |  |  |  |  | $ | 878 |  |  | $ | 1,173 | \nVenclexta | United States |  |  |  |  | $ | 265 |  |  | $ | 228 | \n | International |  |  |  |  | 273 |  |  | 245 | \n | Total |  |  |  |  | $ | 538 |  |  | $ | 473 | \nAesthetics |  |  |  |  |  |  | \nBotox Cosmetic | United States |  |  |  |  | $ | 409 |  |  | $ | 413 | \n | International |  |  |  |  | 250 |  |  | 228 | \n | Total |  |  |  |  | $ | 659 |  |  | $ | 641 | \nJuvederm Collection | United States |  |  |  |  | $ | 122 |  |  | $ | 148 | \n | International |  |  |  |  | 233 |  |  | 262 | \n | Total |  |  |  |  | $ | 355 |  |  | $ | 410 | \nOther Aesthetics | United States |  |  |  |  | $ | 246 |  |  | $ | 285 | \n | International |  |  |  |  | 40 |  |  | 38 | \n | Total |  |  |  |  | $ | 286 |  |  | $ | 323 | \nNeuroscience |  |  |  |  |  |  | \nBotox Therapeutic | United States |  |  |  |  | $ | 587 |  |  | $ | 500 | \n | International |  |  |  |  | 132 |  |  | 114 | \n | Total |  |  |  |  | $ | 719 |  |  | $ | 614 | \nVraylar | United States |  |  |  |  | $ | 560 |  |  | $ | 427 | \n | International |  |  |  |  | 1 |  |  | \u2014 | \n | Total |  |  |  |  | $ | 561 |  |  | $ | 427 | \nDuodopa | United States |  |  |  |  | $ | 25 |  |  | $ | 24 | \n | International |  |  |  |  | 93 |  |  | 97 | \n | Total |  |  |  |  | $ | 118 |  |  | $ | 121 | \nUbrelvy | United States |  |  |  |  | $ | 150 |  |  | $ | 138 | \n | International |  |  |  |  | 2 |  |  | \u2014 | \n | Total |  |  |  |  | $ | 152 |  |  | $ | 138 | \nQulipta | United States |  |  |  |  | $ | 66 |  |  | $ | 11 |   |  |  |  |  | \n2023 Form 10-Q| | 22  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n |  | \n(in\u00a0millions) |  |  |  |  |  | 2023 |  | 2022\nOther Neuroscience | United States |  |  |  |  | $ | 75 |  |  | $ | 173 | \n | International |  |  |  |  | 4 |  |  | 4 | \n | Total |  |  |  |  | $ | 79 |  |  | $ | 177 | \nEye Care |  |  |  |  |  |  | \nOzurdex | United States |  |  |  |  | $ | 39 |  |  | $ | 33 | \n | International |  |  |  |  | 76 |  |  | 74 | \n | Total |  |  |  |  | 115 |  |  | 107 | \nLumigan/Ganfort | United States |  |  |  |  | $ | 63 |  |  | $ | 67 | \n | International |  |  |  |  | 67 |  |  | 73 | \n | Total |  |  |  |  | $ | 130 |  |  | $ | 140 | \nAlphagan/Combigan | United States |  |  |  |  | $ | 28 |  |  | $ | 70 | \n | International |  |  |  |  | 43 |  |  | 37 | \n | Total |  |  |  |  | $ | 71 |  |  | $ | 107 | \nRestasis | United States |  |  |  |  | $ | 79 |  |  | $ | 235 | \n | International |  |  |  |  | 13 |  |  | 11 | \n | Total |  |  |  |  | $ | 92 |  |  | $ | 246 | \nOther Eye Care | United States |  |  |  |  | $ | 110 |  |  | $ | 91 | \n | International |  |  |  |  | 90 |  |  | 80 | \n | Total |  |  |  |  | $ | 200 |  |  | $ | 171 | \nOther Key Products |  |  |  |  |  |  | \nMavyret | United States |  |  |  |  | $ | 171 |  |  | $ | 169 | \n | International |  |  |  |  | 193 |  |  | 211 | \n | Total |  |  |  |  | $ | 364 |  |  | $ | 380 | \nCreon | United States |  |  |  |  | $ | 305 |  |  | $ | 287 | \nLinzess/Constella | United States |  |  |  |  | $ | 251 |  |  | $ | 233 | \n | International |  |  |  |  | 8 |  |  | 7 | \n | Total |  |  |  |  | $ | 259 |  |  | $ | 240 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nAll other |  |  |  |  |  | $ | 691 |  |  | $ | 1,211 | \nTotal net revenues |  |  |  |  | $ | 12,225 |  |  | $ | 13,538 |   |  |  |  |  | \n2023 Form 10-Q| | 23  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 24  |  |  |  |  | \n2023 Form 10-Q| | 25  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | Three months endedMarch 31, |  | Percent\u00a0change\n |  |  |  |  |  |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  |  |  |  |  |  | 2023 |  | 2022 | \nUnited States |  |  |  |  |  |  |  |  |  | $ | 9,201 |  |  | $ | 10,348 |  |  | (11.1) | % |  | (11.1) | %\nInternational |  |  |  |  |  |  |  |  |  | 3,024 |  |  | 3,190 |  |  | (5.2) | % |  | 0.9 | %\nNet revenues |  |  |  |  |  |  |  |  |  | $ | 12,225 |  |  | $ | 13,538 |  |  | (9.7) | % |  | (8.3) | %  |  |  |  |  | \n2023 Form 10-Q| | 26  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | Three months endedMarch 31, |  | Percent\u00a0change\n |  |  |  |  |  |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  |  |  |  |  |  | 2023 |  | 2022 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHumira | United States |  |  |  |  |  |  |  |  |  | $ | 2,948 |  |  | $ | 3,993 |  |  | (26.1) | % |  | (26.1) | %\n | International |  |  |  |  |  |  |  |  |  | 593 |  |  | 743 |  |  | (20.3) | % |  | (14.8) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 3,541 |  |  | $ | 4,736 |  |  | (25.2) | % |  | (24.3) | %\nSkyrizi | United States |  |  |  |  |  |  |  |  |  | $ | 1,139 |  |  | $ | 781 |  |  | 45.9 | % |  | 45.9 | %\n | International |  |  |  |  |  |  |  |  |  | 221 |  |  | 159 |  |  | 38.5 | % |  | 47.7 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 1,360 |  |  | $ | 940 |  |  | 44.7 | % |  | 46.3 | %\nRinvoq | United States |  |  |  |  |  |  |  |  |  | $ | 449 |  |  | $ | 311 |  |  | 44.4 | % |  | 44.4 | %\n | International |  |  |  |  |  |  |  |  |  | 237 |  |  | 154 |  |  | 53.7 | % |  | 64.9 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 686 |  |  | $ | 465 |  |  | 47.5 | % |  | 51.2 | %\nHematologic Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nImbruvica | United States |  |  |  |  |  |  |  |  |  | $ | 638 |  |  | $ | 874 |  |  | (27.0) | % |  | (27.0) | %\n | Collaboration revenues |  |  |  |  |  |  |  |  |  | 240 |  |  | 299 |  |  | (19.7) | % |  | (19.7) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 878 |  |  | $ | 1,173 |  |  | (25.2) | % |  | (25.2) | %\nVenclexta | United States |  |  |  |  |  |  |  |  |  | $ | 265 |  |  | $ | 228 |  |  | 15.7 | % |  | 15.7 | %\n | International |  |  |  |  |  |  |  |  |  | 273 |  |  | 245 |  |  | 11.8 | % |  | 19.2 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 538 |  |  | $ | 473 |  |  | 13.7 | % |  | 17.5 | %\nAesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Cosmetic | United States |  |  |  |  |  |  |  |  |  | $ | 409 |  |  | $ | 413 |  |  | (0.7) | % |  | (0.7) | %\n | International |  |  |  |  |  |  |  |  |  | 250 |  |  | 228 |  |  | 9.4 | % |  | 17.5 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 659 |  |  | $ | 641 |  |  | 2.9 | % |  | 5.8 | %\nJuvederm Collection | United States |  |  |  |  |  |  |  |  |  | $ | 122 |  |  | $ | 148 |  |  | (17.9) | % |  | (17.9) | %\n | International |  |  |  |  |  |  |  |  |  | 233 |  |  | 262 |  |  | (10.9) | % |  | (1.4) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 355 |  |  | $ | 410 |  |  | (13.4) | % |  | (7.4) | %\nOther Aesthetics | United States |  |  |  |  |  |  |  |  |  | $ | 246 |  |  | $ | 285 |  |  | (13.6) | % |  | (13.6) | %\n | International |  |  |  |  |  |  |  |  |  | 40 |  |  | 38 |  |  | 3.6 | % |  | 12.7 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 286 |  |  | $ | 323 |  |  | (11.5) | % |  | (10.4) | %\nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Therapeutic | United States |  |  |  |  |  |  |  |  |  | $ | 587 |  |  | $ | 500 |  |  | 17.5 | % |  | 17.5 | %\n | International |  |  |  |  |  |  |  |  |  | 132 |  |  | 114 |  |  | 15.5 | % |  | 24.2 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 719 |  |  | $ | 614 |  |  | 17.1 | % |  | 18.7 | %\nVraylar | United States |  |  |  |  |  |  |  |  |  | $ | 560 |  |  | $ | 427 |  |  | 31.2 | % |  | 31.2 | %\n | International |  |  |  |  |  |  |  |  |  | 1 |  |  | \u2014 |  |  | n/m |  | n/m\n | Total |  |  |  |  |  |  |  |  |  | $ | 561 |  |  | $ | 427 |  |  | 31.3 | % |  | 31.3 | %\nDuodopa | United States |  |  |  |  |  |  |  |  |  | $ | 25 |  |  | $ | 24 |  |  | 6.5 | % |  | 6.5 | %\n | International |  |  |  |  |  |  |  |  |  | 93 |  |  | 97 |  |  | (4.3) | % |  | 1.7 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 118 |  |  | $ | 121 |  |  | (2.2) | % |  | 2.6 | %\nUbrelvy | United States |  |  |  |  |  |  |  |  |  | $ | 150 |  |  | $ | 138 |  |  | 9.0 | % |  | 9.0 | %\n | International |  |  |  |  |  |  |  |  |  | 2 |  |  | \u2014 |  |  | n/m |  | n/m\n | Total |  |  |  |  |  |  |  |  |  | $ | 152 |  |  | $ | 138 |  |  | 10.0 | % |  | 10.0 | %\nQulipta | United States |  |  |  |  |  |  |  |  |  | $ | 66 |  |  | $ | 11 |  |  | >100.0 % |  | >100.0 %\nOther Neuroscience | United States |  |  |  |  |  |  |  |  |  | $ | 75 |  |  | $ | 173 |  |  | (56.7) | % |  | (56.7) | %\n | International |  |  |  |  |  |  |  |  |  | 4 |  |  | 4 |  |  | 6.9 | % |  | 12.6 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 79 |  |  | $ | 177 |  |  | (55.2) | % |  | (55.1) | %  |  |  |  |  | \n2023 Form 10-Q| | 27  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | Three months endedMarch 31, |  | Percent\u00a0change\n |  |  |  |  |  |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  |  |  |  |  |  | 2023 |  | 2022 | \nEye Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOzurdex | United States |  |  |  |  |  |  |  |  |  | $ | 39 |  |  | $ | 33 |  |  | 16.1 | % |  | 16.1 | %\n | International |  |  |  |  |  |  |  |  |  | 76 |  |  | 74 |  |  | 3.2 | % |  | 10.3 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 115 |  |  | $ | 107 |  |  | 7.3 | % |  | 12.2 | %\nLumigan/Ganfort | United States |  |  |  |  |  |  |  |  |  | $ | 63 |  |  | $ | 67 |  |  | (6.8) | % |  | (6.8) | %\n | International |  |  |  |  |  |  |  |  |  | 67 |  |  | 73 |  |  | (7.2) | % |  | (2.7) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 130 |  |  | $ | 140 |  |  | (7.0) | % |  | (4.7) | %\nAlphagan/Combigan | United States |  |  |  |  |  |  |  |  |  | $ | 28 |  |  | $ | 70 |  |  | (59.4) | % |  | (59.4) | %\n | International |  |  |  |  |  |  |  |  |  | 43 |  |  | 37 |  |  | 16.9 | % |  | 24.2 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 71 |  |  | $ | 107 |  |  | (33.3) | % |  | (30.8) | %\nRestasis | United States |  |  |  |  |  |  |  |  |  | $ | 79 |  |  | $ | 235 |  |  | (66.5) | % |  | (66.5) | %\n | International |  |  |  |  |  |  |  |  |  | 13 |  |  | 11 |  |  | 20.4 | % |  | 25.1 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 92 |  |  | $ | 246 |  |  | (62.8) | % |  | (62.6) | %\nOther Eye Care | United States |  |  |  |  |  |  |  |  |  | $ | 110 |  |  | $ | 91 |  |  | 22.9 | % |  | 22.9 | %\n | International |  |  |  |  |  |  |  |  |  | 90 |  |  | 80 |  |  | 10.3 | % |  | 16.3 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 200 |  |  | $ | 171 |  |  | 16.9 | % |  | 19.8 | %\nOther Key Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMavyret | United States |  |  |  |  |  |  |  |  |  | $ | 171 |  |  | $ | 169 |  |  | 1.2 | % |  | 1.2 | %\n | International |  |  |  |  |  |  |  |  |  | 193 |  |  | 211 |  |  | (8.1) | % |  | (1.8) | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 364 |  |  | $ | 380 |  |  | (4.0) | % |  | (0.5) | %\nCreon | United States |  |  |  |  |  |  |  |  |  | $ | 305 |  |  | $ | 287 |  |  | 6.3 | % |  | 6.3 | %\nLinzess/Constella | United States |  |  |  |  |  |  |  |  |  | $ | 251 |  |  | $ | 233 |  |  | 7.7 | % |  | 7.7 | %\n | International |  |  |  |  |  |  |  |  |  | 8 |  |  | 7 |  |  | 11.9 | % |  | 17.8 | %\n | Total |  |  |  |  |  |  |  |  |  | $ | 259 |  |  | $ | 240 |  |  | 7.8 | % |  | 8.0 | %\nAll other |  |  |  |  |  |  |  |  |  |  | $ | 691 |  |  | $ | 1,211 |  |  | (43.1) | % |  | (42.2) | %\nTotal net revenues |  |  |  |  |  |  |  |  |  | $ | 12,225 |  |  | $ | 13,538 |  |  | (9.7) | % |  | (8.3) | %  |  |  |  |  | \n2023 Form 10-Q| | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(dollars in\u00a0millions) |  |  |  |  |  |  |  | 2023 |  | 2022 |  | % change\nGross margin |  |  |  |  |  |  |  | $ | 8,239 |  | $ | 9,486 |  | (13) | %\nas a % of net revenues |  |  |  |  |  |  |  | 67 | % |  | 70 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(dollars in\u00a0millions) |  |  |  |  |  |  |  | 2023 |  | 2022 |  | % change\nSelling, general and administrative |  |  |  |  |  |  |  | $ | 3,039 |  | $ | 3,127 |  | (3) | %\nas a % of net revenues |  |  |  |  |  |  |  | 25 | % |  | 23 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(dollars in\u00a0millions) |  |  |  |  |  |  |  | 2023 |  | 2022 |  | % change\nResearch and development |  |  |  |  |  |  |  | $ | 2,292 |  | $ | 1,497 |  | 53 | %\nas a % of net revenues |  |  |  |  |  |  |  | 19 | % |  | 11 | % |  | \nAcquired IPR&D and milestones |  |  |  |  |  |  |  | $ | 150 |  | $ | 145 |  | 3 | %  |  |  |  |  | \n2023 Form 10-Q| | 29  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three months endedMarch 31,\n(in\u00a0millions) |  |  |  |  |  | 2023 |  | 2022\nInterest expense |  |  |  |  |  | $ | 553 |  |  | $ | 548 | \nInterest income |  |  |  |  |  | (99) |  |  | (9) | \nInterest expense, net |  |  |  |  |  | $ | 454 |  |  | $ | 539 | \n |  |  |  |  |  |  |  | \nNet foreign exchange loss |  |  |  |  |  | $ | 35 |  |  | $ | 25 | \nOther expense (income), net |  |  |  |  |  | 1,804 |  |  | (776) |   |  |  |  |  |  |  |  |  |  |  | \n | Three months endedMarch 31,\n(in\u00a0millions) | 2023 |  | 2022\nCash flows provided by (used in): |  |  | \nOperating activities | $ | 4,193 |  |  | $ | 4,908 | \nInvesting activities | (499) |  |  | (1,591) | \nFinancing activities | (6,192) |  |  | (6,972) |   |  |  |  |  | \n2023 Form 10-Q| | 30  |  |  |  |  | \n2023 Form 10-Q| | 31  |  | \n  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 32  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | (a)\u00a0TotalNumber\u00a0ofShares(or Units)Purchased |  | (b)\u00a0AveragePrice\u00a0Paidper\u00a0Share(or\u00a0Unit) |  | (c)\u00a0Total\u00a0Numberof\u00a0Shares\u00a0(orUnits)\u00a0Purchasedas\u00a0Part\u00a0of\u00a0PubliclyAnnounced\u00a0Plansor\u00a0Programs |  | (d)\u00a0MaximumNumber\u00a0(orApproximateDollar\u00a0Value)\u00a0ofShares\u00a0(or\u00a0Units)that\u00a0May\u00a0Yet\u00a0BePurchased\u00a0Underthe\u00a0Plans\u00a0orPrograms | \nJanuary 1, 2023 - January 31, 2023 | 844 |  | (1) | $165.36 | (1) | \u2014 |  |  | $1,393,714,917 | \nFebruary 1, 2023 - February 28, 2023 | 7,306,847 |  | (1) | $152.58 | (1) | 7,305,832 |  |  | $5,278,990,201 | (2)\nMarch 1, 2023 - March 31, 2023 | 3,035,907 |  | (1) | $154.86 | (1) | 3,034,981 |  |  | $4,808,991,028 | (2)\nTotal | 10,343,598 |  | (1) | $153.25 | (1) | 10,340,813 |  |  | $4,808,991,028 | (2)  |  |  |  |  | \n2023 Form 10-Q| | 33  |  | \n  |  |  |  |  |  |  |  |  |  |  | \nExhibit\u00a0No. |  | Exhibit\u00a0Description | \n |  |  | \n10.1 |  | Form of AbbVie Inc. Performance-Vested Restricted Stock Unit Agreement* | \n |  |  | \n10.2 |  | Form of AbbVie Inc. Performance Share Award Agreement* | \n |  |  | \n10.3 |  | Form of AbbVie Inc. Non-Employee Director RSU Agreement (US)* | \n |  |  | \n10.4 |  | Form of AbbVie Inc. Non-Qualified Stock Option Agreement* | \n |  |  | \n10.5 |  | Form of AbbVie Inc. Retention RSU Agreement - Ratable Vesting* | \n |  |  | \n10.6 |  | Form of AbbVie Inc. Non-Employee Directors\u2019 Fee Plan, as amended and restated* | \n |  |  | \n31.1 |  | Certification of Chief Executive Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n31.2 |  | Certification of Chief Financial Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n32.1 |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n32.2 |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n101 |  | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form\u00a010-Q for the quarter ended March 31, 2023, filed on May\u00a05, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)\u00a0Condensed Consolidated Statements of Earnings; (ii)\u00a0Condensed Consolidated Statements of Comprehensive Income; (iii)\u00a0Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)\u00a0Condensed Consolidated Statements of Cash Flows; and (vi)\u00a0the Notes to Condensed Consolidated Financial Statements. | \n |  |  | \n104 |  | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). |   |  |  |  |  | \n2023 Form 10-Q| | 34  |  |  |  |  |  |  |  | \n |  | ABBVIE INC.\n |  | \n |  | \n | By: | /s/ Scott T. Reents\n |  | Scott T. Reents\n |  | Executive Vice President,\n |  | Chief Financial Officer (Principal Financial Officer)  |  |  |  |  | \n2023 Form 10-Q| | 35"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For AbbVie, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \n(Exact name of registrant as specified in its charter)\nDelaware |  | 32-0375147\n(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)  |  |  |  |  |  |  |  |  |  |  | \nLarge Accelerated Filer | \u2612 | Accelerated Filer | \u2610\nNon-Accelerated Filer | \u2610 | Smaller reporting company | \u2610\n |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, par value $0.01 per share |  | ABBV |  | New York Stock Exchange\n |  |  |  | Chicago Stock Exchange\n1.500% Senior Notes due 2023 |  | ABBV23B |  | New York Stock Exchange\n1.375% Senior Notes due 2024 |  | ABBV24 |  | New York Stock Exchange\n1.250% Senior Notes due 2024 |  | ABBV24B |  | New York Stock Exchange\n0.750% Senior Notes due 2027 |  | ABBV27 |  | New York Stock Exchange\n2.125% Senior Notes due 2028 |  | ABBV28 |  | New York Stock Exchange\n2.625% Senior Notes due 2028 |  | ABBV28B |  | New York Stock Exchange\n2.125% Senior Notes due 2029 |  | ABBV29 |  | New York Stock Exchange\n1.250% Senior Notes due 2031 |  | ABBV31 |  | New York Stock Exchange  |  | \n  |  |  |  |  |  |  |  | \nPART\u00a0I. | FINANCIAL INFORMATION\n |  | Page\n |  | \nItem 1. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 1\nItem 2. | MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 24\nItem 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 33\nItem 4. | CONTROLS AND PROCEDURES | 34\n |  | \nPART\u00a0II. | OTHER INFORMATION\n |  | \nItem 1. | LEGAL PROCEEDINGS | 35\n |  | \nItem 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 35\nItem 5. | OTHER ITEMS | 35\nItem 6. | EXHIBITS | 36  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet revenues |  | $ | 13,865 |  |  | $ | 14,583 |  |  | $ | 26,090 |  |  | $ | 28,121 | \n |  |  |  |  |  |  |  | \nCost of products sold |  | 4,240 |  |  | 4,170 |  |  | 8,226 |  |  | 8,222 | \nSelling, general and administrative |  | 3,268 |  |  | 5,412 |  |  | 6,307 |  |  | 8,539 | \nResearch and development |  | 1,733 |  |  | 1,609 |  |  | 4,025 |  |  | 3,106 | \nAcquired IPR&D and milestones |  | 280 |  |  | 269 |  |  | 430 |  |  | 414 | \nOther operating income |  | (169) |  |  | (172) |  |  | (179) |  |  | (172) | \nTotal operating costs and expenses |  | 9,352 |  |  | 11,288 |  |  | 18,809 |  |  | 20,109 | \nOperating earnings |  | 4,513 |  |  | 3,295 |  |  | 7,281 |  |  | 8,012 | \n |  |  |  |  |  |  |  | \nInterest expense, net |  | 454 |  |  | 532 |  |  | 908 |  |  | 1,071 | \nNet foreign exchange loss |  | 37 |  |  | 47 |  |  | 72 |  |  | 72 | \nOther expense, net |  | 1,412 |  |  | 1,533 |  |  | 3,216 |  |  | 757 | \nEarnings before income tax expense |  | 2,610 |  |  | 1,183 |  |  | 3,085 |  |  | 6,112 | \nIncome tax expense |  | 583 |  |  | 255 |  |  | 817 |  |  | 691 | \nNet earnings |  | 2,027 |  |  | 928 |  |  | 2,268 |  |  | 5,421 | \nNet earnings attributable to noncontrolling interest |  | 3 |  |  | 4 |  |  | 5 |  |  | 7 | \nNet earnings attributable to AbbVie Inc. |  | $ | 2,024 |  |  | $ | 924 |  |  | $ | 2,263 |  |  | $ | 5,414 | \n |  |  |  |  |  |  |  | \nPer share data |  |  |  |  |  |  |  | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 1.14 |  |  | $ | 0.52 |  |  | $ | 1.27 |  |  | $ | 3.04 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 1.14 |  |  | $ | 0.51 |  |  | $ | 1.26 |  |  | $ | 3.03 | \n |  |  |  |  |  |  |  | \nWeighted-average basic shares outstanding |  | 1,767 |  |  | 1,770 |  |  | 1,768 |  |  | 1,770 | \nWeighted-average diluted shares outstanding |  | 1,771 |  |  | 1,776 |  |  | 1,773 |  |  | 1,777 |   |  |  |  |  | \n2023 Form 10-Q| | 1  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet earnings | $ | 2,027 |  |  | $ | 928 |  |  | $ | 2,268 |  |  | $ | 5,421 | \n |  |  |  |  |  |  | \nForeign currency translation adjustments, net of tax expense (benefit) of $(6) for the three months and $6for the six months ended June 30, 2023 and $(12) for the three months and $(19) for the six months ended June 30, 2022 | (16) |  |  | (823) |  |  | 178 |  |  | (1,054) | \nNet investment hedging activities, net of tax expense (benefit) of $2for the three months and $(58) for the six months ended June 30, 2023 and $146for the three months and $183for the six months ended June 30, 2022 | 11 |  |  | 536 |  |  | (213) |  |  | 666 | \nPension and post-employment benefits, net of tax expense (benefit) of $(4) for the three months and $10for the six months ended June 30, 2023 and $11for the three months and $21for the six months ended June 30, 2022 | (2) |  |  | 48 |  |  | 36 |  |  | 76 | \nCash flow hedging activities, net of tax expense (benefit) of $(4) for the three months and $(8) for the six months ended June 30, 2023 and $5for the three months and $3for the six months ended June 30, 2022 | (13) |  |  | 27 |  |  | (54) |  |  | 15 | \nOther comprehensive loss | (20) |  |  | (212) |  |  | (53) |  |  | (297) | \nComprehensive income | 2,007 |  |  | 716 |  |  | 2,215 |  |  | 5,124 | \nComprehensive income attributable to noncontrolling interest | 3 |  |  | 4 |  |  | 5 |  |  | 7 | \nComprehensive income attributable to AbbVie Inc. | $ | 2,004 |  |  | $ | 712 |  |  | $ | 2,210 |  |  | $ | 5,117 |   |  |  |  |  | \n2023 Form 10-Q| | 2  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions,\u00a0except\u00a0share\u00a0data) | June 30,2023 |  | December 31,2022\n | (unaudited) |  | \nAssets |  |  | \nCurrent assets |  |  | \nCash and equivalents | $ | 8,759 |  |  | $ | 9,201 | \nShort-term investments | 7 |  |  | 28 | \nAccounts receivable, net | 11,491 |  |  | 11,254 | \nInventories | 4,055 |  |  | 3,579 | \nPrepaid expenses and other | 4,540 |  |  | 4,401 | \nTotal current assets | 28,852 |  |  | 28,463 | \n |  |  | \nInvestments | 288 |  |  | 241 | \nProperty and equipment, net | 4,943 |  |  | 4,935 | \nIntangible assets, net | 62,862 |  |  | 67,439 | \nGoodwill | 32,224 |  |  | 32,156 | \nOther assets | 6,198 |  |  | 5,571 | \nTotal assets | $ | 135,367 |  |  | $ | 138,805 | \n |  |  | \nLiabilities and Equity |  |  | \nCurrent liabilities |  |  | \nShort-term borrowings | $ | \u2014 |  |  | $ | 1 | \nCurrent portion of long-term debt and finance lease obligations | 5,203 |  |  | 4,135 | \nAccounts payable and accrued liabilities | 27,036 |  |  | 25,402 | \nTotal current liabilities | 32,239 |  |  | 29,538 | \n |  |  | \nLong-term debt and finance lease obligations | 55,812 |  |  | 59,135 | \nDeferred income taxes | 2,124 |  |  | 2,190 | \nOther long-term liabilities | 32,294 |  |  | 30,655 | \n |  |  | \nCommitments and contingencies |  |  | \n |  |  | \nStockholders' equity |  |  | \nCommon stock, $0.01par value,4,000,000,000shares authorized,1,821,926,709shares issued as of June 30, 2023 and1,813,770,294as of December 31, 2022 | 18 |  |  | 18 | \nCommon stock held in treasury, at cost,57,127,750shares as of June 30, 2023 and44,589,000as of December 31, 2022 | (6,528) |  |  | (4,594) | \nAdditional paid-in capital | 19,839 |  |  | 19,245 | \nRetained earnings | 1,789 |  |  | 4,784 | \nAccumulated other comprehensive loss | (2,252) |  |  | (2,199) | \nTotal stockholders' equity | 12,866 |  |  | 17,254 | \nNoncontrolling interest | 32 |  |  | 33 | \nTotal equity | 12,898 |  |  | 17,287 | \n |  |  | \nTotal liabilities and equity | $ | 135,367 |  |  | $ | 138,805 |   |  |  |  |  | \n2023 Form 10-Q| | 3  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Common shares outstanding |  | Common stock |  | Treasury stock |  | Additional paid-in capital |  | Retained earnings |  | Accumulated other comprehensive loss |  | Noncontrolling interest |  | Total\nBalance at March 31, 2022 | 1,767 |  |  | $ | 18 |  |  | $ | (4,585) |  |  | $ | 18,731 |  |  | $ | 5,103 |  |  | $ | (2,984) |  |  | $ | 31 |  |  | $ | 16,314 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 924 |  |  | \u2014 |  |  | \u2014 |  |  | 924 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (212) |  |  | \u2014 |  |  | (212) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,511) |  |  | \u2014 |  |  | \u2014 |  |  | (2,511) | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (9) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9) | \nStock-based compensation plans and other | 1 |  |  | \u2014 |  |  | 3 |  |  | 175 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 178 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 | \nBalance at June 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,591) |  |  | $ | 18,906 |  |  | $ | 3,516 |  |  | $ | (3,196) |  |  | $ | 35 |  |  | $ | 14,688 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2023 | 1,764 |  |  | $ | 18 |  |  | $ | (6,524) |  |  | $ | 19,619 |  |  | $ | 2,393 |  |  | $ | (2,232) |  |  | $ | 29 |  |  | $ | 13,303 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,024 |  |  | \u2014 |  |  | \u2014 |  |  | 2,024 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (20) |  |  | \u2014 |  |  | (20) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,628) |  |  | \u2014 |  |  | \u2014 |  |  | (2,628) | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (10) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (10) | \nStock-based compensation plans and other | 1 |  |  | \u2014 |  |  | 6 |  |  | 220 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 226 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 3 | \nBalance at June 30, 2023 | 1,765 |  |  | $ | 18 |  |  | $ | (6,528) |  |  | $ | 19,839 |  |  | $ | 1,789 |  |  | $ | (2,252) |  |  | $ | 32 |  |  | $ | 12,898 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,143) |  |  | $ | 18,305 |  |  | $ | 3,127 |  |  | $ | (2,899) |  |  | $ | 28 |  |  | $ | 15,436 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 5,414 |  |  | \u2014 |  |  | \u2014 |  |  | 5,414 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (297) |  |  | \u2014 |  |  | (297) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5,025) |  |  | \u2014 |  |  | \u2014 |  |  | (5,025) | \nPurchases of treasury stock | (10) |  |  | \u2014 |  |  | (1,479) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,479) | \nStock-based compensation plans and other | 10 |  |  | \u2014 |  |  | 31 |  |  | 601 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 632 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7 |  |  | 7 | \nBalance at June 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,591) |  |  | $ | 18,906 |  |  | $ | 3,516 |  |  | $ | (3,196) |  |  | $ | 35 |  |  | $ | 14,688 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2022 | 1,769 |  |  | $ | 18 |  |  | $ | (4,594) |  |  | $ | 19,245 |  |  | $ | 4,784 |  |  | $ | (2,199) |  |  | $ | 33 |  |  | $ | 17,287 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,263 |  |  | \u2014 |  |  | \u2014 |  |  | 2,263 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (53) |  |  | \u2014 |  |  | (53) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5,258) |  |  | \u2014 |  |  | \u2014 |  |  | (5,258) | \nPurchases of treasury stock | (12) |  |  | \u2014 |  |  | (1,965) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,965) | \nStock-based compensation plans and other | 8 |  |  | \u2014 |  |  | 31 |  |  | 594 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 625 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) | \nBalance at June 30, 2023 | 1,765 |  |  | $ | 18 |  |  | $ | (6,528) |  |  | $ | 19,839 |  |  | $ | 1,789 |  |  | $ | (2,252) |  |  | $ | 32 |  |  | $ | 12,898 |   |  |  |  |  | \n2023 Form 10-Q| | 4  |  |  |  |  |  |  |  |  |  |  | \n | Six months endedJune 30,\n(in\u00a0millions)\u00a0(brackets\u00a0denote\u00a0cash\u00a0outflows) | 2023 |  | 2022\nCash flows from operating activities |  |  | \nNet earnings | $ | 2,268 |  |  | $ | 5,421 | \nAdjustments to reconcile net earnings to net cash from operating activities: |  |  | \nDepreciation | 369 |  |  | 401 | \nAmortization of intangible assets | 4,018 |  |  | 3,704 | \nDeferred income taxes | (635) |  |  | (794) | \nChange in fair value of contingent consideration liabilities | 3,424 |  |  | 861 | \nStock-based compensation | 492 |  |  | 413 | \nAcquired IPR&D and milestones | 430 |  |  | 414 | \nGain on divestitures | \u2014 |  |  | (172) | \nNon-cash litigation reserve adjustments, net of cash payments | (118) |  |  | 2,190 | \nImpairment of intangible assets | 710 |  |  | \u2014 | \nOther, net | (173) |  |  | (86) | \nChanges in operating assets and liabilities, net of acquisitions: |  |  | \nAccounts receivable | (275) |  |  | (1,396) | \nInventories | (458) |  |  | (499) | \nPrepaid expenses and other assets | 285 |  |  | 14 | \nAccounts payable and other liabilities | 1,107 |  |  | (448) | \nIncome tax assets and liabilities, net | (932) |  |  | (110) | \nCash flows from operating activities | 10,512 |  |  | 9,913 | \n |  |  | \nCash flows from investing activities |  |  | \nAcquisitions and investments | (513) |  |  | (394) | \nAcquisitions of property and equipment | (353) |  |  | (305) | \nPurchases of investment securities | (35) |  |  | (1,411) | \nSales and maturities of investment securities | 36 |  |  | 50 | \nOther, net | 25 |  |  | 599 | \nCash flows from investing activities | (840) |  |  | (1,461) | \n |  |  | \nCash flows from financing activities |  |  | \nProceeds from issuance of long-term debt | \u2014 |  |  | 2,000 | \nRepayments of long-term debt and finance lease obligations | (2,353) |  |  | (4,881) | \nDividends paid | (5,286) |  |  | (5,033) | \nPurchases of treasury stock | (1,965) |  |  | (1,479) | \nProceeds from the exercise of stock options | 113 |  |  | 198 | \nPayments of contingent consideration liabilities | (641) |  |  | (482) | \nOther, net | 20 |  |  | 26 | \nCash flows from financing activities | (10,112) |  |  | (9,651) | \nEffect of exchange rate changes on cash and equivalents | (2) |  |  | (26) | \nNet change in cash and equivalents | (442) |  |  | (1,225) | \nCash and equivalents, beginning of period | 9,201 |  |  | 9,746 | \n |  |  | \nCash and equivalents, end of period | $ | 8,759 |  |  | $ | 8,521 | \n |  |  | \n |  |  | \n |  |  |   |  |  |  |  | \n2023 Form 10-Q| | 5  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest expense |  | $ | 552 |  |  | $ | 556 |  |  | $ | 1,105 |  |  | $ | 1,104 | \nInterest income |  | (98) |  |  | (24) |  |  | (197) |  |  | (33) | \nInterest expense, net |  | $ | 454 |  |  | $ | 532 |  |  | $ | 908 |  |  | $ | 1,071 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | June 30,2023 |  | December 31,2022\nFinished goods | $ | 1,177 |  |  | $ | 1,162 | \nWork-in-process | 1,606 |  |  | 1,417 | \nRaw materials | 1,272 |  |  | 1,000 | \nInventories | $ | 4,055 |  |  | $ | 3,579 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | June 30,2023 |  | December 31,2022\nProperty and equipment, gross | $ | 11,318 |  |  | $ | 10,986 | \nAccumulated depreciation | (6,375) |  |  | (6,051) | \nProperty and equipment, net | $ | 4,943 |  |  | $ | 4,935 |   |  |  |  |  | \n2023 Form 10-Q| | 6  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions, except per share data) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nBasic EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 2,024 |  |  | $ | 924 |  |  | $ | 2,263 |  |  | $ | 5,414 | \nEarnings allocated to participating securities |  | 11 |  |  | 11 |  |  | 22 |  |  | 26 | \nEarnings available to common shareholders |  | $ | 2,013 |  |  | $ | 913 |  |  | $ | 2,241 |  |  | $ | 5,388 | \nWeighted-average basic shares outstanding |  | 1,767 |  |  | 1,770 |  |  | 1,768 |  |  | 1,770 | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 1.14 |  |  | $ | 0.52 |  |  | $ | 1.27 |  |  | $ | 3.04 | \n |  |  |  |  |  |  |  | \nDiluted EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 2,024 |  |  | $ | 924 |  |  | $ | 2,263 |  |  | $ | 5,414 | \nEarnings allocated to participating securities |  | 11 |  |  | 11 |  |  | 22 |  |  | 26 | \nEarnings available to common shareholders |  | $ | 2,013 |  |  | $ | 913 |  |  | $ | 2,241 |  |  | $ | 5,388 | \nWeighted-average shares of common stock outstanding |  | 1,767 |  |  | 1,770 |  |  | 1,768 |  |  | 1,770 | \nEffect of dilutive securities |  | 4 |  |  | 6 |  |  | 5 |  |  | 7 | \nWeighted-average diluted shares outstanding |  | 1,771 |  |  | 1,776 |  |  | 1,773 |  |  | 1,777 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 1.14 |  |  | $ | 0.51 |  |  | $ | 1.26 |  |  | $ | 3.03 |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 7  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States - Janssen's share of profits (included in cost of products sold) |  | $ | 312 |  |  | $ | 404 |  |  | $ | 609 |  |  | $ | 812 | \nInternational - AbbVie's share of profits (included in net revenues) |  | 241 |  |  | 283 |  |  | 481 |  |  | 582 | \nGlobal - AbbVie's share of other costs (included in respective line items) |  | 57 |  |  | 69 |  |  | 112 |  |  | 133 |   |  |  |  |  | \n2023 Form 10-Q| | 8  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nGenentech's share of profits, including royalties (included in cost of products sold) |  | $ | 214 |  |  | $ | 196 |  |  | $ | 416 |  |  | $ | 374 | \nAbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  | 8 |  |  | 5 |  |  | 19 |  |  | 17 | \nAbbVie's share of development costs (included in R&D) |  | 30 |  |  | 31 |  |  | 58 |  |  | 58 |   |  | \n  |  |  |  |  | \n(in\u00a0millions) | \nBalance as of December 31, 2022 | $ | 32,156 | \nForeign currency translation adjustments | 68 | \nBalance as of June 30, 2023 | $ | 32,224 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\n(in\u00a0millions) | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount |  | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount\nDefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  | \nDeveloped product rights | $ | 87,702 |  |  | $ | (28,400) |  |  | $ | 59,302 |  |  | $ | 87,698 |  |  | $ | (25,003) |  |  | $ | 62,695 | \nLicense agreements | 8,474 |  |  | (5,207) |  |  | 3,267 |  |  | 8,474 |  |  | (4,642) |  |  | 3,832 | \nTotal definite-lived intangible assets | 96,176 |  |  | (33,607) |  |  | 62,569 |  |  | 96,172 |  |  | (29,645) |  |  | 66,527 | \nIndefinite-lived intangible assets | 293 |  |  | \u2014 |  |  | 293 |  |  | 912 |  |  | \u2014 |  |  | 912 | \nTotal intangible assets, net | $ | 96,469 |  |  | $ | (33,607) |  |  | $ | 62,862 |  |  | $ | 97,084 |  |  | $ | (29,645) |  |  | $ | 67,439 |   |  |  |  |  | \n2023 Form 10-Q| | 9  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2023 | 2022 |  | 2023 |  | 2022\nCost of products sold |  | $ | 32 |  | $ | 26 |  |  | $ | 46 |  |  | $ | 57 | \nResearch and development |  | 1 |  | 1 |  |  | 1 |  |  | 10 | \nSelling, general and administrative |  | 51 |  | 76 |  |  | 95 |  |  | 146 | \nTotal charges |  | $ | 84 |  | $ | 103 |  |  | $ | 142 |  |  | $ | 213 |   |  |  |  |  | \n(in millions) | \nAccrued balance as of December 31, 2022 | $ | 107 | \nCharges | 135 | \nPayments and other adjustments | (195) | \nAccrued balance as of June 30, 2023 | $ | 47 |   |  |  |  |  | \n2023 Form 10-Q| | 10  |  |  |  |  | \n(in\u00a0millions) | \nAccrued balance as of December 31, 2022 | $ | 176 | \nRestructuring charges | 24 | \nPayments and other adjustments | (51) | \nAccrued balance as of June 30, 2023 | $ | 149 |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 11  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair value \u2013Derivatives in asset position |  | Fair value \u2013Derivatives\u00a0in\u00a0liability\u00a0position\n(in\u00a0millions) | Balance\u00a0sheet\u00a0caption | June 30,2023 | December 31, 2022 |  | Balance\u00a0sheet\u00a0caption | June 30,2023 | December 31, 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | $ | 32 |  | $ | 49 |  |  | Accounts payable and accrued liabilities | $ | 9 |  | $ | 8 | \nDesignated as cash flow hedges | Other assets | 1 |  | 1 |  |  | Other long-term liabilities | 1 |  | \u2014 | \nDesignated as net investment hedges | Prepaid expenses and other | 3 |  | 6 |  |  | Accounts payable and accrued liabilities | 80 |  | 36 | \nDesignated as net investment hedges | Other assets | 23 |  | 74 |  |  | Other long-term liabilities | 33 |  | 47 | \nNot designated as hedges | Prepaid expenses and other | 44 |  | 33 |  |  | Accounts payable and accrued liabilities | 41 |  | 41 | \nCross-currency swap contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | 9 |  | \u2014 |  |  | Accounts payable and accrued liabilities | \u2014 |  | \u2014 | \nInterest rate swap contracts |  |  |  |  |  |  | \nDesignated as fair value hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 1 |  | 17 | \nDesignated as fair value hedges | Other assets | \u2014 |  | \u2014 |  |  | Other long-term liabilities | 377 |  | 375 | \nTotal derivatives |  | $ | 112 |  | $ | 163 |  |  |  | $ | 542 |  | $ | 524 |   |  |  |  |  | \n2023 Form 10-Q| | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  |  | \nDesignated as cash flow hedges |  | $ | 14 |  |  | $ | 53 |  |  | $ | 5 |  |  | $ | 47 | \nDesignated as net investment hedges |  | 6 |  |  | 304 |  |  | (88) |  |  | 386 | \nCross-currency swap contracts designated as cash flow hedges |  | 9 |  |  | \u2014 |  |  | 9 |  |  | \u2014 | \nInterest rate swap contracts designated as cash flow hedges |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 6 | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) | Statement\u00a0of earnings caption |  | 2023 |  | 2022 |  | 2023 |  | 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Cost of products sold |  | $ | 26 |  |  | $ | 18 |  |  | $ | 56 |  |  | $ | 26 | \nDesignated as net investment hedges | Interest expense, net |  | 29 |  |  | 24 |  |  | 57 |  |  | 38 | \nNot designated as hedges | Net foreign exchange loss |  | 4 |  |  | (123) |  |  | 34 |  |  | (164) | \nTreasury rate lock agreements designated as cash flow hedges | Interest expense, net |  | 6 |  |  | 6 |  |  | 12 |  |  | 12 | \nCross-currency swap contracts designated as cash flow hedges | Net foreign exchange loss |  | 8 |  |  | \u2014 |  |  | 8 |  |  | \u2014 | \nInterest rate swap contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Interest expense, net |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (3) | \nDesignated as fair value hedges | Interest expense, net |  | (21) |  |  | (99) |  |  | 14 |  |  | (283) | \nDebt designated as hedged item in fair value hedges | Interest expense, net |  | 21 |  |  | 99 |  |  | (14) |  |  | 283 |   |  |  |  |  | \n2023 Form 10-Q| | 13  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 8,759 |  |  | $ | 4,697 |  |  | $ | 4,062 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 10 |  |  | \u2014 |  |  | 10 |  |  | \u2014 | \nDebt securities | 30 |  |  | \u2014 |  |  | 30 |  |  | \u2014 | \nEquity securities | 131 |  |  | 107 |  |  | 24 |  |  | \u2014 | \n |  |  |  |  |  |  | \nCross-currency swap contracts | 9 |  |  | \u2014 |  |  | 9 |  |  | \u2014 | \nForeign currency contracts | 103 |  |  | \u2014 |  |  | 103 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 9,042 |  |  | $ | 4,804 |  |  | $ | 4,238 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 378 |  |  | $ | \u2014 |  |  | $ | 378 |  |  | $ | \u2014 | \n |  |  |  |  |  |  | \nForeign currency contracts | 164 |  |  | \u2014 |  |  | 164 |  |  | \u2014 | \nContingent consideration | 19,151 |  |  | \u2014 |  |  | \u2014 |  |  | 19,151 | \nTotal liabilities | $ | 19,693 |  |  | $ | \u2014 |  |  | $ | 542 |  |  | $ | 19,151 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 9,201 |  |  | $ | 4,201 |  |  | $ | 5,000 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 21 |  |  | \u2014 |  |  | 21 |  |  | \u2014 | \nDebt securities | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nEquity securities | 91 |  |  | 59 |  |  | 32 |  |  | \u2014 | \nForeign currency contracts | 163 |  |  | \u2014 |  |  | 163 |  |  | \u2014 | \nTotal assets | $ | 9,504 |  |  | $ | 4,260 |  |  | $ | 5,244 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 392 |  |  | $ | \u2014 |  |  | $ | 392 |  |  | $ | \u2014 | \nForeign currency contracts | 132 |  |  | \u2014 |  |  | 132 |  |  | \u2014 | \nContingent consideration | 16,384 |  |  | \u2014 |  |  | \u2014 |  |  | 16,384 | \nTotal liabilities | $ | 16,908 |  |  | $ | \u2014 |  |  | $ | 524 |  |  | $ | 16,384 |   |  |  |  |  | \n2023 Form 10-Q| | 14  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\n(in\u00a0millions) | Range | Weighted average(a) |  | Range | Weighted average(a)\nDiscount rate | 4.8% -5.8% | 4.9% |  | 4.7%-5.1% | 4.8%\nProbability of payment for unachieved milestones | 100% -100% | 100% |  | 100% -100% | 100%\nProbability of payment for royalties by indication(b) | 89% -100% | 99% |  | 56% -100% | 99%\n |  |  |  |  | \nProjected year of payments | 2023-2034 | 2028 |  | 2023-2034 | 2028  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2023 |  | 2022\nBeginning balance |  | $ | 16,384 |  |  | $ | 14,887 | \nChange in fair value recognized in net earnings |  | 3,424 |  |  | 861 | \nPayments |  | (657) |  |  | (570) | \nEnding balance |  | $ | 19,151 |  |  | $ | 15,178 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | $ | 5,203 |  | $ | 5,096 |  |  | $ | 4,816 |  |  | $ | 280 |  |  | $ | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 56,153 |  | 51,394 |  |  | 50,869 |  |  | 525 |  |  | \u2014 | \nTotal liabilities | $ | 61,356 |  | $ | 56,490 |  |  | $ | 55,685 |  |  | $ | 805 |  |  | $ | \u2014 |   |  |  |  |  | \n2023 Form 10-Q| | 15  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 1 |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 4,152 |  | 4,121 |  |  | 3,930 |  |  | 191 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 59,463 |  | 54,073 |  |  | 53,365 |  |  | 708 |  |  | \u2014 | \nTotal liabilities | $ | 63,616 |  | $ | 58,195 |  |  | $ | 57,295 |  |  | $ | 900 |  |  | $ | \u2014 |   |  |  |  |  | \n2023 Form 10-Q| | 16  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Definedbenefit\u00a0plans |  | Other\u00a0post-employment\u00a0plans\n | Three months endedJune 30, |  | Six months endedJune 30, |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nService cost | $ | 67 |  |  | $ | 113 |  |  | $ | 135 |  |  | $ | 229 |  |  | $ | 10 |  |  | $ | 13 |  |  | $ | 18 |  |  | $ | 25 | \nInterest cost | 109 |  |  | 75 |  |  | 216 |  |  | 149 |  |  | 10 |  |  | 6 |  |  | 19 |  |  | 12 | \nExpected return on plan assets | (182) |  |  | (179) |  |  | (362) |  |  | (359) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nAmortization of prior service cost (credit) | 1 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | (9) |  |  | (9) |  |  | (18) |  |  | (19) | \nAmortization of actuarial loss | 4 |  |  | 59 |  |  | 8 |  |  | 116 |  |  | 3 |  |  | 6 |  |  | 6 |  |  | 13 | \nNet periodic benefit cost (credit) | $ | (1) |  |  | $ | 68 |  |  | $ | (2) |  |  | $ | 136 |  |  | $ | 14 |  |  | $ | 16 |  |  | $ | 25 |  |  | $ | 31 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nCost of products sold |  | $ | 9 |  |  | $ | 6 |  |  | $ | 29 |  |  | $ | 25 | \nResearch and development |  | 57 |  |  | 40 |  |  | 174 |  |  | 147 | \nSelling, general and administrative |  | 113 |  |  | 61 |  |  | 289 |  |  | 241 | \nPre-tax compensation expense |  | 179 |  |  | 107 |  |  | 492 |  |  | 413 | \nTax benefit |  | (30) |  |  | (21) |  |  | (85) |  |  | (77) | \nAfter-tax compensation expense |  | $ | 149 |  |  | $ | 86 |  |  | $ | 407 |  |  | $ | 336 |   |  |  |  |  | \n2023 Form 10-Q| | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2023 |  | 2022\nDate Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share\n06/22/23 |  | 08/15/23 |  | $ | 1.48 |  |  | 10/28/22 |  | 02/15/23 |  | $ | 1.48 | \n02/16/23 |  | 05/15/23 |  | $ | 1.48 |  |  | 09/09/22 |  | 11/15/22 |  | $ | 1.41 | \n |  |  |  |  |  | 06/23/22 |  | 08/15/22 |  | $ | 1.41 | \n |  |  |  |  |  | 02/17/22 |  | 05/16/22 |  | $ | 1.41 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2022 | $ | (1,513) |  |  | $ | 464 |  |  | $ | (1,458) |  |  |  |  | $ | 308 |  |  | $ | (2,199) | \nOther comprehensive income (loss) before reclassifications | 178 |  |  | (168) |  |  | 39 |  |  |  |  | 8 |  |  | 57 | \nNet gains reclassified from accumulated other comprehensive loss | \u2014 |  |  | (45) |  |  | (3) |  |  |  |  | (62) |  |  | (110) | \nNet current-period other comprehensive income (loss) | 178 |  |  | (213) |  |  | 36 |  |  |  |  | (54) |  |  | (53) | \nBalance as of June 30, 2023 | $ | (1,335) |  |  | $ | 251 |  |  | $ | (1,422) |  |  |  |  | $ | 254 |  |  | $ | (2,252) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2021 | $ | (570) |  |  | $ | (91) |  |  | $ | (2,546) |  |  |  |  | $ | 308 |  |  | $ | (2,899) | \nOther comprehensive income (loss) before reclassifications | (1,054) |  |  | 696 |  |  | (11) |  |  |  |  | 45 |  |  | (324) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (30) |  |  | 87 |  |  |  |  | (30) |  |  | 27 | \nNet current-period other comprehensive income (loss) | (1,054) |  |  | 666 |  |  | 76 |  |  |  |  | 15 |  |  | (297) | \nBalance as of June 30, 2022 | $ | (1,624) |  |  | $ | 575 |  |  | $ | (2,470) |  |  |  |  | $ | 323 |  |  | $ | (3,196) |   |  |  |  |  | \n2023 Form 10-Q| | 18  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedJune 30, |  | Six months endedJune 30,\n(in millions) (brackets\u00a0denote\u00a0gains) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet investment hedging activities |  |  |  |  |  |  | \nGains on derivative amount excluded from effectiveness testing(a) | $ | (29) |  |  | $ | (24) |  |  | $ | (57) |  |  | $ | (38) | \nTax expense | 6 |  |  | 6 |  |  | 12 |  |  | 8 | \nTotal reclassifications, net of tax | $ | (23) |  |  | $ | (18) |  |  | $ | (45) |  |  | $ | (30) | \nPension and post-employment benefits |  |  |  |  |  |  | \nAmortization of actuarial losses and other(b) | $ | (1) |  |  | $ | 56 |  |  | $ | (3) |  |  | $ | 111 | \nTax benefit | \u2014 |  |  | (12) |  |  | \u2014 |  |  | (24) | \nTotal reclassifications, net of tax | $ | (1) |  |  | $ | 44 |  |  | $ | (3) |  |  | $ | 87 | \nCash flow hedging activities |  |  |  |  |  |  | \nGains on foreign currency forward exchange contracts(c) | $ | (26) |  |  | $ | (18) |  |  | $ | (56) |  |  | $ | (26) | \nGains on treasury rate lock agreements(a) | (6) |  |  | (6) |  |  | (12) |  |  | (12) | \nGains on cross-currency swap contracts(d) | (8) |  |  | \u2014 |  |  | (8) |  |  | \u2014 | \nLosses on interest rate swap contracts(a) | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 3 | \nTax expense | 9 |  |  | 4 |  |  | 14 |  |  | 5 | \nTotal reclassifications, net of tax | $ | (31) |  |  | $ | (19) |  |  | $ | (62) |  |  | $ | (30) |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 19  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 20  |  |  |  |  | \n2023 Form 10-Q| | 21  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n |  | \n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nImmunology |  |  |  |  |  |  | \nHumira | United States | $ | 3,452 |  |  | $ | 4,664 |  |  | $ | 6,400 |  |  | $ | 8,657 | \n | International | 560 |  |  | 699 |  |  | 1,153 |  |  | 1,442 | \n | Total | $ | 4,012 |  |  | $ | 5,363 |  |  | $ | 7,553 |  |  | $ | 10,099 | \nSkyrizi | United States | $ | 1,634 |  |  | $ | 1,079 |  |  | $ | 2,773 |  |  | $ | 1,860 | \n | International | 249 |  |  | 173 |  |  | 470 |  |  | 332 | \n | Total | $ | 1,883 |  |  | $ | 1,252 |  |  | $ | 3,243 |  |  | $ | 2,192 | \nRinvoq | United States | $ | 645 |  |  | $ | 412 |  |  | $ | 1,094 |  |  | $ | 723 | \n | International | 273 |  |  | 180 |  |  | 510 |  |  | 334 | \n | Total | $ | 918 |  |  | $ | 592 |  |  | $ | 1,604 |  |  | $ | 1,057 | \nHematologic Oncology |  |  |  |  |  |  | \nImbruvica | United States | $ | 666 |  |  | $ | 862 |  |  | $ | 1,304 |  |  | $ | 1,736 | \n | Collaboration revenues | 241 |  |  | 283 |  |  | 481 |  |  | 582 | \n | Total | $ | 907 |  |  | $ | 1,145 |  |  | $ | 1,785 |  |  | $ | 2,318 | \nVenclexta | United States | $ | 265 |  |  | $ | 253 |  |  | $ | 530 |  |  | $ | 481 | \n | International | 306 |  |  | 252 |  |  | 579 |  |  | 497 | \n | Total | $ | 571 |  |  | $ | 505 |  |  | $ | 1,109 |  |  | $ | 978 | \nAesthetics |  |  |  |  |  |  | \nBotox Cosmetic | United States | $ | 420 |  |  | $ | 449 |  |  | $ | 829 |  |  | $ | 862 | \n | International | 265 |  |  | 246 |  |  | 515 |  |  | 474 | \n | Total | $ | 685 |  |  | $ | 695 |  |  | $ | 1,344 |  |  | $ | 1,336 | \nJuvederm Collection | United States | $ | 125 |  |  | $ | 147 |  |  | $ | 247 |  |  | $ | 295 | \n | International | 243 |  |  | 197 |  |  | 476 |  |  | 459 | \n | Total | $ | 368 |  |  | $ | 344 |  |  | $ | 723 |  |  | $ | 754 | \nOther Aesthetics | United States | $ | 284 |  |  | $ | 287 |  |  | $ | 530 |  |  | $ | 572 | \n | International | 47 |  |  | 45 |  |  | 87 |  |  | 83 | \n | Total | $ | 331 |  |  | $ | 332 |  |  | $ | 617 |  |  | $ | 655 | \nNeuroscience |  |  |  |  |  |  | \nBotox Therapeutic | United States | $ | 614 |  |  | $ | 557 |  |  | $ | 1,201 |  |  | $ | 1,057 | \n | International | 134 |  |  | 121 |  |  | 266 |  |  | 235 | \n | Total | $ | 748 |  |  | $ | 678 |  |  | $ | 1,467 |  |  | $ | 1,292 | \nVraylar | United States | $ | 657 |  |  | $ | 492 |  |  | $ | 1,217 |  |  | $ | 919 | \n | International | 1 |  |  | \u2014 |  |  | 2 |  |  | \u2014 | \n | Total | $ | 658 |  |  | $ | 492 |  |  | $ | 1,219 |  |  | $ | 919 | \nDuodopa | United States | $ | 24 |  |  | $ | 26 |  |  | $ | 49 |  |  | $ | 50 | \n | International | 93 |  |  | 94 |  |  | 186 |  |  | 191 | \n | Total | $ | 117 |  |  | $ | 120 |  |  | $ | 235 |  |  | $ | 241 | \nUbrelvy | United States | $ | 194 |  |  | $ | 185 |  |  | $ | 344 |  |  | $ | 323 | \n | International | 2 |  |  | \u2014 |  |  | 4 |  |  | \u2014 | \n | Total | $ | 196 |  |  | $ | 185 |  |  | $ | 348 |  |  | $ | 323 |   |  |  |  |  | \n2023 Form 10-Q| | 22  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n |  | \n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nQulipta | United States | $ | 95 |  |  | $ | 33 |  |  | $ | 161 |  |  | $ | 44 | \n | International | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 | \n | Total | $ | 96 |  |  | $ | 33 |  |  | $ | 162 |  |  | $ | 44 | \nOther Neuroscience | United States | $ | 65 |  |  | $ | 145 |  |  | $ | 140 |  |  | $ | 318 | \n | International | 5 |  |  | 5 |  |  | 9 |  |  | 9 | \n | Total | $ | 70 |  |  | $ | 150 |  |  | $ | 149 |  |  | $ | 327 | \nEye Care |  |  |  |  |  |  | \nOzurdex | United States | $ | 34 |  |  | $ | 36 |  |  | $ | 73 |  |  | $ | 69 | \n | International | 85 |  |  | 74 |  |  | 161 |  |  | 148 | \n | Total | $ | 119 |  |  | $ | 110 |  |  | $ | 234 |  |  | $ | 217 | \nLumigan/Ganfort | United States | $ | 51 |  |  | $ | 60 |  |  | $ | 114 |  |  | $ | 127 | \n | International | 68 |  |  | 70 |  |  | 135 |  |  | 143 | \n | Total | $ | 119 |  |  | $ | 130 |  |  | $ | 249 |  |  | $ | 270 | \nAlphagan/Combigan | United States | $ | 32 |  |  | $ | 54 |  |  | $ | 60 |  |  | $ | 124 | \n | International | 33 |  |  | 38 |  |  | 76 |  |  | 75 | \n | Total | $ | 65 |  |  | $ | 92 |  |  | $ | 136 |  |  | $ | 199 | \nRestasis | United States | $ | 82 |  |  | $ | 151 |  |  | $ | 161 |  |  | $ | 386 | \n | International | 17 |  |  | 17 |  |  | 30 |  |  | 28 | \n | Total | $ | 99 |  |  | $ | 168 |  |  | $ | 191 |  |  | $ | 414 | \nOther Eye Care | United States | $ | 110 |  |  | $ | 106 |  |  | $ | 220 |  |  | $ | 197 | \n | International | 105 |  |  | 111 |  |  | 195 |  |  | 191 | \n | Total | $ | 215 |  |  | $ | 217 |  |  | $ | 415 |  |  | $ | 388 | \nOther Key Products |  |  |  |  |  |  | \nMavyret | United States | $ | 193 |  |  | $ | 203 |  |  | $ | 364 |  |  | $ | 372 | \n | International | 194 |  |  | 195 |  |  | 387 |  |  | 406 | \n | Total | $ | 387 |  |  | $ | 398 |  |  | $ | 751 |  |  | $ | 778 | \nCreon | United States | $ | 282 |  |  | $ | 318 |  |  | $ | 587 |  |  | $ | 605 | \nLinzess/Constella | United States | $ | 269 |  |  | $ | 247 |  |  | $ | 520 |  |  | $ | 480 | \n | International | 9 |  |  | 8 |  |  | 17 |  |  | 15 | \n | Total | $ | 278 |  |  | $ | 255 |  |  | $ | 537 |  |  | $ | 495 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nAll other |  | $ | 741 |  |  | $ | 1,009 |  |  | $ | 1,432 |  |  | $ | 2,220 | \nTotal net revenues | $ | 13,865 |  |  | $ | 14,583 |  |  | $ | 26,090 |  |  | $ | 28,121 |   |  |  |  |  | \n2023 Form 10-Q| | 23  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 24  |  |  |  |  | \n2023 Form 10-Q| | 25  |  |  |  |  | \n2023 Form 10-Q| | 26  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Percent\u00a0change |  | Six months endedJune 30, |  | Percent\u00a0change\n |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nUnited States |  | $ | 10,720 |  |  | $ | 11,410 |  |  | (6.0) | % |  | (6.0) | % |  | $ | 19,921 |  |  | $ | 21,758 |  |  | (8.4) | % |  | (8.4) | %\nInternational |  | 3,145 |  |  | 3,173 |  |  | (0.9) | % |  | 2.6 | % |  | 6,169 |  |  | 6,363 |  |  | (3.0) | % |  | 1.8 | %\nNet revenues |  | $ | 13,865 |  |  | $ | 14,583 |  |  | (4.9) | % |  | (4.2) | % |  | $ | 26,090 |  |  | $ | 28,121 |  |  | (7.2) | % |  | (6.1) | %  |  |  |  |  | \n2023 Form 10-Q| | 27  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedJune 30, |  | Percent\u00a0change |  | Six months endedJune 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHumira | United States |  | $ | 3,452 |  |  | $ | 4,664 |  |  | (26.0) | % |  | (26.0) | % |  | $ | 6,400 |  |  | $ | 8,657 |  |  | (26.1) | % |  | (26.1) | %\n | International |  | 560 |  |  | 699 |  |  | (19.8) | % |  | (17.0) | % |  | 1,153 |  |  | 1,442 |  |  | (20.1) | % |  | (15.9) | %\n | Total |  | $ | 4,012 |  |  | $ | 5,363 |  |  | (25.2) | % |  | (24.8) | % |  | $ | 7,553 |  |  | $ | 10,099 |  |  | (25.2) | % |  | (24.6) | %\nSkyrizi | United States |  | $ | 1,634 |  |  | $ | 1,079 |  |  | 51.4 | % |  | 51.4 | % |  | $ | 2,773 |  |  | $ | 1,860 |  |  | 49.1 | % |  | 49.1 | %\n | International |  | 249 |  |  | 173 |  |  | 44.2 | % |  | 48.6 | % |  | 470 |  |  | 332 |  |  | 41.5 | % |  | 48.2 | %\n | Total |  | $ | 1,883 |  |  | $ | 1,252 |  |  | 50.4 | % |  | 51.0 | % |  | $ | 3,243 |  |  | $ | 2,192 |  |  | 48.0 | % |  | 49.0 | %\nRinvoq | United States |  | $ | 645 |  |  | $ | 412 |  |  | 56.4 | % |  | 56.4 | % |  | $ | 1,094 |  |  | $ | 723 |  |  | 51.2 | % |  | 51.2 | %\n | International |  | 273 |  |  | 180 |  |  | 52.2 | % |  | 57.5 | % |  | 510 |  |  | 334 |  |  | 52.9 | % |  | 61.0 | %\n | Total |  | $ | 918 |  |  | $ | 592 |  |  | 55.1 | % |  | 56.7 | % |  | $ | 1,604 |  |  | $ | 1,057 |  |  | 51.7 | % |  | 54.2 | %\nHematologic Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nImbruvica | United States |  | $ | 666 |  |  | $ | 862 |  |  | (22.8) | % |  | (22.8) | % |  | $ | 1,304 |  |  | $ | 1,736 |  |  | (24.9) | % |  | (24.9) | %\n | Collaboration revenues |  | 241 |  |  | 283 |  |  | (14.7) | % |  | (14.7) | % |  | 481 |  |  | 582 |  |  | (17.3) | % |  | (17.3) | %\n | Total |  | $ | 907 |  |  | $ | 1,145 |  |  | (20.8) | % |  | (20.8) | % |  | $ | 1,785 |  |  | $ | 2,318 |  |  | (23.0) | % |  | (23.0) | %\nVenclexta | United States |  | $ | 265 |  |  | $ | 253 |  |  | 5.2 | % |  | 5.2 | % |  | $ | 530 |  |  | $ | 481 |  |  | 10.2 | % |  | 10.2 | %\n | International |  | 306 |  |  | 252 |  |  | 21.0 | % |  | 24.9 | % |  | 579 |  |  | 497 |  |  | 16.5 | % |  | 22.1 | %\n | Total |  | $ | 571 |  |  | $ | 505 |  |  | 13.1 | % |  | 15.0 | % |  | $ | 1,109 |  |  | $ | 978 |  |  | 13.4 | % |  | 16.2 | %\nAesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Cosmetic | United States |  | $ | 420 |  |  | $ | 449 |  |  | (6.5) | % |  | (6.5) | % |  | $ | 829 |  |  | $ | 862 |  |  | (3.8) | % |  | (3.8) | %\n | International |  | 265 |  |  | 246 |  |  | 7.9 | % |  | 13.8 | % |  | 515 |  |  | 474 |  |  | 8.7 | % |  | 15.7 | %\n | Total |  | $ | 685 |  |  | $ | 695 |  |  | (1.4) | % |  | 0.7 | % |  | $ | 1,344 |  |  | $ | 1,336 |  |  | 0.6 | % |  | 3.1 | %\nJuvederm Collection | United States |  | $ | 125 |  |  | $ | 147 |  |  | (14.5) | % |  | (14.5) | % |  | $ | 247 |  |  | $ | 295 |  |  | (16.2) | % |  | (16.2) | %\n | International |  | 243 |  |  | 197 |  |  | 22.8 | % |  | 27.6 | % |  | 476 |  |  | 459 |  |  | 3.6 | % |  | 11.1 | %\n | Total |  | $ | 368 |  |  | $ | 344 |  |  | 6.9 | % |  | 9.7 | % |  | $ | 723 |  |  | $ | 754 |  |  | (4.1) | % |  | 0.4 | %\nOther Aesthetics | United States |  | $ | 284 |  |  | $ | 287 |  |  | (1.3) | % |  | (1.3) | % |  | $ | 530 |  |  | $ | 572 |  |  | (7.4) | % |  | (7.4) | %\n | International |  | 47 |  |  | 45 |  |  | 6.8 | % |  | 12.0 | % |  | 87 |  |  | 83 |  |  | 5.3 | % |  | 12.3 | %\n | Total |  | $ | 331 |  |  | $ | 332 |  |  | (0.2) | % |  | 0.5 | % |  | $ | 617 |  |  | $ | 655 |  |  | (5.8) | % |  | (4.9) | %\nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Therapeutic | United States |  | $ | 614 |  |  | $ | 557 |  |  | 10.1 | % |  | 10.1 | % |  | $ | 1,201 |  |  | $ | 1,057 |  |  | 13.6 | % |  | 13.6 | %\n | International |  | 134 |  |  | 121 |  |  | 10.7 | % |  | 17.0 | % |  | 266 |  |  | 235 |  |  | 13.0 | % |  | 20.4 | %\n | Total |  | $ | 748 |  |  | $ | 678 |  |  | 10.2 | % |  | 11.3 | % |  | $ | 1,467 |  |  | $ | 1,292 |  |  | 13.5 | % |  | 14.9 | %\nVraylar | United States |  | $ | 657 |  |  | $ | 492 |  |  | 33.7 | % |  | 33.7 | % |  | $ | 1,217 |  |  | $ | 919 |  |  | 32.5 | % |  | 32.5 | %\n | International |  | 1 |  |  | \u2014 |  |  | >100.0 % |  | >100.0 % |  | 2 |  |  | \u2014 |  |  | >100.0 % |  | >100.0 %\n | Total |  | $ | 658 |  |  | $ | 492 |  |  | 33.9 | % |  | 33.9 | % |  | $ | 1,219 |  |  | $ | 919 |  |  | 32.7 | % |  | 32.7 | %\nDuodopa | United States |  | $ | 24 |  |  | $ | 26 |  |  | (7.6) | % |  | (7.6) | % |  | $ | 49 |  |  | $ | 50 |  |  | (0.8) | % |  | (0.8) | %\n | International |  | 93 |  |  | 94 |  |  | (1.6) | % |  | (0.5) | % |  | 186 |  |  | 191 |  |  | (3.0) | % |  | 0.6 | %\n | Total |  | $ | 117 |  |  | $ | 120 |  |  | (2.9) | % |  | (2.0) | % |  | $ | 235 |  |  | $ | 241 |  |  | (2.5) | % |  | 0.3 | %\nUbrelvy | United States |  | $ | 194 |  |  | $ | 185 |  |  | 4.5 | % |  | 4.5 | % |  | $ | 344 |  |  | $ | 323 |  |  | 6.4 | % |  | 6.4 | %\n | International |  | 2 |  |  | \u2014 |  |  | n/m |  | n/m |  | 4 |  |  | \u2014 |  |  | n/m |  | n/m\n | Total |  | $ | 196 |  |  | $ | 185 |  |  | 5.9 | % |  | 6.0 | % |  | $ | 348 |  |  | $ | 323 |  |  | 7.7 | % |  | 7.7 | %\nQulipta | United States |  | $ | 95 |  |  | $ | 33 |  |  | >100.0 % |  | >100.0 % |  | $ | 161 |  |  | $ | 44 |  |  | >100.0 % |  | >100.0 %\n | International |  | 1 |  |  | \u2014 |  |  | n/m |  | n/m |  | 1 |  |  | \u2014 |  |  | n/m |  | n/m\n | Total |  | $ | 96 |  |  | $ | 33 |  |  | >100.0 % |  | >100.0 % |  | $ | 162 |  |  | $ | 44 |  |  | >100.0 % |  | >100.0 %\nOther Neuroscience | United States |  | $ | 65 |  |  | $ | 145 |  |  | (55.9) | % |  | (55.9) | % |  | $ | 140 |  |  | $ | 318 |  |  | (56.3) | % |  | (56.3) | %\n | International |  | 5 |  |  | 5 |  |  | 4.7 | % |  | 11.4 | % |  | 9 |  |  | 9 |  |  | 5.7 | % |  | 12.0 | %\n | Total |  | $ | 70 |  |  | $ | 150 |  |  | (53.8) | % |  | (53.6) | % |  | $ | 149 |  |  | $ | 327 |  |  | (54.6) | % |  | (54.4) | %  |  |  |  |  | \n2023 Form 10-Q| | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedJune 30, |  | Percent\u00a0change |  | Six months endedJune 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nEye Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOzurdex | United States |  | $ | 34 |  |  | $ | 36 |  |  | (3.3) | % |  | (3.3) | % |  | $ | 73 |  |  | $ | 69 |  |  | 6.3 | % |  | 6.3 | %\n | International |  | 85 |  |  | 74 |  |  | 14.2 | % |  | 16.6 | % |  | 161 |  |  | 148 |  |  | 8.7 | % |  | 13.4 | %\n | Total |  | $ | 119 |  |  | $ | 110 |  |  | 8.6 | % |  | 10.2 | % |  | $ | 234 |  |  | $ | 217 |  |  | 8.0 | % |  | 11.2 | %\nLumigan/Ganfort | United States |  | $ | 51 |  |  | $ | 60 |  |  | (13.1) | % |  | (13.1) | % |  | $ | 114 |  |  | $ | 127 |  |  | (9.7) | % |  | (9.7) | %\n | International |  | 68 |  |  | 70 |  |  | (3.9) | % |  | (1.1) | % |  | 135 |  |  | 143 |  |  | (5.6) | % |  | (1.9) | %\n | Total |  | $ | 119 |  |  | $ | 130 |  |  | (8.1) | % |  | (6.6) | % |  | $ | 249 |  |  | $ | 270 |  |  | (7.5) | % |  | (5.5) | %\nAlphagan/Combigan | United States |  | $ | 32 |  |  | $ | 54 |  |  | (41.7) | % |  | (41.7) | % |  | $ | 60 |  |  | $ | 124 |  |  | (51.8) | % |  | (51.8) | %\n | International |  | 33 |  |  | 38 |  |  | (13.3) | % |  | (8.6) | % |  | 76 |  |  | 75 |  |  | 1.4 | % |  | 7.4 | %\n | Total |  | $ | 65 |  |  | $ | 92 |  |  | (29.7) | % |  | (27.7) | % |  | $ | 136 |  |  | $ | 199 |  |  | (31.7) | % |  | (29.4) | %\nRestasis | United States |  | $ | 82 |  |  | $ | 151 |  |  | (45.8) | % |  | (45.8) | % |  | $ | 161 |  |  | $ | 386 |  |  | (58.4) | % |  | (58.4) | %\n | International |  | 17 |  |  | 17 |  |  | (0.7) | % |  | 5.2 | % |  | 30 |  |  | 28 |  |  | 7.3 | % |  | 12.8 | %\n | Total |  | $ | 99 |  |  | $ | 168 |  |  | (41.1) | % |  | (40.5) | % |  | $ | 191 |  |  | $ | 414 |  |  | (54.0) | % |  | (53.6) | %\nOther Eye Care | United States |  | $ | 110 |  |  | $ | 106 |  |  | 1.9 | % |  | 1.9 | % |  | $ | 220 |  |  | $ | 197 |  |  | 11.3 | % |  | 11.3 | %\n | International |  | 105 |  |  | 111 |  |  | (4.1) | % |  | \u2014 | % |  | 195 |  |  | 191 |  |  | 2.1 | % |  | 7.0 | %\n | Total |  | $ | 215 |  |  | $ | 217 |  |  | (1.1) | % |  | 1.0 | % |  | $ | 415 |  |  | $ | 388 |  |  | 6.8 | % |  | 9.2 | %\nOther Key Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMavyret | United States |  | $ | 193 |  |  | $ | 203 |  |  | (5.0) | % |  | (5.0) | % |  | $ | 364 |  |  | $ | 372 |  |  | (2.2) | % |  | (2.2) | %\n | International |  | 194 |  |  | 195 |  |  | (0.9) | % |  | 1.9 | % |  | 387 |  |  | 406 |  |  | (4.7) | % |  | (0.1) | %\n | Total |  | $ | 387 |  |  | $ | 398 |  |  | (3.0) | % |  | (1.6) | % |  | $ | 751 |  |  | $ | 778 |  |  | (3.5) | % |  | (1.1) | %\nCreon | United States |  | $ | 282 |  |  | $ | 318 |  |  | (11.4) | % |  | (11.4) | % |  | $ | 587 |  |  | $ | 605 |  |  | (3.0) | % |  | (3.0) | %\nLinzess/Constella | United States |  | $ | 269 |  |  | $ | 247 |  |  | 8.6 | % |  | 8.6 | % |  | $ | 520 |  |  | $ | 480 |  |  | 8.1 | % |  | 8.1 | %\n | International |  | 9 |  |  | 8 |  |  | 26.7 | % |  | 31.1 | % |  | 17 |  |  | 15 |  |  | 19.1 | % |  | 24.3 | %\n | Total |  | $ | 278 |  |  | $ | 255 |  |  | 9.1 | % |  | 9.2 | % |  | $ | 537 |  |  | $ | 495 |  |  | 8.5 | % |  | 8.7 | %\nAll other |  |  | $ | 741 |  |  | $ | 1,009 |  |  | (26.4) | % |  | (25.3) | % |  | $ | 1,432 |  |  | $ | 2,220 |  |  | (35.5) | % |  | (34.5) | %\nTotal net revenues |  | $ | 13,865 |  |  | $ | 14,583 |  |  | (4.9) | % |  | (4.2) | % |  | $ | 26,090 |  |  | $ | 28,121 |  |  | (7.2) | % |  | (6.1) | %  |  |  |  |  | \n2023 Form 10-Q| | 29  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\nGross margin |  | $ | 9,625 |  | $ | 10,413 |  | (8) | % |  | $ | 17,864 |  | $ | 19,899 |  | (10) | %\nas a % of net revenues |  | 69 | % |  | 71 | % |  |  |  | 68 | % |  | 71 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\nSelling, general and administrative |  | $ | 3,268 |  | $ | 5,412 |  | (40) | % |  | $ | 6,307 |  | $ | 8,539 |  | (26) | %\nas a % of net revenues |  | 24 | % |  | 37 | % |  |  |  | 24 | % |  | 30 | % |  |   |  |  |  |  | \n2023 Form 10-Q| | 30  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\nResearch and development |  | $ | 1,733 |  |  | $ | 1,609 |  |  | 8 | % |  | $ | 4,025 |  | $ | 3,106 |  | 30 | %\nas a % of net revenues |  | 12 | % |  | 11 | % |  |  |  | 15 | % |  | 11 | % |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nUpfront charges |  | $ | 220 |  |  | $ | 222 |  |  | $ | 352 |  |  | $ | 352 | \nDevelopment milestones |  | 60 |  |  | 47 |  |  | 78 |  |  | 62 | \nAcquired IPR&D and milestones |  | $ | 280 |  |  | $ | 269 |  |  | $ | 430 |  |  | $ | 414 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedJune 30, |  | Six months endedJune 30,\n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest expense |  | $ | 552 |  |  | $ | 556 |  |  | $ | 1,105 |  |  | $ | 1,104 | \nInterest income |  | (98) |  |  | (24) |  |  | (197) |  |  | (33) | \nInterest expense, net |  | $ | 454 |  |  | $ | 532 |  |  | $ | 908 |  |  | $ | 1,071 | \n |  |  |  |  |  |  |  | \nNet foreign exchange loss |  | $ | 37 |  |  | $ | 47 |  |  | $ | 72 |  |  | $ | 72 | \nOther expense, net |  | 1,412 |  |  | 1,533 |  |  | 3,216 |  |  | 757 |   |  |  |  |  | \n2023 Form 10-Q| | 31  |  |  |  |  |  |  |  |  |  |  | \n | Six months endedJune 30,\n(in\u00a0millions) | 2023 |  | 2022\nCash flows provided by (used in): |  |  | \nOperating activities | $ | 10,512 |  |  | $ | 9,913 | \nInvesting activities | (840) |  |  | (1,461) | \nFinancing activities | (10,112) |  |  | (9,651) |   |  |  |  |  | \n2023 Form 10-Q| | 32  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 33  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 34  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | (a)\u00a0TotalNumber\u00a0ofShares(or Units)Purchased |  | (b)\u00a0AveragePrice\u00a0Paidper\u00a0Share(or\u00a0Unit) |  | (c)\u00a0Total\u00a0Numberof\u00a0Shares\u00a0(orUnits)\u00a0Purchasedas\u00a0Part\u00a0of\u00a0PubliclyAnnounced\u00a0Plansor\u00a0Programs |  | (d)\u00a0MaximumNumber\u00a0(orApproximateDollar\u00a0Value)\u00a0ofShares\u00a0(or\u00a0Units)that\u00a0May\u00a0Yet\u00a0BePurchased\u00a0Underthe\u00a0Plans\u00a0orPrograms | \nApril 1, 2023 - April 30, 2023 | 1,006 |  | (1) | $161.23 | (1) | \u2014 |  |  | $4,808,991,028 | \nMay 1, 2023 - May 31, 2023 | 1,105 |  | (1) | $147.29 | (1) | \u2014 |  |  | $4,808,991,028 | \nJune 1, 2023 - June 30, 2023 | 1,194 |  | (1) | $136.06 | (1) | \u2014 |  |  | $4,808,991,028 | \nTotal | 3,305 |  | (1) | $147.48 | (1) | \u2014 |  |  | $4,808,991,028 | (2)  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 35  |  | \n  |  |  |  |  |  |  |  |  |  |  | \nExhibit\u00a0No. |  | Exhibit\u00a0Description | \n |  |  | \n31.1 |  | Certification of Chief Executive Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n31.2 |  | Certification of Chief Financial Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n32.1 |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n32.2 |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n101 |  | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form\u00a010-Q for the quarter ended June 30, 2023, filed on August\u00a07, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)\u00a0Condensed Consolidated Statements of Earnings; (ii)\u00a0Condensed Consolidated Statements of Comprehensive Income; (iii)\u00a0Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)\u00a0Condensed Consolidated Statements of Cash Flows; and (vi)\u00a0the Notes to Condensed Consolidated Financial Statements. | \n |  |  | \n104 |  | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). |   |  |  |  |  | \n2023 Form 10-Q| | 36  |  |  |  |  |  |  |  | \n |  | ABBVIE INC.\n |  | \n |  | \n | By: | /s/ Scott T. Reents\n |  | Scott T. Reents\n |  | Executive Vice President,\n |  | Chief Financial Officer (Principal Financial Officer)  |  |  |  |  | \n2023 Form 10-Q| | 37"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For AbbVie, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \n(Exact name of registrant as specified in its charter)\nDelaware |  | 32-0375147\n(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)  |  |  |  |  |  |  |  |  |  |  | \nLarge Accelerated Filer | \u2612 | Accelerated Filer | \u2610\nNon-Accelerated Filer | \u2610 | Smaller reporting company | \u2610\n |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, par value $0.01 per share |  | ABBV |  | New York Stock Exchange\n |  |  |  | Chicago Stock Exchange\n1.500% Senior Notes due 2023 |  | ABBV23B |  | New York Stock Exchange\n1.375% Senior Notes due 2024 |  | ABBV24 |  | New York Stock Exchange\n1.250% Senior Notes due 2024 |  | ABBV24B |  | New York Stock Exchange\n0.750% Senior Notes due 2027 |  | ABBV27 |  | New York Stock Exchange\n2.125% Senior Notes due 2028 |  | ABBV28 |  | New York Stock Exchange\n2.625% Senior Notes due 2028 |  | ABBV28B |  | New York Stock Exchange\n2.125% Senior Notes due 2029 |  | ABBV29 |  | New York Stock Exchange\n1.250% Senior Notes due 2031 |  | ABBV31 |  | New York Stock Exchange  |  | \n  |  |  |  |  |  |  |  | \nPART\u00a0I. | FINANCIAL INFORMATION\n |  | Page\n |  | \nItem 1. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 1\nItem 2. | MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 25\nItem 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 36\nItem 4. | CONTROLS AND PROCEDURES | 36\n |  | \nPART\u00a0II. | OTHER INFORMATION\n |  | \nItem 1. | LEGAL PROCEEDINGS | 37\n |  | \nItem 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 37\nItem 5. | OTHER ITEMS | 37\nItem 6. | EXHIBITS | 38  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet revenues |  | $ | 13,927 |  |  | $ | 14,812 |  |  | $ | 40,017 |  |  | $ | 42,933 | \n |  |  |  |  |  |  |  | \nCost of products sold |  | 6,485 |  |  | 5,022 |  |  | 14,711 |  |  | 13,244 | \nSelling, general and administrative |  | 3,372 |  |  | 3,304 |  |  | 9,679 |  |  | 11,843 | \nResearch and development |  | 1,723 |  |  | 1,614 |  |  | 5,748 |  |  | 4,720 | \nAcquired IPR&D and milestones |  | 66 |  |  | 40 |  |  | 496 |  |  | 454 | \nOther operating expense (income), net |  | \u2014 |  |  | 229 |  |  | (179) |  |  | 57 | \nTotal operating costs and expenses |  | 11,646 |  |  | 10,209 |  |  | 30,455 |  |  | 30,318 | \nOperating earnings |  | 2,281 |  |  | 4,603 |  |  | 9,562 |  |  | 12,615 | \n |  |  |  |  |  |  |  | \nInterest expense, net |  | 398 |  |  | 497 |  |  | 1,306 |  |  | 1,568 | \nNet foreign exchange loss |  | 25 |  |  | 36 |  |  | 97 |  |  | 108 | \nOther expense (income), net |  | (95) |  |  | (330) |  |  | 3,121 |  |  | 427 | \nEarnings before income tax expense |  | 1,953 |  |  | 4,400 |  |  | 5,038 |  |  | 10,512 | \nIncome tax expense |  | 172 |  |  | 448 |  |  | 989 |  |  | 1,139 | \nNet earnings |  | 1,781 |  |  | 3,952 |  |  | 4,049 |  |  | 9,373 | \nNet earnings attributable to noncontrolling interest |  | 3 |  |  | 3 |  |  | 8 |  |  | 10 | \nNet earnings attributable to AbbVie Inc. |  | $ | 1,778 |  |  | $ | 3,949 |  |  | $ | 4,041 |  |  | $ | 9,363 | \n |  |  |  |  |  |  |  | \nPer share data |  |  |  |  |  |  |  | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 1.00 |  |  | $ | 2.22 |  |  | $ | 2.27 |  |  | $ | 5.26 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 1.00 |  |  | $ | 2.21 |  |  | $ | 2.26 |  |  | $ | 5.24 | \n |  |  |  |  |  |  |  | \nWeighted-average basic shares outstanding |  | 1,767 |  |  | 1,771 |  |  | 1,768 |  |  | 1,771 | \nWeighted-average diluted shares outstanding |  | 1,771 |  |  | 1,776 |  |  | 1,772 |  |  | 1,777 |   |  |  |  |  | \n2023 Form 10-Q| | 1  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet earnings | $ | 1,781 |  |  | $ | 3,952 |  |  | $ | 4,049 |  |  | $ | 9,373 | \n |  |  |  |  |  |  | \nForeign currency translation adjustments, net of tax expense (benefit) of $(17) for the three months and $(11) for the nine months ended September 30, 2023 and $(11) for the three months and $(30) for the nine months ended September 30, 2022 | (457) |  |  | (989) |  |  | (279) |  |  | (2,043) | \nNet investment hedging activities, net of tax expense (benefit) of $84for the three months and $26for the nine months ended September 30, 2023 and $165for the three months and $348for the nine months ended September 30, 2022 | 302 |  |  | 599 |  |  | 89 |  |  | 1,265 | \nPension and post-employment benefits, net of tax expense (benefit) of $1for the three months and $11for the nine months ended September 30, 2023 and $14for the three months and $35for the nine months ended September 30, 2022 | 2 |  |  | 60 |  |  | 38 |  |  | 136 | \nCash flow hedging activities, net of tax expense (benefit) of $7for the three months and $(1) for the nine months ended September 30, 2023 and $14for the three months and $17for the nine months ended September 30, 2022 | 52 |  |  | 83 |  |  | (2) |  |  | 98 | \nOther comprehensive loss | (101) |  |  | (247) |  |  | (154) |  |  | (544) | \nComprehensive income | 1,680 |  |  | 3,705 |  |  | 3,895 |  |  | 8,829 | \nComprehensive income attributable to noncontrolling interest | 3 |  |  | 3 |  |  | 8 |  |  | 10 | \nComprehensive income attributable to AbbVie Inc. | $ | 1,677 |  |  | $ | 3,702 |  |  | $ | 3,887 |  |  | $ | 8,819 |   |  |  |  |  | \n2023 Form 10-Q| | 2  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions,\u00a0except\u00a0share\u00a0data) | September 30,2023 |  | December 31,2022\n | (unaudited) |  | \nAssets |  |  | \nCurrent assets |  |  | \nCash and equivalents | $ | 13,287 |  |  | $ | 9,201 | \nShort-term investments | 3 |  |  | 28 | \nAccounts receivable, net | 11,412 |  |  | 11,254 | \nInventories | 3,981 |  |  | 3,579 | \nPrepaid expenses and other | 4,541 |  |  | 4,401 | \nTotal current assets | 33,224 |  |  | 28,463 | \n |  |  | \nInvestments | 275 |  |  | 241 | \nProperty and equipment, net | 4,934 |  |  | 4,935 | \nIntangible assets, net | 58,603 |  |  | 67,439 | \nGoodwill | 32,091 |  |  | 32,156 | \nOther assets | 7,094 |  |  | 5,571 | \nTotal assets | $ | 136,221 |  |  | $ | 138,805 | \n |  |  | \nLiabilities and Equity |  |  | \nCurrent liabilities |  |  | \nShort-term borrowings | $ | 2 |  |  | $ | 1 | \nCurrent portion of long-term debt and finance lease obligations | 5,113 |  |  | 4,135 | \nAccounts payable and accrued liabilities | 29,658 |  |  | 25,402 | \nTotal current liabilities | 34,773 |  |  | 29,538 | \n |  |  | \nLong-term debt and finance lease obligations | 55,631 |  |  | 59,135 | \nDeferred income taxes | 2,044 |  |  | 2,190 | \nOther long-term liabilities | 31,644 |  |  | 30,655 | \n |  |  | \nCommitments and contingencies |  |  | \n |  |  | \nStockholders' equity |  |  | \nCommon stock, $0.01par value,4,000,000,000shares authorized,1,822,577,212shares issued as of September 30, 2023 and1,813,770,294as of December 31, 2022 | 18 |  |  | 18 | \nCommon stock held in treasury, at cost,57,091,177shares as of September 30, 2023 and44,589,000as of December 31, 2022 | (6,525) |  |  | (4,594) | \nAdditional paid-in capital | 20,021 |  |  | 19,245 | \nRetained earnings | 933 |  |  | 4,784 | \nAccumulated other comprehensive loss | (2,353) |  |  | (2,199) | \nTotal stockholders' equity | 12,094 |  |  | 17,254 | \nNoncontrolling interest | 35 |  |  | 33 | \nTotal equity | 12,129 |  |  | 17,287 | \n |  |  | \nTotal liabilities and equity | $ | 136,221 |  |  | $ | 138,805 |   |  |  |  |  | \n2023 Form 10-Q| | 3  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) | Common shares outstanding |  | Common stock |  | Treasury stock |  | Additional paid-in capital |  | Retained earnings |  | Accumulated other comprehensive loss |  | Noncontrolling interest |  | Total\nBalance at June 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,591) |  |  | $ | 18,906 |  |  | $ | 3,516 |  |  | $ | (3,196) |  |  | $ | 35 |  |  | $ | 14,688 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,949 |  |  | \u2014 |  |  | \u2014 |  |  | 3,949 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (247) |  |  | \u2014 |  |  | (247) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,512) |  |  | \u2014 |  |  | \u2014 |  |  | (2,512) | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) | \nStock-based compensation plans and other | \u2014 |  |  | \u2014 |  |  | 5 |  |  | 150 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 155 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | (2) | \nBalance at September 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,590) |  |  | $ | 19,056 |  |  | $ | 4,953 |  |  | $ | (3,443) |  |  | $ | 33 |  |  | $ | 16,027 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2023 | 1,765 |  |  | $ | 18 |  |  | $ | (6,528) |  |  | $ | 19,839 |  |  | $ | 1,789 |  |  | $ | (2,252) |  |  | $ | 32 |  |  | $ | 12,898 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1,778 |  |  | \u2014 |  |  | \u2014 |  |  | 1,778 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (101) |  |  | \u2014 |  |  | (101) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,634) |  |  | \u2014 |  |  | \u2014 |  |  | (2,634) | \nPurchases of treasury stock | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) | \nStock-based compensation plans and other | \u2014 |  |  | \u2014 |  |  | 7 |  |  | 182 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 189 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 3 | \nBalance at September 30, 2023 | 1,765 |  |  | $ | 18 |  |  | $ | (6,525) |  |  | $ | 20,021 |  |  | $ | 933 |  |  | $ | (2,353) |  |  | $ | 35 |  |  | $ | 12,129 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2021 | 1,768 |  |  | $ | 18 |  |  | $ | (3,143) |  |  | $ | 18,305 |  |  | $ | 3,127 |  |  | $ | (2,899) |  |  | $ | 28 |  |  | $ | 15,436 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 9,363 |  |  | \u2014 |  |  | \u2014 |  |  | 9,363 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (544) |  |  | \u2014 |  |  | (544) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7,537) |  |  | \u2014 |  |  | \u2014 |  |  | (7,537) | \nPurchases of treasury stock | (10) |  |  | \u2014 |  |  | (1,483) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,483) | \nStock-based compensation plans and other | 10 |  |  | \u2014 |  |  | 36 |  |  | 751 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 787 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 5 |  |  | 5 | \nBalance at September 30, 2022 | 1,768 |  |  | $ | 18 |  |  | $ | (4,590) |  |  | $ | 19,056 |  |  | $ | 4,953 |  |  | $ | (3,443) |  |  | $ | 33 |  |  | $ | 16,027 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at December 31, 2022 | 1,769 |  |  | $ | 18 |  |  | $ | (4,594) |  |  | $ | 19,245 |  |  | $ | 4,784 |  |  | $ | (2,199) |  |  | $ | 33 |  |  | $ | 17,287 | \nNet earnings attributable to AbbVie Inc. | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,041 |  |  | \u2014 |  |  | \u2014 |  |  | 4,041 | \nOther comprehensive loss, net of tax | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (154) |  |  | \u2014 |  |  | (154) | \nDividends declared | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7,892) |  |  | \u2014 |  |  | \u2014 |  |  | (7,892) | \nPurchases of treasury stock | (12) |  |  | \u2014 |  |  | (1,969) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,969) | \nStock-based compensation plans and other | 8 |  |  | \u2014 |  |  | 38 |  |  | 776 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 814 | \nChange in noncontrolling interest | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 2 | \nBalance at September 30, 2023 | 1,765 |  |  | $ | 18 |  |  | $ | (6,525) |  |  | $ | 20,021 |  |  | $ | 933 |  |  | $ | (2,353) |  |  | $ | 35 |  |  | $ | 12,129 |   |  |  |  |  | \n2023 Form 10-Q| | 4  |  |  |  |  |  |  |  |  |  |  | \n | Nine months endedSeptember 30,\n(in\u00a0millions)\u00a0(brackets\u00a0denote\u00a0cash\u00a0outflows) | 2023 |  | 2022\nCash flows from operating activities |  |  | \nNet earnings | $ | 4,049 |  |  | $ | 9,373 | \nAdjustments to reconcile net earnings to net cash from operating activities: |  |  | \nDepreciation | 565 |  |  | 582 | \nAmortization of intangible assets | 6,057 |  |  | 5,728 | \nDeferred income taxes | (1,498) |  |  | (1,415) | \nChange in fair value of contingent consideration liabilities | 3,432 |  |  | 647 | \nPayments of contingent consideration liabilities | (407) |  |  | (161) | \nStock-based compensation | 622 |  |  | 539 | \nAcquired IPR&D and milestones | 496 |  |  | 454 | \nGain on divestitures | \u2014 |  |  | (172) | \nNon-cash litigation reserve adjustments, net of cash payments | (205) |  |  | 2,261 | \nImpairment of intangible assets | 2,824 |  |  | 770 | \nOther, net | (219) |  |  | (151) | \nChanges in operating assets and liabilities, net of acquisitions: |  |  | \nAccounts receivable | (273) |  |  | (1,039) | \nInventories | (513) |  |  | (516) | \nPrepaid expenses and other assets | 394 |  |  | (60) | \nAccounts payable and other liabilities | 3,661 |  |  | 491 | \nIncome tax assets and liabilities, net | (899) |  |  | 184 | \nCash flows from operating activities | 18,086 |  |  | 17,515 | \n |  |  | \nCash flows from investing activities |  |  | \nAcquisitions and investments | (670) |  |  | (494) | \nAcquisitions of property and equipment | (572) |  |  | (482) | \nPurchases of investment securities | (43) |  |  | (1,428) | \nSales and maturities of investment securities | 41 |  |  | 1,460 | \nOther, net | 35 |  |  | 769 | \nCash flows from investing activities | (1,209) |  |  | (175) | \n |  |  | \nCash flows from financing activities |  |  | \nProceeds from issuance of long-term debt | \u2014 |  |  | 2,000 | \nRepayments of long-term debt and finance lease obligations | (2,355) |  |  | (7,582) | \nDividends paid | (7,913) |  |  | (7,537) | \nPurchases of treasury stock | (1,969) |  |  | (1,483) | \nProceeds from the exercise of stock options | 149 |  |  | 209 | \nPayments of contingent consideration liabilities | (735) |  |  | (817) | \nOther, net | 50 |  |  | 41 | \nCash flows from financing activities | (12,773) |  |  | (15,169) | \nEffect of exchange rate changes on cash and equivalents | (18) |  |  | (85) | \nNet change in cash and equivalents | 4,086 |  |  | 2,086 | \nCash and equivalents, beginning of period | 9,201 |  |  | 9,746 | \n |  |  | \nCash and equivalents, end of period | $ | 13,287 |  |  | $ | 11,832 | \n |  |  | \n |  |  | \n |  |  |   |  |  |  |  | \n2023 Form 10-Q| | 5  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest expense |  | $ | 555 |  |  | $ | 560 |  |  | $ | 1,660 |  |  | $ | 1,664 | \nInterest income |  | (157) |  |  | (63) |  |  | (354) |  |  | (96) | \nInterest expense, net |  | $ | 398 |  |  | $ | 497 |  |  | $ | 1,306 |  |  | $ | 1,568 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | September 30,2023 |  | December 31,2022\nFinished goods | $ | 1,035 |  |  | $ | 1,162 | \nWork-in-process | 1,690 |  |  | 1,417 | \nRaw materials | 1,256 |  |  | 1,000 | \nInventories | $ | 3,981 |  |  | $ | 3,579 |   |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | September 30,2023 |  | December 31,2022\nProperty and equipment, gross | $ | 11,374 |  |  | $ | 10,986 | \nAccumulated depreciation | (6,440) |  |  | (6,051) | \nProperty and equipment, net | $ | 4,934 |  |  | $ | 4,935 |   |  |  |  |  | \n2023 Form 10-Q| | 6  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions, except per share data) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nBasic EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 1,778 |  |  | $ | 3,949 |  |  | $ | 4,041 |  |  | $ | 9,363 | \nEarnings allocated to participating securities |  | 11 |  |  | 18 |  |  | 32 |  |  | 43 | \nEarnings available to common shareholders |  | $ | 1,767 |  |  | $ | 3,931 |  |  | $ | 4,009 |  |  | $ | 9,320 | \nWeighted-average basic shares outstanding |  | 1,767 |  |  | 1,771 |  |  | 1,768 |  |  | 1,771 | \nBasic earnings per share attributable to AbbVie Inc. |  | $ | 1.00 |  |  | $ | 2.22 |  |  | $ | 2.27 |  |  | $ | 5.26 | \n |  |  |  |  |  |  |  | \nDiluted EPS |  |  |  |  |  |  |  | \nNet earnings attributable to AbbVie Inc. |  | $ | 1,778 |  |  | $ | 3,949 |  |  | $ | 4,041 |  |  | $ | 9,363 | \nEarnings allocated to participating securities |  | 11 |  |  | 18 |  |  | 32 |  |  | 43 | \nEarnings available to common shareholders |  | $ | 1,767 |  |  | $ | 3,931 |  |  | $ | 4,009 |  |  | $ | 9,320 | \nWeighted-average shares of common stock outstanding |  | 1,767 |  |  | 1,771 |  |  | 1,768 |  |  | 1,771 | \nEffect of dilutive securities |  | 4 |  |  | 5 |  |  | 4 |  |  | 6 | \nWeighted-average diluted shares outstanding |  | 1,771 |  |  | 1,776 |  |  | 1,772 |  |  | 1,777 | \nDiluted earnings per share attributable to AbbVie Inc. |  | $ | 1.00 |  |  | $ | 2.21 |  |  | $ | 2.26 |  |  | $ | 5.24 |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 7  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States - Janssen's share of profits (included in cost of products sold) |  | $ | 316 |  |  | $ | 398 |  |  | $ | 925 |  |  | $ | 1,210 | \nInternational - AbbVie's share of profits (included in net revenues) |  | 230 |  |  | 286 |  |  | 711 |  |  | 868 | \nGlobal - AbbVie's share of other costs (included in respective line items) |  | 59 |  |  | 63 |  |  | 171 |  |  | 196 |   |  |  |  |  | \n2023 Form 10-Q| | 8  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nGenentech's share of profits, including royalties (included in cost of products sold) |  | $ | 225 |  |  | $ | 204 |  |  | $ | 641 |  |  | $ | 578 | \nAbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  | 13 |  |  | 10 |  |  | 32 |  |  | 27 | \nAbbVie's share of development costs (included in R&D) |  | 24 |  |  | 29 |  |  | 82 |  |  | 87 |   |  | \n  |  |  |  |  | \n(in\u00a0millions) | \nBalance as of December 31, 2022 | $ | 32,156 | \nForeign currency translation adjustments | (65) | \nBalance as of September 30, 2023 | $ | 32,091 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\n(in\u00a0millions) | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount |  | Grosscarryingamount |  | Accumulatedamortization |  | Netcarryingamount\nDefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  | \nDeveloped product rights | $ | 76,526 |  |  | $ | (21,170) |  |  | $ | 55,356 |  |  | $ | 87,698 |  |  | $ | (25,003) |  |  | $ | 62,695 | \nLicense agreements | 8,261 |  |  | (5,299) |  |  | 2,962 |  |  | 8,474 |  |  | (4,642) |  |  | 3,832 | \nTotal definite-lived intangible assets | 84,787 |  |  | (26,469) |  |  | 58,318 |  |  | 96,172 |  |  | (29,645) |  |  | 66,527 | \nIndefinite-lived intangible assets | 285 |  |  | \u2014 |  |  | 285 |  |  | 912 |  |  | \u2014 |  |  | 912 | \nTotal intangible assets, net | $ | 85,072 |  |  | $ | (26,469) |  |  | $ | 58,603 |  |  | $ | 97,084 |  |  | $ | (29,645) |  |  | $ | 67,439 |   |  |  |  |  | \n2023 Form 10-Q| | 9  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2023 | 2022 |  | 2023 |  | 2022\nCost of products sold |  | $ | 20 |  | $ | 24 |  |  | $ | 66 |  |  | $ | 81 | \nResearch and development |  | 1 |  | 4 |  |  | 2 |  |  | 14 | \nSelling, general and administrative |  | 39 |  | 88 |  |  | 134 |  |  | 234 | \nTotal charges |  | $ | 60 |  | $ | 116 |  |  | $ | 202 |  |  | $ | 329 |   |  |  |  |  | \n(in millions) | \nAccrued balance as of December 31, 2022 | $ | 107 | \nCharges | 192 | \nPayments and other adjustments | (258) | \nAccrued balance as of September 30, 2023 | $ | 41 |   |  |  |  |  | \n2023 Form 10-Q| | 10  |  |  |  |  | \n(in\u00a0millions) | \nAccrued balance as of December 31, 2022 | $ | 176 | \nRestructuring charges | 31 | \nPayments and other adjustments | (64) | \nAccrued balance as of September 30, 2023 | $ | 143 |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 11  |  |  |  |  | \n2023 Form 10-Q| | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair value \u2013Derivatives in asset position |  | Fair value \u2013Derivatives\u00a0in\u00a0liability\u00a0position\n(in\u00a0millions) | Balance\u00a0sheet\u00a0caption | September 30, 2023 | December 31, 2022 |  | Balance\u00a0sheet\u00a0caption | September 30, 2023 | December 31, 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | $ | 90 |  | $ | 49 |  |  | Accounts payable and accrued liabilities | $ | 3 |  | $ | 8 | \nDesignated as cash flow hedges | Other assets | \u2014 |  | 1 |  |  | Other long-term liabilities | \u2014 |  | \u2014 | \nDesignated as net investment hedges | Prepaid expenses and other | 32 |  | 6 |  |  | Accounts payable and accrued liabilities | 29 |  | 36 | \nDesignated as net investment hedges | Other assets | 157 |  | 74 |  |  | Other long-term liabilities | 9 |  | 47 | \nNot designated as hedges | Prepaid expenses and other | 30 |  | 33 |  |  | Accounts payable and accrued liabilities | 49 |  | 41 | \nCross-currency swap contracts |  |  |  |  |  |  | \nDesignated as cash flow hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 5 |  | \u2014 | \nInterest rate swap contracts |  |  |  |  |  |  | \nDesignated as fair value hedges | Prepaid expenses and other | \u2014 |  | \u2014 |  |  | Accounts payable and accrued liabilities | 2 |  | 17 | \nDesignated as fair value hedges | Other assets | \u2014 |  | \u2014 |  |  | Other long-term liabilities | 434 |  | 375 | \nTotal derivatives |  | $ | 309 |  | $ | 163 |  |  |  | $ | 531 |  | $ | 524 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  |  | \nDesignated as cash flow hedges |  | $ | 76 |  |  | $ | 124 |  |  | $ | 81 |  |  | $ | 171 | \nDesignated as net investment hedges |  | 241 |  |  | 362 |  |  | 153 |  |  | 748 | \nCross-currency swap contracts designated as cash flow hedges |  | (14) |  |  | \u2014 |  |  | (5) |  |  | \u2014 | \nInterest rate swap contracts designated as cash flow hedges |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6 | \n |  |  |  |  |  |  |  |   |  |  |  |  | \n2023 Form 10-Q| | 13  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) | Statement\u00a0of earnings caption |  | 2023 |  | 2022 |  | 2023 |  | 2022\nForeign currency forward exchange contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Cost of products sold |  | $ | 11 |  |  | $ | 21 |  |  | $ | 67 |  |  | $ | 47 | \nDesignated as net investment hedges | Interest expense, net |  | 28 |  |  | 29 |  |  | 85 |  |  | 67 | \nNot designated as hedges | Net foreign exchange loss |  | (41) |  |  | (121) |  |  | (7) |  |  | (285) | \nTreasury rate lock agreements designated as cash flow hedges | Interest expense, net |  | 6 |  |  | 6 |  |  | 18 |  |  | 18 | \nCross-currency swap contracts designated as cash flow hedges | Net foreign exchange loss |  | (14) |  |  | \u2014 |  |  | (6) |  |  | \u2014 | \nInterest rate swap contracts |  |  |  |  |  |  |  |  | \nDesignated as cash flow hedges | Interest expense, net |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) | \nDesignated as fair value hedges | Interest expense, net |  | (58) |  |  | (141) |  |  | (44) |  |  | (424) | \nDebt designated as hedged item in fair value hedges | Interest expense, net |  | 58 |  |  | 141 |  |  | 44 |  |  | 424 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 13,287 |  |  | $ | 5,531 |  |  | $ | 7,756 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 10 |  |  | \u2014 |  |  | 10 |  |  | \u2014 | \nDebt securities | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nEquity securities | 109 |  |  | 86 |  |  | 23 |  |  | \u2014 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nForeign currency contracts | 309 |  |  | \u2014 |  |  | 309 |  |  | \u2014 | \n |  |  |  |  |  |  | \nTotal assets | $ | 13,743 |  |  | $ | 5,617 |  |  | $ | 8,126 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 436 |  |  | $ | \u2014 |  |  | $ | 436 |  |  | $ | \u2014 | \nCross-currency swap contracts | 5 |  |  | \u2014 |  |  | 5 |  |  | \u2014 | \nForeign currency contracts | 90 |  |  | \u2014 |  |  | 90 |  |  | \u2014 | \nContingent consideration | 18,674 |  |  | \u2014 |  |  | \u2014 |  |  | 18,674 | \nTotal liabilities | $ | 19,205 |  |  | $ | \u2014 |  |  | $ | 531 |  |  | $ | 18,674 |   |  |  |  |  | \n2023 Form 10-Q| | 14  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Total |  | Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets(Level\u00a01) |  | Significant other observableinputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\nAssets |  |  |  |  |  |  | \nCash and equivalents | $ | 9,201 |  |  | $ | 4,201 |  |  | $ | 5,000 |  |  | $ | \u2014 | \nMoney market funds and time deposits | 21 |  |  | \u2014 |  |  | 21 |  |  | \u2014 | \nDebt securities | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nEquity securities | 91 |  |  | 59 |  |  | 32 |  |  | \u2014 | \nForeign currency contracts | 163 |  |  | \u2014 |  |  | 163 |  |  | \u2014 | \nTotal assets | $ | 9,504 |  |  | $ | 4,260 |  |  | $ | 5,244 |  |  | $ | \u2014 | \nLiabilities |  |  |  |  |  |  | \nInterest rate swap contracts | $ | 392 |  |  | $ | \u2014 |  |  | $ | 392 |  |  | $ | \u2014 | \nForeign currency contracts | 132 |  |  | \u2014 |  |  | 132 |  |  | \u2014 | \nContingent consideration | 16,384 |  |  | \u2014 |  |  | \u2014 |  |  | 16,384 | \nTotal liabilities | $ | 16,908 |  |  | $ | \u2014 |  |  | $ | 524 |  |  | $ | 16,384 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\n(in\u00a0millions) | Range | Weighted average(a) |  | Range | Weighted average(a)\nDiscount rate | 5.3% -6.1% | 5.5% |  | 4.7%-5.1% | 4.8%\nProbability of payment for unachieved milestones | 100% -100% | 100% |  | 100% -100% | 100%\nProbability of payment for royalties by indication(b) | 89% -100% | 99% |  | 56% -100% | 99%\nProjected year of payments | 2023-2034 | 2027 |  | 2023-2034 | 2028  |  |  |  |  | \n2023 Form 10-Q| | 15  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2023 |  | 2022\nBeginning balance |  | $ | 16,384 |  |  | $ | 14,887 | \nChange in fair value recognized in net earnings |  | 3,432 |  |  | 647 | \nPayments |  | (1,142) |  |  | (978) | \nEnding balance |  | $ | 18,674 |  |  | $ | 14,556 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 2 |  | $ | 2 |  |  | $ | \u2014 |  |  | $ | 2 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 5,113 |  | 5,041 |  |  | 4,763 |  |  | 278 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 56,035 |  | 49,633 |  |  | 49,124 |  |  | 509 |  |  | \u2014 | \nTotal liabilities | $ | 61,150 |  | $ | 54,676 |  |  | $ | 53,887 |  |  | $ | 789 |  |  | $ | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Basis\u00a0of\u00a0fair\u00a0value\u00a0measurement\n(in\u00a0millions) | Book value | Approximate fair value |  | Quoted\u00a0prices in\u00a0active markets for identical assets(Level\u00a01) |  | Significant otherobservable inputs(Level\u00a02) |  | Significant unobservable inputs(Level\u00a03)\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  | \nShort-term borrowings | $ | 1 |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 | \nCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges | 4,152 |  | 4,121 |  |  | 3,930 |  |  | 191 |  |  | \u2014 | \nLong-term debt and finance lease obligations, excluding fair value hedges | 59,463 |  | 54,073 |  |  | 53,365 |  |  | 708 |  |  | \u2014 | \nTotal liabilities | $ | 63,616 |  | $ | 58,195 |  |  | $ | 57,295 |  |  | $ | 900 |  |  | $ | \u2014 |   |  |  |  |  | \n2023 Form 10-Q| | 16  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Definedbenefit\u00a0plans |  | Other\u00a0post-employment\u00a0plans\n | Three months endedSeptember 30, |  | Nine months endedSeptember 30, |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nService cost | $ | 68 |  |  | $ | 113 |  |  | $ | 203 |  |  | $ | 342 |  |  | $ | 9 |  |  | $ | 13 |  |  | $ | 27 |  |  | $ | 38 | \nInterest cost | 108 |  |  | 74 |  |  | 324 |  |  | 223 |  |  | 9 |  |  | 6 |  |  | 28 |  |  | 18 | \nExpected return on plan assets | (181) |  |  | (177) |  |  | (543) |  |  | (536) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nAmortization of prior service cost (credit) | \u2014 |  |  | 1 |  |  | 1 |  |  | 2 |  |  | (9) |  |  | (10) |  |  | (27) |  |  | (29) | \nAmortization of actuarial loss | 4 |  |  | 57 |  |  | 12 |  |  | 173 |  |  | 3 |  |  | 7 |  |  | 9 |  |  | 20 | \nNet periodic benefit cost (credit) | $ | (1) |  |  | $ | 68 |  |  | $ | (3) |  |  | $ | 204 |  |  | $ | 12 |  |  | $ | 16 |  |  | $ | 37 |  |  | $ | 47 |   |  |  |  |  | \n2023 Form 10-Q| | 17  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nCost of products sold |  | $ | 9 |  |  | $ | 8 |  |  | $ | 38 |  |  | $ | 33 | \nResearch and development |  | 53 |  |  | 47 |  |  | 227 |  |  | 194 | \nSelling, general and administrative |  | 68 |  |  | 71 |  |  | 357 |  |  | 312 | \nPre-tax compensation expense |  | 130 |  |  | 126 |  |  | 622 |  |  | 539 | \nTax benefit |  | (26) |  |  | (25) |  |  | (111) |  |  | (102) | \nAfter-tax compensation expense |  | $ | 104 |  |  | $ | 101 |  |  | $ | 511 |  |  | $ | 437 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2023 |  | 2022\nDate Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share\n10/26/23 |  | 02/15/24 |  | $ | 1.55 |  |  | 10/28/22 |  | 02/15/23 |  | $ | 1.48 | \n09/08/23 |  | 11/15/23 |  | $ | 1.48 |  |  | 09/09/22 |  | 11/15/22 |  | $ | 1.41 | \n06/22/23 |  | 08/15/23 |  | $ | 1.48 |  |  | 06/23/22 |  | 08/15/22 |  | $ | 1.41 | \n02/16/23 |  | 05/15/23 |  | $ | 1.48 |  |  | 02/17/22 |  | 05/16/22 |  | $ | 1.41 |   |  |  |  |  | \n2023 Form 10-Q| | 18  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2022 | $ | (1,513) |  |  | $ | 464 |  |  | $ | (1,458) |  |  |  |  | $ | 308 |  |  | $ | (2,199) | \nOther comprehensive income (loss) before reclassifications | (279) |  |  | 156 |  |  | 43 |  |  |  |  | 61 |  |  | (19) | \nNet gains reclassified from accumulated other comprehensive loss | \u2014 |  |  | (67) |  |  | (5) |  |  |  |  | (63) |  |  | (135) | \nNet current-period other comprehensive income (loss) | (279) |  |  | 89 |  |  | 38 |  |  |  |  | (2) |  |  | (154) | \nBalance as of September 30, 2023 | $ | (1,792) |  |  | $ | 553 |  |  | $ | (1,420) |  |  |  |  | $ | 306 |  |  | $ | (2,353) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in\u00a0millions) | Foreign currencytranslation adjustments |  | Net investmenthedging activities |  | Pensionand post-employmentbenefits |  |  |  | Cash flow hedgingactivities |  | Total\nBalance as of December 31, 2021 | $ | (570) |  |  | $ | (91) |  |  | $ | (2,546) |  |  |  |  | $ | 308 |  |  | $ | (2,899) | \nOther comprehensive income (loss) before reclassifications | (2,043) |  |  | 1,318 |  |  | 6 |  |  |  |  | 151 |  |  | (568) | \nNet losses (gains) reclassified from accumulated other comprehensive loss | \u2014 |  |  | (53) |  |  | 130 |  |  |  |  | (53) |  |  | 24 | \nNet current-period other comprehensive income (loss) | (2,043) |  |  | 1,265 |  |  | 136 |  |  |  |  | 98 |  |  | (544) | \nBalance as of September 30, 2022 | $ | (2,613) |  |  | $ | 1,174 |  |  | $ | (2,410) |  |  |  |  | $ | 406 |  |  | $ | (3,443) |   |  |  |  |  | \n2023 Form 10-Q| | 19  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in millions) (brackets\u00a0denote\u00a0gains) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet investment hedging activities |  |  |  |  |  |  | \nGains on derivative amount excluded from effectiveness testing(a) | $ | (28) |  |  | $ | (29) |  |  | $ | (85) |  |  | $ | (67) | \nTax expense | 6 |  |  | 6 |  |  | 18 |  |  | 14 | \nTotal reclassifications, net of tax | $ | (22) |  |  | $ | (23) |  |  | $ | (67) |  |  | $ | (53) | \nPension and post-employment benefits |  |  |  |  |  |  | \nAmortization of actuarial losses and other(b) | $ | (2) |  |  | $ | 55 |  |  | $ | (5) |  |  | $ | 166 | \nTax benefit | \u2014 |  |  | (12) |  |  | \u2014 |  |  | (36) | \nTotal reclassifications, net of tax | $ | (2) |  |  | $ | 43 |  |  | $ | (5) |  |  | $ | 130 | \nCash flow hedging activities |  |  |  |  |  |  | \nGains on foreign currency forward exchange contracts(c) | $ | (11) |  |  | $ | (21) |  |  | $ | (67) |  |  | $ | (47) | \nGains on treasury rate lock agreements(a) | (6) |  |  | (6) |  |  | (18) |  |  | (18) | \nLosses on cross-currency swap contracts(d) | 14 |  |  | \u2014 |  |  | 6 |  |  | \u2014 | \nLosses on interest rate swap contracts(a) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nTax expense | 2 |  |  | 4 |  |  | 16 |  |  | 9 | \nTotal reclassifications, net of tax | $ | (1) |  |  | $ | (23) |  |  | $ | (63) |  |  | $ | (53) |   |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 20  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 21  |  |  |  |  | \n2023 Form 10-Q| | 22  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n |  | \n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nImmunology |  |  |  |  |  |  | \nHumira | United States | $ | 3,020 |  |  | $ | 4,956 |  |  | $ | 9,420 |  |  | $ | 13,613 | \n | International | 527 |  |  | 603 |  |  | 1,680 |  |  | 2,045 | \n | Total | $ | 3,547 |  |  | $ | 5,559 |  |  | $ | 11,100 |  |  | $ | 15,658 | \nSkyrizi | United States | $ | 1,875 |  |  | $ | 1,221 |  |  | $ | 4,648 |  |  | $ | 3,081 | \n | International | 251 |  |  | 176 |  |  | 721 |  |  | 508 | \n | Total | $ | 2,126 |  |  | $ | 1,397 |  |  | $ | 5,369 |  |  | $ | 3,589 | \nRinvoq | United States | $ | 801 |  |  | $ | 505 |  |  | $ | 1,895 |  |  | $ | 1,228 | \n | International | 309 |  |  | 190 |  |  | 819 |  |  | 524 | \n | Total | $ | 1,110 |  |  | $ | 695 |  |  | $ | 2,714 |  |  | $ | 1,752 | \nOncology |  |  |  |  |  |  | \nImbruvica | United States | $ | 678 |  |  | $ | 849 |  |  | $ | 1,982 |  |  | $ | 2,585 | \n | Collaboration revenues | 230 |  |  | 286 |  |  | 711 |  |  | 868 | \n | Total | $ | 908 |  |  | $ | 1,135 |  |  | $ | 2,693 |  |  | $ | 3,453 | \nVenclexta | United States | $ | 281 |  |  | $ | 259 |  |  | $ | 811 |  |  | $ | 740 | \n | International | 309 |  |  | 256 |  |  | 888 |  |  | 753 | \n | Total | $ | 590 |  |  | $ | 515 |  |  | $ | 1,699 |  |  | $ | 1,493 | \nEpkinly | Collaboration revenues | $ | 14 |  |  | $ | \u2014 |  |  | $ | 14 |  |  | $ | \u2014 | \nAesthetics |  |  |  |  |  |  | \nBotox Cosmetic | United States | $ | 388 |  |  | $ | 370 |  |  | $ | 1,217 |  |  | $ | 1,232 | \n | International | 232 |  |  | 267 |  |  | 747 |  |  | 741 | \n | Total | $ | 620 |  |  | $ | 637 |  |  | $ | 1,964 |  |  | $ | 1,973 | \nJuvederm Collection | United States | $ | 116 |  |  | $ | 125 |  |  | $ | 363 |  |  | $ | 420 | \n | International | 205 |  |  | 227 |  |  | 681 |  |  | 686 | \n | Total | $ | 321 |  |  | $ | 352 |  |  | $ | 1,044 |  |  | $ | 1,106 | \nOther Aesthetics | United States | $ | 255 |  |  | $ | 265 |  |  | $ | 785 |  |  | $ | 837 | \n | International | 43 |  |  | 47 |  |  | 130 |  |  | 130 | \n | Total | $ | 298 |  |  | $ | 312 |  |  | $ | 915 |  |  | $ | 967 | \nNeuroscience |  |  |  |  |  |  | \nBotox Therapeutic | United States | $ | 626 |  |  | $ | 584 |  |  | $ | 1,827 |  |  | $ | 1,641 | \n | International | 122 |  |  | 115 |  |  | 388 |  |  | 350 | \n | Total | $ | 748 |  |  | $ | 699 |  |  | $ | 2,215 |  |  | $ | 1,991 | \nVraylar | United States | $ | 750 |  |  | $ | 554 |  |  | $ | 1,967 |  |  | $ | 1,473 | \n | International | 1 |  |  | \u2014 |  |  | 3 |  |  | \u2014 | \n | Total | $ | 751 |  |  | $ | 554 |  |  | $ | 1,970 |  |  | $ | 1,473 | \nDuodopa | United States | $ | 25 |  |  | $ | 22 |  |  | $ | 74 |  |  | $ | 72 | \n | International | 93 |  |  | 88 |  |  | 279 |  |  | 279 | \n | Total | $ | 118 |  |  | $ | 110 |  |  | $ | 353 |  |  | $ | 351 | \nUbrelvy | United States | $ | 230 |  |  | $ | 160 |  |  | $ | 574 |  |  | $ | 483 | \n | International | 3 |  |  | \u2014 |  |  | 7 |  |  | \u2014 | \n | Total | $ | 233 |  |  | $ | 160 |  |  | $ | 581 |  |  | $ | 483 |   |  |  |  |  | \n2023 Form 10-Q| | 23  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n |  | \n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nQulipta | United States | $ | 131 |  |  | $ | 62 |  |  | $ | 292 |  |  | $ | 106 | \n | International | 1 |  |  | \u2014 |  |  | 2 |  |  | \u2014 | \n | Total | $ | 132 |  |  | $ | 62 |  |  | $ | 294 |  |  | $ | 106 | \nOther Neuroscience | United States | $ | 55 |  |  | $ | 82 |  |  | $ | 195 |  |  | $ | 400 | \n | International | 6 |  |  | 5 |  |  | 15 |  |  | 14 | \n | Total | $ | 61 |  |  | $ | 87 |  |  | $ | 210 |  |  | $ | 414 | \nEye Care |  |  |  |  |  |  | \nOzurdex | United States | $ | 34 |  |  | $ | 35 |  |  | $ | 107 |  |  | $ | 104 | \n | International | 86 |  |  | 71 |  |  | 247 |  |  | 219 | \n | Total | $ | 120 |  |  | $ | 106 |  |  | $ | 354 |  |  | $ | 323 | \nLumigan/Ganfort | United States | $ | 28 |  |  | $ | 59 |  |  | $ | 142 |  |  | $ | 186 | \n | International | 63 |  |  | 62 |  |  | 198 |  |  | 205 | \n | Total | $ | 91 |  |  | $ | 121 |  |  | $ | 340 |  |  | $ | 391 | \nAlphagan/Combigan | United States | $ | 30 |  |  | $ | 37 |  |  | $ | 90 |  |  | $ | 161 | \n | International | 40 |  |  | 36 |  |  | 116 |  |  | 111 | \n | Total | $ | 70 |  |  | $ | 73 |  |  | $ | 206 |  |  | $ | 272 | \nRestasis | United States | $ | 104 |  |  | $ | 132 |  |  | $ | 265 |  |  | $ | 518 | \n | International | 13 |  |  | 10 |  |  | 43 |  |  | 38 | \n | Total | $ | 117 |  |  | $ | 142 |  |  | $ | 308 |  |  | $ | 556 | \nOther Eye Care | United States | $ | 114 |  |  | $ | 99 |  |  | $ | 334 |  |  | $ | 296 | \n | International | 93 |  |  | 82 |  |  | 288 |  |  | 273 | \n | Total | $ | 207 |  |  | $ | 181 |  |  | $ | 622 |  |  | $ | 569 | \nOther Key Products |  |  |  |  |  |  | \nMavyret | United States | $ | 167 |  |  | $ | 190 |  |  | $ | 531 |  |  | $ | 562 | \n | International | 203 |  |  | 193 |  |  | 590 |  |  | 599 | \n | Total | $ | 370 |  |  | $ | 383 |  |  | $ | 1,121 |  |  | $ | 1,161 | \nCreon | United States | $ | 305 |  |  | $ | 336 |  |  | $ | 892 |  |  | $ | 941 | \nLinzess/Constella | United States | $ | 279 |  |  | $ | 262 |  |  | $ | 799 |  |  | $ | 742 | \n | International | 9 |  |  | 9 |  |  | 26 |  |  | 24 | \n | Total | $ | 288 |  |  | $ | 271 |  |  | $ | 825 |  |  | $ | 766 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nAll other |  | $ | 782 |  |  | $ | 925 |  |  | $ | 2,214 |  |  | $ | 3,145 | \nTotal net revenues | $ | 13,927 |  |  | $ | 14,812 |  |  | $ | 40,017 |  |  | $ | 42,933 |   |  |  |  |  | \n2023 Form 10-Q| | 24  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 25  |  |  |  |  | \n2023 Form 10-Q| | 26  |  |  |  |  | \n2023 Form 10-Q| | 27  |  |  |  |  | \n2023 Form 10-Q| | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Percent\u00a0change |  | Nine months endedSeptember 30, |  | Percent\u00a0change\n |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency\u00a0rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nUnited States |  | $ | 10,852 |  |  | $ | 11,763 |  |  | (7.7) | % |  | (7.7) | % |  | $ | 30,773 |  |  | $ | 33,521 |  |  | (8.2) | % |  | (8.2) | %\nInternational |  | 3,075 |  |  | 3,049 |  |  | 0.8 | % |  | 1.4 | % |  | 9,244 |  |  | 9,412 |  |  | (1.8) | % |  | 1.6 | %\nNet revenues |  | $ | 13,927 |  |  | $ | 14,812 |  |  | (6.0) | % |  | (5.8) | % |  | $ | 40,017 |  |  | $ | 42,933 |  |  | (6.8) | % |  | (6.0) | %  |  |  |  |  | \n2023 Form 10-Q| | 29  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedSeptember 30, |  | Percent\u00a0change |  | Nine months endedSeptember 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHumira | United States |  | $ | 3,020 |  |  | $ | 4,956 |  |  | (39.1) | % |  | (39.1) | % |  | $ | 9,420 |  |  | $ | 13,613 |  |  | (30.8) | % |  | (30.8) | %\n | International |  | 527 |  |  | 603 |  |  | (12.6) | % |  | (12.2) | % |  | 1,680 |  |  | 2,045 |  |  | (17.9) | % |  | (14.8) | %\n | Total |  | $ | 3,547 |  |  | $ | 5,559 |  |  | (36.2) | % |  | (36.2) | % |  | $ | 11,100 |  |  | $ | 15,658 |  |  | (29.1) | % |  | (28.7) | %\nSkyrizi | United States |  | $ | 1,875 |  |  | $ | 1,221 |  |  | 53.5 | % |  | 53.5 | % |  | $ | 4,648 |  |  | $ | 3,081 |  |  | 50.9 | % |  | 50.9 | %\n | International |  | 251 |  |  | 176 |  |  | 42.5 | % |  | 40.7 | % |  | 721 |  |  | 508 |  |  | 41.8 | % |  | 45.5 | %\n | Total |  | $ | 2,126 |  |  | $ | 1,397 |  |  | 52.1 | % |  | 51.9 | % |  | $ | 5,369 |  |  | $ | 3,589 |  |  | 49.6 | % |  | 50.1 | %\nRinvoq | United States |  | $ | 801 |  |  | $ | 505 |  |  | 59.0 | % |  | 59.0 | % |  | $ | 1,895 |  |  | $ | 1,228 |  |  | 54.4 | % |  | 54.4 | %\n | International |  | 309 |  |  | 190 |  |  | 61.8 | % |  | 61.2 | % |  | 819 |  |  | 524 |  |  | 56.1 | % |  | 61.0 | %\n | Total |  | $ | 1,110 |  |  | $ | 695 |  |  | 59.8 | % |  | 59.6 | % |  | $ | 2,714 |  |  | $ | 1,752 |  |  | 54.9 | % |  | 56.4 | %\nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nImbruvica | United States |  | $ | 678 |  |  | $ | 849 |  |  | (20.2) | % |  | (20.2) | % |  | $ | 1,982 |  |  | $ | 2,585 |  |  | (23.4) | % |  | (23.4) | %\n | Collaboration revenues |  | 230 |  |  | 286 |  |  | (19.6) | % |  | (19.6) | % |  | 711 |  |  | 868 |  |  | (18.0) | % |  | (18.0) | %\n | Total |  | $ | 908 |  |  | $ | 1,135 |  |  | (20.0) | % |  | (20.0) | % |  | $ | 2,693 |  |  | $ | 3,453 |  |  | (22.0) | % |  | (22.0) | %\nVenclexta | United States |  | $ | 281 |  |  | $ | 259 |  |  | 8.1 | % |  | 8.1 | % |  | $ | 811 |  |  | $ | 740 |  |  | 9.4 | % |  | 9.4 | %\n | International |  | 309 |  |  | 256 |  |  | 21.1 | % |  | 19.9 | % |  | 888 |  |  | 753 |  |  | 18.1 | % |  | 21.4 | %\n | Total |  | $ | 590 |  |  | $ | 515 |  |  | 14.6 | % |  | 14.0 | % |  | $ | 1,699 |  |  | $ | 1,493 |  |  | 13.8 | % |  | 15.5 | %\nEpkinly | Collaboration revenues |  | $ | 14 |  |  | $ | \u2014 |  |  | n/m |  | n/m |  | $ | 14 |  |  | $ | \u2014 |  |  | n/m |  | n/m\nAesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Cosmetic | United States |  | $ | 388 |  |  | $ | 370 |  |  | 5.0 | % |  | 5.0 | % |  | $ | 1,217 |  |  | $ | 1,232 |  |  | (1.1) | % |  | (1.1) | %\n | International |  | 232 |  |  | 267 |  |  | (13.3) | % |  | (10.9) | % |  | 747 |  |  | 741 |  |  | 0.7 | % |  | 6.0 | %\n | Total |  | $ | 620 |  |  | $ | 637 |  |  | (2.7) | % |  | (1.7) | % |  | $ | 1,964 |  |  | $ | 1,973 |  |  | (0.4) | % |  | 1.6 | %\nJuvederm Collection | United States |  | $ | 116 |  |  | $ | 125 |  |  | (6.4) | % |  | (6.4) | % |  | $ | 363 |  |  | $ | 420 |  |  | (13.3) | % |  | (13.3) | %\n | International |  | 205 |  |  | 227 |  |  | (9.8) | % |  | (8.7) | % |  | 681 |  |  | 686 |  |  | (0.8) | % |  | 4.5 | %\n | Total |  | $ | 321 |  |  | $ | 352 |  |  | (8.6) | % |  | (7.9) | % |  | $ | 1,044 |  |  | $ | 1,106 |  |  | (5.6) | % |  | (2.3) | %\nOther Aesthetics | United States |  | $ | 255 |  |  | $ | 265 |  |  | (4.0) | % |  | (4.0) | % |  | $ | 785 |  |  | $ | 837 |  |  | (6.3) | % |  | (6.3) | %\n | International |  | 43 |  |  | 47 |  |  | (8.1) | % |  | (7.0) | % |  | 130 |  |  | 130 |  |  | 0.5 | % |  | 5.4 | %\n | Total |  | $ | 298 |  |  | $ | 312 |  |  | (4.6) | % |  | (4.4) | % |  | $ | 915 |  |  | $ | 967 |  |  | (5.4) | % |  | (4.7) | %\nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBotox Therapeutic | United States |  | $ | 626 |  |  | $ | 584 |  |  | 7.2 | % |  | 7.2 | % |  | $ | 1,827 |  |  | $ | 1,641 |  |  | 11.3 | % |  | 11.3 | %\n | International |  | 122 |  |  | 115 |  |  | 6.5 | % |  | 8.6 | % |  | 388 |  |  | 350 |  |  | 10.9 | % |  | 16.6 | %\n | Total |  | $ | 748 |  |  | $ | 699 |  |  | 7.1 | % |  | 7.4 | % |  | $ | 2,215 |  |  | $ | 1,991 |  |  | 11.3 | % |  | 12.3 | %\nVraylar | United States |  | $ | 750 |  |  | $ | 554 |  |  | 35.2 | % |  | 35.2 | % |  | $ | 1,967 |  |  | $ | 1,473 |  |  | 33.6 | % |  | 33.6 | %\n | International |  | 1 |  |  | \u2014 |  |  | >100.0 % |  | >100.0 % |  | 3 |  |  | \u2014 |  |  | >100.0 % |  | >100.0 %\n | Total |  | $ | 751 |  |  | $ | 554 |  |  | 35.4 | % |  | 35.4 | % |  | $ | 1,970 |  |  | $ | 1,473 |  |  | 33.7 | % |  | 33.7 | %\nDuodopa | United States |  | $ | 25 |  |  | $ | 22 |  |  | 10.6 | % |  | 10.6 | % |  | $ | 74 |  |  | $ | 72 |  |  | 2.8 | % |  | 2.8 | %\n | International |  | 93 |  |  | 88 |  |  | 6.6 | % |  | 2.3 | % |  | 279 |  |  | 279 |  |  | \u2014 | % |  | 1.1 | %\n | Total |  | $ | 118 |  |  | $ | 110 |  |  | 7.4 | % |  | 4.0 | % |  | $ | 353 |  |  | $ | 351 |  |  | 0.6 | % |  | 1.5 | %\nUbrelvy | United States |  | $ | 230 |  |  | $ | 160 |  |  | 43.7 | % |  | 43.7 | % |  | $ | 574 |  |  | $ | 483 |  |  | 18.8 | % |  | 18.8 | %\n | International |  | 3 |  |  | \u2014 |  |  | >100.0 % |  | >100.0 % |  | 7 |  |  | \u2014 |  |  | >100.0 % |  | >100.0 %\n | Total |  | $ | 233 |  |  | $ | 160 |  |  | 45.6 | % |  | 45.6 | % |  | $ | 581 |  |  | $ | 483 |  |  | 20.3 | % |  | 20.3 | %\nQulipta | United States |  | $ | 131 |  |  | $ | 62 |  |  | >100.0 % |  | >100.0 % |  | $ | 292 |  |  | $ | 106 |  |  | >100.0 % |  | >100.0 %\n | International |  | 1 |  |  | \u2014 |  |  | n/m |  | n/m |  | 2 |  |  | \u2014 |  |  | n/m |  | n/m\n | Total |  | $ | 132 |  |  | $ | 62 |  |  | >100.0 % |  | >100.0 % |  | $ | 294 |  |  | $ | 106 |  |  | >100.0 % |  | >100.0 %  |  |  |  |  | \n2023 Form 10-Q| | 30  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Three months endedSeptember 30, |  | Percent\u00a0change |  | Nine months endedSeptember 30, |  | Percent\u00a0change\n |  |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates |  |  | At\u00a0actualcurrency rates |  | At\u00a0constantcurrency rates\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nOther Neuroscience | United States |  | $ | 55 |  |  | $ | 82 |  |  | (31.9) | % |  | (31.9) | % |  | $ | 195 |  |  | $ | 400 |  |  | (51.3) | % |  | (51.3) | %\n | International |  | 6 |  |  | 5 |  |  | 6.2 | % |  | 9.6 | % |  | 15 |  |  | 14 |  |  | 6.4 | % |  | 11.8 | %\n | Total |  | $ | 61 |  |  | $ | 87 |  |  | (29.9) | % |  | (29.7) | % |  | $ | 210 |  |  | $ | 414 |  |  | (49.3) | % |  | (49.1) | %\nEye Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOzurdex | United States |  | $ | 34 |  |  | $ | 35 |  |  | (4.5) | % |  | (4.5) | % |  | $ | 107 |  |  | $ | 104 |  |  | 2.6 | % |  | 2.6 | %\n | International |  | 86 |  |  | 71 |  |  | 22.3 | % |  | 21.7 | % |  | 247 |  |  | 219 |  |  | 13.1 | % |  | 16.1 | %\n | Total |  | $ | 120 |  |  | $ | 106 |  |  | 13.2 | % |  | 12.8 | % |  | $ | 354 |  |  | $ | 323 |  |  | 9.7 | % |  | 11.7 | %\nLumigan/Ganfort | United States |  | $ | 28 |  |  | $ | 59 |  |  | (53.0) | % |  | (53.0) | % |  | $ | 142 |  |  | $ | 186 |  |  | (23.6) | % |  | (23.6) | %\n | International |  | 63 |  |  | 62 |  |  | 2.7 | % |  | 1.4 | % |  | 198 |  |  | 205 |  |  | (3.1) | % |  | (0.9) | %\n | Total |  | $ | 91 |  |  | $ | 121 |  |  | (24.8) | % |  | (25.5) | % |  | $ | 340 |  |  | $ | 391 |  |  | (12.9) | % |  | (11.8) | %\nAlphagan/Combigan | United States |  | $ | 30 |  |  | $ | 37 |  |  | (16.0) | % |  | (16.0) | % |  | $ | 90 |  |  | $ | 161 |  |  | (43.5) | % |  | (43.5) | %\n | International |  | 40 |  |  | 36 |  |  | 10.1 | % |  | 17.3 | % |  | 116 |  |  | 111 |  |  | 4.2 | % |  | 10.6 | %\n | Total |  | $ | 70 |  |  | $ | 73 |  |  | (3.1) | % |  | 0.4 | % |  | $ | 206 |  |  | $ | 272 |  |  | (24.0) | % |  | (21.4) | %\nRestasis | United States |  | $ | 104 |  |  | $ | 132 |  |  | (20.7) | % |  | (20.7) | % |  | $ | 265 |  |  | $ | 518 |  |  | (48.8) | % |  | (48.8) | %\n | International |  | 13 |  |  | 10 |  |  | 35.0 | % |  | 42.1 | % |  | 43 |  |  | 38 |  |  | 14.2 | % |  | 20.1 | %\n | Total |  | $ | 117 |  |  | $ | 142 |  |  | (17.0) | % |  | (16.5) | % |  | $ | 308 |  |  | $ | 556 |  |  | (44.5) | % |  | (44.1) | %\nOther Eye Care | United States |  | $ | 114 |  |  | $ | 99 |  |  | 16.3 | % |  | 16.3 | % |  | $ | 334 |  |  | $ | 296 |  |  | 13.0 | % |  | 13.0 | %\n | International |  | 93 |  |  | 82 |  |  | 11.9 | % |  | 12.0 | % |  | 288 |  |  | 273 |  |  | 5.1 | % |  | 8.6 | %\n | Total |  | $ | 207 |  |  | $ | 181 |  |  | 14.2 | % |  | 14.2 | % |  | $ | 622 |  |  | $ | 569 |  |  | 9.2 | % |  | 10.9 | %\nOther Key Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMavyret | United States |  | $ | 167 |  |  | $ | 190 |  |  | (12.3) | % |  | (12.3) | % |  | $ | 531 |  |  | $ | 562 |  |  | (5.6) | % |  | (5.6) | %\n | International |  | 203 |  |  | 193 |  |  | 5.2 | % |  | 5.8 | % |  | 590 |  |  | 599 |  |  | (1.5) | % |  | 1.8 | %\n | Total |  | $ | 370 |  |  | $ | 383 |  |  | (3.5) | % |  | (3.2) | % |  | $ | 1,121 |  |  | $ | 1,161 |  |  | (3.5) | % |  | (1.8) | %\nCreon | United States |  | $ | 305 |  |  | $ | 336 |  |  | (9.1) | % |  | (9.1) | % |  | $ | 892 |  |  | $ | 941 |  |  | (5.2) | % |  | (5.2) | %\nLinzess/Constella | United States |  | $ | 279 |  |  | $ | 262 |  |  | 6.8 | % |  | 6.8 | % |  | $ | 799 |  |  | $ | 742 |  |  | 7.7 | % |  | 7.7 | %\n | International |  | 9 |  |  | 9 |  |  | (11.1) | % |  | (13.0) | % |  | 26 |  |  | 24 |  |  | 7.0 | % |  | 9.3 | %\n | Total |  | $ | 288 |  |  | $ | 271 |  |  | 6.2 | % |  | 6.1 | % |  | $ | 825 |  |  | $ | 766 |  |  | 7.7 | % |  | 7.8 | %\nAll other |  |  | $ | 782 |  |  | $ | 925 |  |  | (15.5) | % |  | (14.1) | % |  | $ | 2,214 |  |  | $ | 3,145 |  |  | (29.6) | % |  | (28.5) | %\nTotal net revenues |  | $ | 13,927 |  |  | $ | 14,812 |  |  | (6.0) | % |  | (5.8) | % |  | $ | 40,017 |  |  | $ | 42,933 |  |  | (6.8) | % |  | (6.0) | %  |  |  |  |  | \n2023 Form 10-Q| | 31  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\nGross margin |  | $ | 7,442 |  | $ | 9,790 |  | (24) | % |  | $ | 25,306 |  | $ | 29,689 |  | (15) | %\nas a % of net revenues |  | 53 | % |  | 66 | % |  |  |  | 63 | % |  | 69 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\nSelling, general and administrative |  | $ | 3,372 |  | $ | 3,304 |  | 2 | % |  | $ | 9,679 |  | $ | 11,843 |  | (18) | %\nas a % of net revenues |  | 24 | % |  | 22 | % |  |  |  | 24 | % |  | 28 | % |  |   |  |  |  |  | \n2023 Form 10-Q| | 32  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\nResearch and development |  | $ | 1,723 |  |  | $ | 1,614 |  |  | 7 | % |  | $ | 5,748 |  | $ | 4,720 |  | 22 | %\nas a % of net revenues |  | 12 | % |  | 11 | % |  |  |  | 14 | % |  | 11 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(dollars in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nUpfront charges |  | $ | 44 |  |  | $ | 40 |  |  | $ | 396 |  |  | $ | 392 | \nDevelopment milestones |  | 22 |  |  | \u2014 |  |  | 100 |  |  | 62 | \nAcquired IPR&D and milestones |  | $ | 66 |  |  | $ | 40 |  |  | $ | 496 |  |  | $ | 454 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three months endedSeptember 30, |  | Nine months endedSeptember 30,\n(in\u00a0millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest expense |  | $ | 555 |  |  | $ | 560 |  |  | $ | 1,660 |  |  | $ | 1,664 | \nInterest income |  | (157) |  |  | (63) |  |  | (354) |  |  | (96) | \nInterest expense, net |  | $ | 398 |  |  | $ | 497 |  |  | $ | 1,306 |  |  | $ | 1,568 | \n |  |  |  |  |  |  |  | \nNet foreign exchange loss |  | $ | 25 |  |  | $ | 36 |  |  | $ | 97 |  |  | $ | 108 | \nOther expense (income), net |  | (95) |  |  | (330) |  |  | 3,121 |  |  | 427 |   |  |  |  |  | \n2023 Form 10-Q| | 33  |  |  |  |  |  |  |  |  |  |  | \n | Nine months endedSeptember 30,\n(in\u00a0millions) | 2023 |  | 2022\nCash flows provided by (used in): |  |  | \nOperating activities | $ | 18,086 |  |  | $ | 17,515 | \nInvesting activities | (1,209) |  |  | (175) | \nFinancing activities | (12,773) |  |  | (15,169) |   |  |  |  |  | \n2023 Form 10-Q| | 34  |  |  |  |  | \n2023 Form 10-Q| | 35  |  | \n  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 36  |  | \n  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | (a)\u00a0TotalNumber\u00a0ofShares(or Units)Purchased |  | (b)\u00a0AveragePrice\u00a0Paidper\u00a0Share(or\u00a0Unit) |  | (c)\u00a0Total\u00a0Numberof\u00a0Shares\u00a0(orUnits)\u00a0Purchasedas\u00a0Part\u00a0of\u00a0PubliclyAnnounced\u00a0Plansor\u00a0Programs |  | (d)\u00a0MaximumNumber\u00a0(orApproximateDollar\u00a0Value)\u00a0ofShares\u00a0(or\u00a0Units)that\u00a0May\u00a0Yet\u00a0BePurchased\u00a0Underthe\u00a0Plans\u00a0orPrograms | \nJuly 1, 2023 - July 31, 2023 | 1,132 |  | (1) | $136.90 | (1) | \u2014 |  |  | $4,808,991,028 | \nAugust 1, 2023 - August 31, 2023 | 984 |  | (1) | $149.66 | (1) | \u2014 |  |  | $4,808,991,028 | \nSeptember 1, 2023 - September 30, 2023 | 1,059 |  | (1) | $144.25 | (1) | \u2014 |  |  | $4,808,991,028 | \nTotal | 3,175 |  | (1) | $143.31 | (1) | \u2014 |  |  | $4,808,991,028 | (2)  |  | \n  |  |  |  |  | \n2023 Form 10-Q| | 37  |  | \n  |  |  |  |  |  |  |  |  |  |  | \nExhibit\u00a0No. |  | Exhibit\u00a0Description | \n |  |  | \n10.1 |  | Amendment to the AbbVie 2013 Performance Incentive Plan.* | \n31.1 |  | Certification of Chief Executive Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n31.2 |  | Certification of Chief Financial Officer Required by Rule\u00a013a-14(a)\u00a0(17 CFR 240.13a-14(a)). | \n |  |  | \n32.1 |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n32.2 |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. | \n |  |  | \n101 |  | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form\u00a010-Q for the quarter ended September 30, 2023, filed on November\u00a06, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)\u00a0Condensed Consolidated Statements of Earnings; (ii)\u00a0Condensed Consolidated Statements of Comprehensive Income; (iii)\u00a0Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)\u00a0Condensed Consolidated Statements of Cash Flows; and (vi)\u00a0the Notes to Condensed Consolidated Financial Statements. | \n |  |  | \n104 |  | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). |   |  |  |  |  | \n2023 Form 10-Q| | 38  |  |  |  |  |  |  |  | \n |  | ABBVIE INC.\n |  | \n |  | \n | By: | /s/ Scott T. Reents\n |  | Scott T. Reents\n |  | Executive Vice President,\n |  | Chief Financial Officer (Principal Financial Officer)  |  |  |  |  | \n2023 Form 10-Q| | 39"}]}
